,Name,Binds_to,Origin,VH,VL,Reference,Description,Date_added
0,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgesltisckasgyrftsnwitwvrqmpgkglewmgridpddpysnsspsfqghatlsldkaintaylhwsslkasdtamyycarvnrvgdgpdfwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfndygvswvrqapgqglewmggiiaifgtanyaqkfqgrvaitadeststaymelsglrsedtavyfcaslggdsyisgthydrsgydpwgqgtlvivss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewltlisydginkyygdsvkgrftisrdnskntlyiqmnslrpedtavyycarayggnyyygmdvwghgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3,not found,SARS-CoV-2,Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftfstywmswvrqapgkglewvadikqdgsekyyvdsvkgrftisrdnaknslylqmnslrvedtalyycargglwgtfdywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
4,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgasissssyywgwirqppgkglewigtmyyrgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycarrvpgdyycldvwgkgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
5,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssypitwvrqapgqgfewmgkiipilgiadyaqsfqgrvtitadkstttaymelsslrsedtavyycarekgysssssatyyldfwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
6,not found,SARS-CoV-2,Homo sapiens (human),qvqlrlwgagllkpsetlsltcavsggsfidyywtwirqppgkglewigeinhfggsgynpslksrvsisvdtsknqfslrlnsvtaadtaiyycarkpllhssvnpgafdiwgqgtmltvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
7,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssypmywvrqapgigleyvsgitdnggstyygdsvkgrftisrdnskntlnlqmnnlrtedtavyycvkgkiqlwlgadywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
8,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfssytiiwvrqapgqglewmgrvipvvhithyaqrfrgrvtisadkststaymelsslrsedtavyycarglwfgdsetvwfdpwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
9,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfstsvvqwvrqprgqrlewiggivvgrgntkyaqnfqervtitrdmststaymelsnlrsedtavyycaadpfadywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
10,not found,SARS-CoV-2,Homo sapiens (human),evqlvefggglvqpgrslrlscatsgftfedfdmhwvrqapgkglewvsgstwnsgiigyadsvkgrfttsrdnaknslymqmnnlreedtalyycakdigrydhynifgrvggafdiwgqgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
11,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdgdkryspslknrltitedtsknqvvltmtnmdpvdtatyycahhtvptiydywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
12,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglilpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarggwpsgdtfdiwgqgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
13,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsktqfslklssvtaadtavyycardrrgggwtasfdfwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
14,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlssyamnwvrqapgkglewvsaisgsggstyyadsvkgrvtisrdnskntlylqmnslrvedtavyycakdafyygsgshfyyyyymdvwgkgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
15,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsdnymswvrqapgkglqwvsviysggntyyadfvkgrfnitrddsknmlylqmnslrredtavyycvrdrrivgyyfgldvwgqgttvtvfs,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
16,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsctasggdftyyplswmrqapgrglewlggiipgyggahvarrfqdrvtitadestttvnmelrslrsddsavyycareegsgwwkhdywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
17,not found,SARS-CoV-2,Homo sapiens (human),qitleesgptlvtptqtltltcsfsgfsldtigvavawirqppgkalewlgtvfwdydkryspplssrltvikdtsqqyvvlrltdvgpgdtatyycarlliehdafdiwgqgavvivss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
18,not found,SARS-CoV-2,Homo sapiens (human),evhlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggntyyadsvkgrftisrdnskntlylqmnslraedtavyycardrriigyyfgmdvwgrgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
19,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnsysmnwvrqapgkglewvsyistssstmyyadsvkgrftisrdnaknslylqmnslraedtavyycareggwysvgwvdpwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
20,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlsctasgitvstnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraddtavyyctrggwpsgdtfdiwglgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
21,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgitfkdygmhwvrqapgrglewvafisydgsvqhygdsvkgrftisrddlkstlflqmnslrgddtavyycvkgatkidywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
22,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansyiteyaasvkgrftisrddsknslylqmnslktedtavyycarvrggewvgdlgwyyyygmdvwgqgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
23,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscvdseftfityamswvrqapgkglewvstisgsgdstsyadsvkgrftisrdsskntlflqmhslraedtalyycaksativlmvsaiywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
24,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyswswirqspgtglewvgdiystgstnynpslksrltmsldtskshfslklssvaaadtavyycargageqrlvgglfgvshfyyymdvwgkgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
25,not found,SARS-CoV-2,Homo sapiens (human),qvqlqvsgpgllkpsetlsltcivsggsisshywswfrqppgkglewigyiyysgstnynpslksrvaisvdtsknhfslnltsvtaadtavyycargfdywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
26,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvtliwfdgsnqyyadsvkgrftisrdnskntlylqmnslrgedtavyycaregavgatsgldywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
27,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggsfssyafswvrqapgqglewmggivgmfgttsysqkfqgrliitadeltstaymelsslrsedtavyfcarsggyrlwfgelwgpgtqvivss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
28,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwisayngstnyaqklqgrvtmttdtststaymelrslrsddtavyycardpasyydlwsgyvdyyyygmdvwgqgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
29,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
30,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
31,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgdratlscrasqsissflawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
32,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtatitcsadklgkkyvcwyqqkpgqspvlviyqnnrrpsgiperfsgsnsgntatltisgtqpmdeadyycqawdsstasfvfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
33,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavywcqqfayslytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
34,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtvtcrasqsisdylnwyqqkpgkapklliyaasslqtgvpprfsgsgsgtdftltisslqpedfatyycqqsfsarvptfgggtkvesk,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
35,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtaprlliyrnsnrpsgvpdrfsgsksgtaaslaisglqaedeadyycqsydssltalvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
36,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeraalscrasqsvagtylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyatsprtfgqgtqleir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
37,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcranqtissylnwyqqkpgkapkvlifaassleggvpsrfsgsgsgtdftltisslqpedfatyscqqsyntpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
38,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnityylnwyqqkpgkapnlliytasslqsgvpsrfigsgsgtdftltisslqpedfatyccqqsystpptfgqgtkveir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
39,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnignntvnwnhqvpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslnawvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
40,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtiscqtsqdisvslnwyqqkpgkppkvliydasnleagapsrfsgsgsgtdftftisslqpediatyycqhydnlprfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
41,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctatssdvgnynyvswyqhhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnplvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
42,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
43,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvtssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
44,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvrnynlvswyqqhpgkapklmifedskrpsgvsnrfsgsksgntasltiaglqpedeadyyccsyattwvfgggtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
45,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisdylawyqekpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlsgypytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
46,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlynsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhystpgytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
47,not found,SARS-CoV-2,Homo sapiens (human),,dvvvtqspvslpatpgepasiscrasqsllhrngkhylhwylqrpgqspqlliylgsnrasgvpdrfsgsgsgtvfslkisrveaedvgiyycmqalhfpytfgqgtkldik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
48,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssyvgsfdlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccpyadtwvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
49,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqtvssnflawyqqkpgqaprlliygasiratgipdrfsgsgsatdftltisrlepedfavyycqqygssrtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
50,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
51,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsydhvswfqqhagkgpnvvifdvnsrpsgvsnrfsgsksgntasltisglqaedeadyycfsytsggtrvfgsgttvtvv,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
52,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsnghnfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
53,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkaprlmiydvsdrpsgvsnrfsgsksgntasltisglrtedeadyycssytststlvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
54,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
55,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvgsiylawyqqkpgqaprllifgassraigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
56,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedtkrpsgiperfsgsssgtmatltisgaqvedeadyycysrdssgnplfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
57,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratfscrasqsvnnnylawyqqkpgqaprlltsgtftratgipdrfsgsgsgtdftltisrvesedfavyycqqyggspatfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
58,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygssrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
59,not found,SARS-CoV-2,Homo sapiens (human),,elvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnsrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
60,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsddsinsyywswirqppgrglewigyiyysgstnydpslksratisldtsknqlslkltsvtaadtavyycarsgsygdrtfdhwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
61,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgfntnyadsvkgrftisrdnskntlylqmnslraedtavyycakygwgllaaagdafdiwgqgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
62,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkisckpsgytftnyliqwvrqapgqslewmgwinagdgysknslsfrgrvtftrdtsastasmelsslnsedtavyycarggfnyghgldywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
63,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasryafttyaihwvrqapgqglewmgwintntgdpmyahgftgrfvfslatsvstayleisslkaedtavyycaredtfyfdywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
64,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngdtkysqkfqgrvtitrdtsastaymelrslrsedtavyycarpprgyydrsgyynvllyfqhwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
65,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftsydlhwvrqapgqrlewmgwinvgngntkysqkflgrvtftrdtsastvymelsslrsedtamyycarpprgyydrtgyynvvhyfqhwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
66,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsasywswirqppgkglewigeihhsgstnynpslesrvtisvdtsknqfslklssvtatdtavyycareysstvwdnwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
67,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqslsltcnvsggsissnnyywnwirqpagkglewigrgyssgstnynpslksrltisldtsknqfslklssvtaadtavyycarstyyydrsgystsdgmdvwgqgttvivss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
68,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgggvvqpgrslrlscavsgftfssygmhwvrqapgkglewvtfisydgsneyyadsvkgrftisrdsskntlylqmnslrpedtavyycakseysyaykvhfldywgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
69,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsnysissgyywgwirqppgkglewigsifhsgstyynpslkgrvtisvdrsknqfslkltsvtaadtavylcakegargrgattsfyyyymdvwgkgttvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
70,not found,SARS-CoV-2,Homo sapiens (human),evqlvdsggglvqpggslrvscaasgftvssnhmswvrqapgkglewvsliygdgsthyadsvkgrftmsrdkskntlylqmnslraedtavyycardvthafdlwgqgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
71,not found,SARS-CoV-2,Homo sapiens (human),evllvesggglvkpggslrlscaasgfsfssynmnwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycanmrtnydiftgyypdafdiwgqgtmvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
72,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
73,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
74,not found,SARS-CoV-2,Homo sapiens (human),,dvvliqsplslpvtlgqpasiscrssqslvygdgdtylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
75,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvfwyqqhsgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagvtnnlifgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
76,not found,SARS-CoV-2,Homo sapiens (human),,esvltqspgtlalspgeratlscrasqsvgsrylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspsfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
77,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqyvnlpltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
78,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlsltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
79,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgrhnyvswyqqypgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssayvvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
80,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgervtlscrasqsvsnslawyqqkpgqaprllidgassratgipdrfsgsgsetdftltisrlepedfavyycqqygsspltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
81,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnsvqwyqqrpgsapttviyednqrpswvpdrfsgsidsssnsasltisglkaedesdyycqsydssnhvlfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
82,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigaghdvhwyqqlpgtapklliygntnrpsgvpdrvsgsksgtsaslaisglqaedeadyycqsydislngwvlgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
83,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqiigmwlawyqqkpgkapklliykassleygvpsrfsgsgsgteftltisslqpddfatyycqqynsdlytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
84,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscsasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslesedfavyycqqyynwppwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
85,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapsllisgsssratdipdrfsgsgsgtdftltisrlepedfavyfcqqygsspytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
86,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatqggrfycsggscyryyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
87,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsdgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfvvvvaarshddyyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
88,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwagadgmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
89,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvrpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
90,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlsvaggmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
91,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardydyvwgsypsaccywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
92,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmywvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaralygsgsystqagyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
93,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarellllgycsggscypvgpdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
94,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissayywgwirqppgkglewigsffhsgstyynpslksrvtitvdtskkqfslklssvtaadtavyycarddygdyavsywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
95,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsshymswvrqapgkglewvsvlysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlhssgpfdafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
96,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhegstsplmvknyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
97,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyfcardyggnqnyfgywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
98,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivlmvyaiprgyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
99,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqksqervtitrdlstrtaymelsslrsedtavyycaapycsggscfdafdmwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
100,not found,SARS-CoV-2,Homo sapiens (human),qvqlresgpglakpsgtlsltcavsggsitsiywwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyfcasapgtpwfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
101,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmsslraedtavyycardlavygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
102,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgysftshamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycartsgwsgpsygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
103,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssyymnwvrqppgkglewvsviynggnayyadsvkgrftisrdnsrntlylqmnslraedtavyycargkwlrgafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
104,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfsnygmhwvrqapgkglewvavisydgssqyyadsvkgrftisrdnskntlylqmnslrgddtavyycakdrsvgattsqynyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
105,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqsspklgddafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
106,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgitftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggtchdgfdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
107,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkssetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrlgprgpfdnhgnhfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
108,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgrirsktdggtpdyaaplkgrftisrddskntlylqmnslktedtavyycttdsldvgggsyvnfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
109,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsihysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhagpyssswianwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
110,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaprpgdswfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
111,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisddgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgstgttlgyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
112,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkarnyydssgyehdafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
113,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycardltqdwyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
114,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgcirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhvgpysgydknnwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
115,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnilraedtavyycarsqstswhdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
116,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqlwlrsnfdswgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
117,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgdsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknlfslklssvtaadtavyycarrgwlrgyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
118,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasrftfsnywmswvrqapgkglewvanikqdgsekycvdsvkgrftisrdnaknslylqmnslraedtavyycaralsmvrgviippyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
119,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargiaarpgdwhfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
120,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriqsktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdpnqqpprgyyfyygldvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
121,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpsltsrvtisvdtsknqfslklssvtaadtavyycarqfwtrppsvwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
122,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargtamaygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
123,not found,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslriscaasgltvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycardlitygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
124,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftsygitwvrqapgqglewmgwisvdngntkyaeklqgrvtmttdtststaymelrslgsddtavyycardggwtgimgainfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
125,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsrsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstsaaymelsslrsedtavyycaapacsstrcydgfdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
126,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgahywswirqhpgkglewigyiyysggtyynpslkslvtisvdtsknhfslklssvtaadtavyycarttaprpgsswfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
127,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasglivssnymswvrqapgkglewvsvlysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarwgrvgatglafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
128,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrnaiswvrqapgqglewmggiipifgtahyaqkfqgrvtitadeststaymelsslrsedtavyycarreysstdwfdpwgqgtrvtvs,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
129,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycarggavipvwyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
130,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvafisydgddkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakavysyayavlyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
131,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglqwvaiisydesskyyadsvkgrftisrdnskntlylqmnslraedtamyycakdppqfavagtgyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
132,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysggtysnpslksrvtisvdtsknqlslklssvtaadtavyycarevapikqwlvsyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
133,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmkslraedtavyycardrfydysssgysldafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
134,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyytpslksrvtisvdtsknqfslklssvtaadtavyycarftrfaglyyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
135,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmsgthssgwyerwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
136,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqvawlprddyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
137,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
138,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaraaydiltgyyrgmdvwgkgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
139,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmsslragdtavyycarghfygligymdvwgkgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
140,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaignagdtyypasvkgrftisrenarnslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
141,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakdtyydifpdvfdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
142,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgdtnytqkfqervtitrdmststaymelsslrsedtavyycaapycsgsscldgfdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
143,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakapyaycsstscyadyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
144,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycarggivpaatllfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
145,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgshntnyaqkfqervtitrdmststaymelssltsedtavyycaaaiiasaapdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
146,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnyemnwvrqapgkglewvsyissggttmyyadsvkgrftisrdnaknslylemnslraedtalyycarvghpdtlfgveywgqgilvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
147,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifnnyemnwvrqapgkglewisyissggttvyyadsvkgrftisrdnaknslylqmsslraedtalyycvrvghpdtlfgvdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
148,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggwydykgyyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
149,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgtqpipdygdffdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
150,not found,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwaqqlvpsenlkpyyyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
151,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarqpreyydfwsgyrrlfyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
152,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsggscydafdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
153,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgtshyydssgyygadrnwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
154,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsihysgstyynpslksrvtisvdtsknqfslklssmtaadtavyycarhtgyydssgyyrleyfqhwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
155,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewiayiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgynyglglgwfdpwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
156,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnglraedtavyycakvlgsycsggscyggsfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
157,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksgapaamrgyyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
158,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdafgdpqglygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
159,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgddygdlfyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
160,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfsnygfswvrqapgqglewmggtsplfhtpnyvqkfqdrvtitadesttsvymelnsltsddtavyycacssgrwgvlgnyfdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
161,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssygiswvrqapgqglewmggiipifgtayyaqkfqgrvtitadeststaymelsslrsedtavyycassspllryfdwpheaifdywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
162,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddsknmlylqmnslktedtavyycttdpgytyspaywgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
163,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvssissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdvtvdtamvtifdnwgqgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
164,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtsgdtyypgsvkgrftisrenaknslylqmnslragdtavyycargggdgynlglwyfdlwgrgtlvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
165,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfpssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcgggscydgfdiwgqgtmvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
166,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
167,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
168,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyknfpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
169,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssqytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
170,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
171,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
172,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsglsnrfsgsksgntasltisglqaedeadyycssytsstnwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
173,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyraftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
174,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
175,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
176,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvaitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqydivgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
177,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
178,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqditnslnwyqqkpgkapklliydasnletgvpssfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
179,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeaayycssytsssppvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
180,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
181,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
182,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsfsssylawyqqipgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsslitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
183,not found,SARS-CoV-2,Homo sapiens (human),,qavvtqepsltvspggtvtltcasstgavtsgyypnwfqqkpgqapraliysisnkhswtparfsgsllggkaaltlsgvqpedeaeyycllyfggaqyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
184,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapitviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdlwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
185,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqfpgtapklliydndkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwetslsaevfgggtrltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
186,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
187,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
188,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrviitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltvsslqpedfatyycqqlnsypwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
189,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsvsvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
190,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteltltisslqpedfatyycqqlnsypltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
191,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqafsswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfptfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
192,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
193,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
194,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgthftlaisslqpedfatyycqqsystppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
195,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
196,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidtssnsasltisglktedeadyycqsydnnnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
197,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwhqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
198,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
199,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidiysnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
200,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
201,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqapmtlicdtsnkhswtparfsgsllgdkaaltlsgaqpedeaeyycllsysgapvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
202,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignyyvswyqqlprtapklliydnnerpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
203,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtaritcggnniggqsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
204,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyscqhlltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
205,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywcqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
206,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapslliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
207,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdntlspgrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
208,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtariscggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsdsnsgntatltisrveagdeadyycqvwdsssdhhyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
209,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
210,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyshpgitfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
211,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsfasnsvqwyqqrpgsapttmiyednhrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydynnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
212,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtaritcggnnigsknvhwyhqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
213,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvqwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsglvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
214,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvseaprqrvtiscsgsssnignnavnwfqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
215,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglraddeadyycssyagtvlfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
216,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
217,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvgfynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnyvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
218,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
219,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgidftltisslqpedfatyycqqsyniastfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
220,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqklgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
221,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
222,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitiscagtssdlggyyyvswyqhhpgkapklmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlpvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
223,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftlaisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
224,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
225,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyscsfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
226,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
227,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscgasqsisstlawyqhkpgqaprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
228,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqapslliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
229,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
230,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppctfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
231,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
232,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
233,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
234,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedgadyycqsydsslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
235,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylywyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
236,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyddvpftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
237,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydassleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlpsfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
238,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpedeadyycllsysgarevfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-01
239,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfaqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
240,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrtltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
241,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqditdylnwyqqkpgqapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqyanllltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
242,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwsgitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
243,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcragqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
244,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
245,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqrkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnppptfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
246,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
247,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylacyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.","VL: anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-01
248,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpspyyygsgsysggfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.","VH: Chain H, Heavy Chain",2022-03-01
249,not found,SARS-CoV-2,Homo sapiens (human),,asdivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqydnwplmhtfgqgtkleikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.","VL: Chain L, Light Chain",2022-03-01
250,not found,SARS-CoV-2,Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvssgpggqhhhhhhgaeqkliseedls,,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.","VH: Chain F, Nanobody",2022-03-01
251,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","VH: Chain H, Heavy ChaIn variable",2022-03-01
252,P5C3,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","VL: Chain B, Variable Light Chain P5C3 (VL)",2022-03-01
253,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgnanyaprfqervtitrdmstntaymelsslrsedtavyycaapncsrtlcydgfnmwgqgtmvtv,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain B, PDI 222 Fab Heavy Chain",2022-03-01
254,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymnwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycarvggycssancvsdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 231 heavy chain",2022-03-01
255,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkgpewvsyisggssftnyadsvqgrftiyrdnaknsmflrmnslraedtavyycarspptgdssdwydspaynnyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 215 heavy chain",2022-03-01
256,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlqqwgagllkpsetlsltcvvygetlsgyywtwirqspgkglewigeislrgtanynpslksrvtlsveasknqfslkmtsvtaadtavyycvggvvldnvvwfdpwgqgipvtvslastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 210 heavy chain",2022-03-01
257,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 96 heavy chain",2022-03-01
258,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain N, PDI 96 heavy chain",2022-03-01
259,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain F, WCSL 129 heavy chain",2022-03-01
260,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain C, WCSL 129 heavy chain",2022-03-01
261,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain N, PDI 93 heavy chain",2022-03-01
262,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 93 heavy chain",2022-03-01
263,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain F, WCSL 129 heavy chain",2022-03-01
264,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain C, WCSL 129 heavy chain",2022-03-01
265,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, WCSL 129 heavy chain",2022-03-01
266,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain B, WCSL 119 heavy chain",2022-03-01
267,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, WCSL 119 heavy chain",2022-03-01
268,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsvfypggstynadsvkgrftisrdnskntlylqmnslraedtavyycardavyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 42 heavy chain",2022-03-01
269,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggttyyadsvkgrftisrdsskntlylqmnslraedtavyycardrgdylfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VH: Chain H, PDI 37 heavy chain",2022-03-01
270,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,eivltqspgslslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyycqqydsspwtfgqgtkvei,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain C, PDI 222 Fab Light Chain",2022-03-01
271,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapkimiydasiletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtqleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 231 light chain",2022-03-01
272,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,eivltqspvtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsptvtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 215 light chain",2022-03-01
273,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,esvltqspvslslspgeratlscrasqsvgtylawyqhrpgqaprlliynaskratgiparfsgsgsgtdftltisslepedlavyfcqqrsnwltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 210 light chain",2022-03-01
274,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain D, WCSL 129 light chain",2022-03-01
275,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 96 light chain",2022-03-01
276,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain M, PDI 96 light chain",2022-03-01
277,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain E, WCSL 129 light chain",2022-03-01
278,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain M, PDI 93 light chain",2022-03-01
279,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 93 light chain",2022-03-01
280,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain E, WCSL 129 light chain",2022-03-01
281,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain D, WCSL 129 light chain",2022-03-01
282,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, WCSL 129 light chain",2022-03-01
283,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain C, WCSL 119 light chain",2022-03-01
284,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, WCSL 119 light chain",2022-03-01
285,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqesystpglftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 42 light chain",2022-03-01
286,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,diqmtqppsplfasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgseteftltisslqpddfatyycqqynsyfptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.","VL: Chain L, PDI 37 light chain",2022-03-01
287,not found,SARS-CoV-2,Homo sapiens (human),mgwslillflvavatrvlsevqlvqsgaevkkpgeslkiscqfseyklisfwiawvrqrpgkglewmgiiypddsdtkyspssqgqvtisadksirtaylqwsslmasdtamyyctsgsyygtldfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain H, H",2022-03-01
288,BD-813L,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrtsqsistylhwyqqkpgkapklliyaasslhsgvpsrfsgsgsgthfvltinglqpedfatyycqhtdttpltffgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VL: Chain L, BD-813L",2022-03-01
289,not found,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","VH: Chain H, immunoglobulin mu heavy chain",2022-03-01
290,not found,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","VH: Chain G, immunoglobulin mu heavy chain",2022-03-01
291,not found,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.","VH: Chain F, immunoglobulin mu heavy chain",2022-03-01
292,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain D, H",2022-03-01
293,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain O, H",2022-03-01
294,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain N, H",2022-03-01
295,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain D, H",2022-03-01
296,BD-623,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvap,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VL: Chain D, BD-623 Fab L",2022-03-01
297,BD-623,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvap,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VL: Chain B, BD-623 Fab L",2022-03-01
298,N11,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VL: Chain N, N11 Fab Light chain",2022-03-01
299,N11,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VL: Chain L, N11 Fab Light chain",2022-03-01
300,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VH: Chain O, Fab Heavy chain of enhancing antibody 2490",2022-03-01
301,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VH: Chain M, Fab Heavy chain of enhancing antibody 2490",2022-03-01
302,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VH: Chain H, Fab Heavy chain of enhancing antibody 2490",2022-03-01
303,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycardwdydiltgswfgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VH: Chain H, Fab Heavy chain of enhancing antibody",2022-03-01
304,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VL: Chain P, Fab light chain of enhancing antibody 2490",2022-03-01
305,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VL: Chain N, Fab light chain of enhancing antibody 2490",2022-03-01
306,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VL: Chain L, Fab light chain of enhancing antibody 2490",2022-03-01
307,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.","VL: Chain L, Fab light chain of enhancing antibody",2022-03-01
308,not found,SARS-CoV-2,Camelus bactrianus (Bactrian camel),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain D, Nanobody against SARS-CoV-2",2022-03-01
309,not found,SARS-CoV-2,Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain F, Nanobody against SARS-CoV-2 glycoprotein",2022-03-01
310,not found,SARS-CoV-2,Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain E, Nanobody against SARS-CoV-2 glycoprotein",2022-03-01
311,not found,SARS-CoV-2,Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain D, Nanobody against SARS-CoV-2 glycoprotein",2022-03-01
312,not found,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain I, Nanobody against spike glycoprotein VHH V",2022-03-01
313,not found,SARS-CoV-2,Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain H, Nanobody against SARS-CoV-2 VHH E",2022-03-01
314,not found,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain G, Nanobody against spike glycoprotein VHH V",2022-03-01
315,not found,SARS-CoV-2,Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain F, Nanobody against SARS-CoV-2 VHH E",2022-03-01
316,not found,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain E, Nanobody against spike glycoprotein VHH V",2022-03-01
317,not found,SARS-CoV-2,Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain D, Nanobody against SARS-CoV-2 VHH E",2022-03-01
318,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssgdsthyvdsvkgrftisrdnakntvylqmnslkpedtavyycaaqsgsyywcgsdwheydyrgqgtqvtvssgglpetgghhhhhh,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain B, VHH W",2022-03-01
319,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssgglpetgghhhhhh,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain C, VHH V",2022-03-01
320,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain F, VHH U",2022-03-01
321,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain E, VHH U",2022-03-01
322,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain D, VHH E",2022-03-01
323,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain C, VHH E",2022-03-01
324,not found,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgkslewigginpnngdntynqklkgkatltvhkssstaymelrsltsedsavyycardgypyyyaldywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkpliysassrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynnypwtfgggtkleikaaahhhhhhhh,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","VH: Chain B, antibody scFv",2022-03-01
325,not found,SARS-CoV-2,Mus musculus (house mouse),mkflvnvalvfmvvyisyiyadgsqvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvssggggsggggsggggsdivltqspaslavspgqratitcrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsgtdftltinpveandvanyycqqsnedpwtfgqgtkveikaaahhhhhhhh,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","VH: Chain D, antibody scFv",2022-03-01
326,not found,SARS-CoV-2,Mus musculus (house mouse),mkflvnvalvfmvvyisyiyadgsqvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvssggggsggggsggggsdivltqspaslavspgqratitcrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsgtdftltinpveandvanyycqqsnedpwtfgqgtkveikaaahhhhhhhh,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","VH: Chain B, antibody scFv",2022-03-01
327,not found,SARS-CoV-2,Homo sapiens (human),gsevqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikgggshhhhhh,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","VH: Chain C, antibody scFv",2022-03-01
328,not found,SARS-CoV-2,Homo sapiens (human),gsevqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikgggshhhhhh,,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.","VH: Chain A, antibody scFv",2022-03-01
329,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","VH: Chain I, Fab 15033 heavy chain",2022-03-01
330,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","VH: Chain H, Fab 15033 heavy chain",2022-03-01
331,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","VL: Chain M, Fab 15033 light chain",2022-03-01
332,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","VL: Chain L, Fab 15033 light chain",2022-03-01
333,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasggtfstygiswvrqapgqglewmgwispnsggtdlaqkfqgrvtmtrdtststvymelsslrsedtavyycasdprddiaggywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","VH: Chain B, Fab Heavy Chain",2022-03-01
334,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","VH: Chain H, Fab Heavy Chain",2022-03-01
335,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","VL: Chain A, Fab Light Chain",2022-03-01
336,not found,SARS-CoV-2,Homo sapiens (human),,sdiqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.","VL: Chain L, Fab Light Chain",2022-03-01
337,not found,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VH: Chain C, heavy chain",2022-03-01
338,not found,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VH: Chain H, heavy chain",2022-03-01
339,not found,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvt,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VH: Chain C, Heavy chain",2022-03-01
340,not found,MERS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvtvs,,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VH: Chain H, Heavy chain",2022-03-01
341,not found,MERS-CoV,Homo sapiens (human),,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VL: Chain D, light chain",2022-03-01
342,not found,MERS-CoV,Homo sapiens (human),,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VL: Chain L, light chain",2022-03-01
343,not found,MERS-CoV,Homo sapiens (human),,ltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqlt,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VL: Chain D, Light chain",2022-03-01
344,not found,MERS-CoV,Homo sapiens (human),,gsqpvltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.","VL: Chain L, Light chain",2022-03-01
345,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaiisydgsnkyyadsvkgrftisrdnsnntvylqinslrtedtavyycaksragsyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
346,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisctgsgysfttywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtfsadksistaylqwsslkasdtaiyycarhgnryssgwyqptgvdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
347,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasigsyywswirqppgkgleyigyiyysgstdynpslksrvtisidtsknlfslnltsvtaadtavyycargfdswgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
348,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfstyamhwvrqapgkglewvslisydginkyyagsvkgrfsisrdnskntlylqmnslrvedtavyycarslsggyyygmgvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
349,not found,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwyhgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardretstnyvghyyngmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
350,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwvnpnsgatncaqkfqgrvtmtrdtsittvymelsrlkfddtavyycargvdfsifgaaisddwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
351,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsenlsltcnvagdsisgyywswirqtpgkglefigymyyggstiynpslrtrvtisidtsknqfslnlnsvtaadtaiyycargfdlwgrgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
352,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsgyamhwvrqapgkglewvavisydgdnkyyadsvrgrftisrdnskntlylqmnslrvedtavyycarsssgsyfaafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
353,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyfwtwirqppgkglewighifysgstyynpslksrvtisldtsknqfslklssvtaadtavyycarvvlaknyydrsgyfhgdwyfygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
354,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvssvsgsgdrtyyadsvkghfiisrdnskntlylqmnslraedtavyycatdsyyhdrdgfvnyafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
355,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfnfnnvwmswvrqapgkglewvgliksksdggtkdyaapvrgrftisrddprnnlylqmnslktedtavyycstapyyydysaypqihfeywgrgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
356,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglecvsviygggptyyadsvkgrftisrdnskntlylqmnslraedtavyycardkripyyfygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
357,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrfpfstygmhwarrapgkglewvslisddgknkyyadsvkgrftisrdnyentlylemnslrpedtavyycakailrgvkyylygvdiwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
358,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgvvkpsetlsltctvsgdsissyywswirqspgkglewigyiyssgstnynpslksrvamsvdtsknhfslkmtsvtaadtavyycargfdfwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
359,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsnrymswvrqtpgkglewvsiiysagstyyadsvkgrftisrdnskntlylqmnslrvedtavyycaragsplslrwrphidywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
360,not found,SARS-CoV-2,Homo sapiens (human),qvqvqqwgagllkpsetlsltcavyggsfsdyswtwirqspgkglewigeindsgitnydptlksriimsvdrsknqfslrltsvtaadtavyfcargstvlglsslryyssldvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
361,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsggevkkpgasvkvsckasgytftnyglswvrqapgqglewmgwisgnngntnyaqkfqgrvtmttdtststgymelrslrsddtavyycardqstvvtfgtfdywgqgtlltvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
362,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfssygmhwvrqapgkglewvafirydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaspsryydssgyylaeyfqhwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
363,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgpvkpsgtlsltcavsgdsitntnwwswvrqspggglewigeihhsgttnyksslksrviisidksknqfslkmrsvtaadtalyycargrynwnggyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
364,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvnvsckasggtfssyaiswvrqapgqglewmggifplygttkyaqqfqgrvtfsadestrtaymdlrslrsedtavyycarsadgdyvvgyyhymdvwgkgttvivss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
365,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfssytfswvrqapgqglewmgvfipifgttsyaqkfqgrvtitadestytsymelssltsedtamyycasrlgcpngachepdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
366,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfntyaihwvrqapgkglesvalisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycargtggnyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
367,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmagimpifgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycasrhsgyryshfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
368,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggwvqpggslrlscaasefsvstnymtwvrqapgkglewvsiiysdgrtfyadsvkgrftisrdnskntvylqmnnlrpedtavyfcararvtiivvvvdyffdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
369,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfynawmswvrqapgkglewvghikgntnggttdyaapvkgrftisrddskntlylqmnslrtedtgvyycttetllwfgespfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
370,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgvtvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrddsmntlylqmsnvraedtavyycardlyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
371,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnsyaftwvrqapgqglewmgaiipilgianheqkfqdratitadkststaymelrslrsddtavyycasgvvvpatdyyyamdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
372,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgfifsssamswvrqapgkglewvsgisdsglrtyygdsvkgrftisrdnskntvsllmnslraedtavyycaygyspdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
373,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnnlrdedtamyycardlivygmdvwgqgtpvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
374,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymswvrqapgkglewvsiiyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyyctrdlvyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
375,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglaqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfysdsvkgrftisrdgpkntlylhmhslraedtavyycardlvhygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
376,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwirqapgkglewvaviwsdginkyyvdsvkgrftisrdnskntlylqmnslraddtavyycarapqdpdsssyyyfyygldvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
377,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftayyihwvrqapgqglewmawinpmsgatnytqkfqgrvtmtrdtsittvymelsrlrsadtavyycarvspptifgvtvdhwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
378,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymnwirqapgkglewvssisttgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddssgyyygsaldwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
379,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfytdsvkgrftisrdnskntlylqmnslraedtavyycardlvvlygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
380,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaapgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
381,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnnyainwvrqapgqglewmgriipmlgvvnhaqkfqgrvtitadkststaymelsslrsedtavyycatrvsvttmgvnfdgmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
382,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymtwvrqapgkglewvsvlyaggssfyadsvkgrftisrdnskntlflqmnslraedtavyycardlvaygmdvwgqgttvsvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
383,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpessvkvsckvsggtfssygiswvrqapgqglewmgriipslgvvnyaqrfqgrvtftadkststaymdlsslksedtavyycakttvvtpglgkdafdvwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
384,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgyiftnfwiawvrqmpgkglewmgiiypddsdvrysppfqgqvtisadksintaylqwsslkasdtamyycarlsflpsgfshyyaldvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
385,not found,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvalisydgsneyyadsvrgrftisrdnskntlylqmsslraedttmyycaranrgnyyygmdvwgpgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
386,not found,SARS-CoV-2,Homo sapiens (human),qvqleqsgaevkkpgssvkvsckasgssfssyaitwvrqapgqglewmggiipifgtanyaqifqgrvtltaeestgaaymelsslrsedtalyyctiigmfdssgsythywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
387,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifntyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskstlylqmnslriedtavyycarsrsgsyfsafdiwgqgtkvtvsp,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
388,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvrpgrslrlscaasgftfssygmhwvrqapgkglewvalisydginkyypdsvkgrftisrdnsnntlylqmnslraedtavyycanaktgnyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
389,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsistyywswirqppgkrlewigyiyysgstnynpslksrvtisvdtsknqfslklnsvtaadtaiyycargfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
390,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgdkkyytdsvkgrftisrdnskntlflqmnslraedtavyycararegtyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
391,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarlsfgyssssnyyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
392,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscavsgftfrsyamswvrqapgkglewvstisgsggrtdyadsvkgrftisrdnskntlyvqmsslraedtavyycalpylgwlrsfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
393,not found,SARS-CoV-2,Homo sapiens (human),qlqlqisgpglekpsgtlsltctvsggsvsrsdfywgwvrqppgkglewigsihysgstyynpslksrvtisvdtsenqlslrlssvtaadtavyycarsggysygravwfdnwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
394,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsisaihwvrqapgkglewvavisydgfnkyyedsvkgrfiisrdnskntlylqmnslrvedtavyycakgggsyyhpfdnwgqgtlvsvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
395,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptvvkptqtltltctfsgfslsisgegvgwirqppgkalewlaliywnderrytpslksrlsitkdtsknqvvltmtnmdpvdtatyycahtyyydsrgyafdnwgqgtlvpvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
396,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavfggsfsayywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargsreqwlvrrawyfdlwgrgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
397,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsggsisiyywswirqppgkglewigyishsgdtnynpslksrvtisvdtsknqfslrlssvtaadtalyycargdimwtqwltsggrfldywgqgalvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
398,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisgyywswirqspgkglewmgylyysgsinynpslksrvtisidtsknqfslkmrsvtaadtavyycargfeswgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
399,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgntfidsymhwvrqapgqglewmglidpsgknryypqnfqgrltltrdaststtymqlsslrsqdtavyycarmteagswdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
400,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlslqlnslraedtavyycarmhsgsyigyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
401,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfitysfhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarqksqwellfrgdafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
402,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaliaydgdkkyyadsvrgrftlsrdnskntlylemnslraedtavyycarpysgsyygafeiwgqgtmvtvsa,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
403,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnsnstlylqmnslraedtalyycarggyhyfrhfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
404,not found,SARS-CoV-2,Homo sapiens (human),dvllvesggglvqpggslrlscsasgfpfitywmswvrqapgkglewvanikedgsekyyvdsvrgrftisrdnaenslslqmnslraddtavyycartggrgsldrgrfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
405,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscvvsgftfntyamhwvrqapgkglewvavisydgnnhysadsvrgrfsvsrdnskktlflqmnslraedtavyycarsyggnylgyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
406,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstnynpslksrvtisldtsknqfslkltsvtaadtavyycarrrrgysyghptyhafdmwgqgtmvtvsa,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
407,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarhslrggtrggyyyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
408,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggavvqpgrslrlsceasgftfstyamhwvrqapgkglewvalvsydgsnkyyadsvkgrftisrdnskntlylqmdslraedsavyycaralsgsyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
409,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfgsywmswvrqapgrglewvanirqdgsekyyvdsvkgrftisrdnaknsmylqmnslraedtavyycakenivavpaargydyyyymdvwgkgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
410,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlsceasgltfinawmswvrqapgkglewvgriksktdggttdfaapvkgrftisrddskntvflqmnslktedtavyycatdllfprdpgdnwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
411,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevqkpgeslkiscrasgytftdqwigwvrqmpgkglewvgviypgdsdtryspsfqgqvtisvdksistaylqwsslkasdtamyycarqsafwtgylyyyafdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
412,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaseftfstytmhwvrqapgkglewvalisydgshkyyadsvkgrftisrdnskntlslqmnslraddtavyycararggnyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
413,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggmvqpgrslrlscaasgftfstyaihwvrqapgkglewvavvsydglnkyyadsvrgrftisrdnskntlylqmnnlraedtalyycarsasggywselpywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
414,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisrtnyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarlppwynsgwagldsltyqyymdvwgkgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
415,not found,SARS-CoV-2,Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglqwvavisydgnnkyyadsvkgrftisrdnskntlylqintlraedtavyycargyggnyhyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
416,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpseilsltctvsggsisshywswirqppgkglewigyisysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
417,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaelkkpgeslrisckgsgysftsywiiwvrqmpgkglewmgridpsdsytkyspsfqghvtissdksistaylqwnslktsdtavyycarqfatlenvigpaaldwfdpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
418,not found,SARS-CoV-2,Homo sapiens (human),qmhlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnygqkfqervtitrdlststvymelislrsedtavyfcaapyctggscfdafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
419,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewmavisydgsnkyyadsmkarfsisrdnskntlylhmnslrpedtavyycaraaggnyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
420,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvscraseyaftdyyihwvrqapgqtlewmgiinpsggsaryaqkfqgrvtmtrdtststvymevsslrfedtavyycardpsggssvttqnyfdswgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
421,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgkglewvsvlysggstfyadsvkgrftisrdnskntlhlqmnslrvedtavyycardlvaygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
422,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnlgfswvrqapgqglewmggiipivalanyaekfqgrvtitadkststvymelsslrsedtavyycatkgdghnyfyyygvdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
423,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgmglewvsviypggttyyadsvkgrftisrdnskntlflqmnslriddtalyycardlvyrgmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
424,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsvifpggstfsadsvkgrftisrdnsnntlylqmnslraedtavyycargegwdlpfdywgqgilvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
425,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftsydinwvrqatgqglewmgwmnpnsgnrgyaqmfqgrvtmtsnpsigtaymeltslrsedtavyycargtkfgsnwfwfdhwgqgtlltvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
426,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsiiypggstfyaesvkgrftisrdnskntlflqmnnlraedtaiyycardygdyyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
427,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltcsvsgdsitnimsywgwirqspgkalewigsaynsgnsyynpslksrvtisvdtsknqfslklrsvtaadtsvyfcarhryyydgspgyffdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
428,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmggiipilhipnyaqkfqarltitadrststaymelsslksedtavyycagtaaehdylwgtyreiygldvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
429,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifisygiswlrqapgqglewmgwispynsntnyaqkfqgrvtmttdtststaymelrslrsddtavyycardgewggwfdpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
430,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymtwvrqapgkglewvsvlyvggstfyadsvkgrftisrdkskntlylqmnnlraedtavyycardryvlgmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
431,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyainwvrqapgqglewmgrifpmldkatyaqnfqgrvtftadkstntasmelsslssedtafyycargivgptpfyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
432,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfvinwvrqapgqglewmggiipisatanyaqkfqgrvtitadestrtaymelsslrsedtavyycargsrkpfstdiyghvdyyyygmdvwgqgtavtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
433,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesaggvvqpgrslrlscaasgftfsdygmkwvrqapgkglewvaviwhdgsnkyyedsvkgrftisrdnsqntlylhmnslrvedtaiyfcargsgssdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
434,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsssamywvrqapgkglewvavisndgsnkyyadtvkgrftisrdiskntlyllmnslrvedtgiyycardslpgyngydapdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
435,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadkststasmelsslelsslrsedtavyycarthsydssgyyvdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
436,not found,SARS-CoV-2,Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgfifssfamhwvrqtpgkglewvavisydginkyyadsvkgrftvsrdnskntlslqmnslrgedtavyycargqgayktafdswgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
437,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssyggyvgyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
438,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgasissggyywswirqhpgkglewigyiyytgstyyspslkgrvtisvdtsknqfslklssltaadtavyycargsgpevvvirpyyldnwgpgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
439,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifskysmdwvrqapgkglewvsyidsggssryyadsvkgrftisrdnaknslylqmnslraedtavyycvrdardghsnndfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
440,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyamhwvrqapgkglewvavisydgsnkhyvdsvrgrftisrdnskntlylqmislitedtavyycardwsakmatignfdywgqgslvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
441,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfdssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdvstntaymelrslgsedtavyfcaaphcnrttcydafdlwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
442,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsistgayywswirqhpgkgleligyiyysettyynpslksrvtmsvdtsenqfslklnsvtaadtavyycarvvhcsgggcsrhnyfdpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
443,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfaihwvrqapgkglewvtvisfdgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglsgnyyyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
444,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssfaihwvrqapgkglewvavisydgsnkyyadsvkgrfsisrdnskntlylqmnslrsedtaiyycarplggnyggafdiwgqgalvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
445,not found,SARS-CoV-2,Homo sapiens (human),qvqleesgpglvkpsetlsltcsvsadsisnyywswirqppgkglewigyiyysgstsynpslksrvtmsvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
446,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsiastyyywgwirqspgkglewianihyngstynkpslknrvtlsvdtsknqfslklssvtaadtavyycarygpyyydrsgsllsdpfdnwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
447,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsetlslsctvsggsissyfwswlrqppgkglewigyisyigstnhnpslksrvtmsvdtskkqfslrlssvtdadtavyycarrfphhydstglssdafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
448,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvnsgsyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycarvrfcsgsscrshnwfdpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
449,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvhpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgnnkysadsvkgrftisrdnskntlylqmnslrpedsavyycarglggnyyaadywgqgslvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
450,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgynkyyadsvkgrftisrdnskntlylqmnslrvedtamyycaralggnyyygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
451,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvtvsckasgytftsyyihwvrqapgqglewmgiinpgagstsnaqkfqgrvtmtsdtststvymelsslrsedtavyycasgmdtlipaaqrafdiwgqgtvvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
452,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsissgsvfwtwirqhpgkglewighiyyrgttnynpslksrisisvdtsknqfslnltsvtaadtaiyycarkaggcggdcyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
453,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqperslrlscaasgftfsrdgmhwvrrapgkglewvavisydgsnkvyaesvkgrftvsrdsskntvylqmnslraedtavyycakdgpqafgtyfdywgqgtlvivss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
454,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaeviqpgaslkvsckasgytftayylfwvrqapgrglewmgwinpnnggtnyaqnfqgrvtmtrdtsmstaymelsrlssddtavyfcarwmvavagmgdrgynyhyymdvwgkgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
455,not found,SARS-CoV-2,Homo sapiens (human),evqveesggglvkpggslrlscaasgfnfssygmnwvrqapgkglewvssisrssdfiyyadsvkgrftisrdnaknavflqmnrlrvedtavyycarnlkirssgdlfrgyyyhgmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
456,not found,SARS-CoV-2,Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpgsgnylgyfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
457,not found,SARS-CoV-2,Homo sapiens (human),qvqlvlsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwinpmsgatnfarkfqgrvtltrdtsittaymelsrlrsddtavyycarvppfyengahfdnwgqgslvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
458,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargfwvpaaipgvwfdpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
459,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsa,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
460,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgsslrlscaasgfsfisygmhwlrqapgeglewvaiiwfdgrnkyyadsvkgrftisrdnsksmlylqmnslraedtavyycardlpaqkrgdafdiwglgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
461,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyythwvrqapgqglewmgwinpnsggtiyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycarwvpprgygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
462,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmnwvrqapgkglewvaviwydgnnkyyadsvkgrftisrdnskttlylqmkslraedtavyycaralqyydiltgdysvvrsdafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
463,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardrafgvvtvdfdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
464,not found,SARS-CoV-2,Homo sapiens (human),evqllesggtlvkpggslrlscaasgftfsdyamswvrqapgrglewvsalsdsggstffadsvkgrftisrdnskntlylqmsslraedtakyycargevqpfllafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
465,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvsrnymswvrqapgkglewvsviyaggstfyadsvkgrftisrhnskntlylqmnslrvedtavyycvrdlvdygmdvwgqgttvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
466,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmsvnwirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdsvdtatyycarsvpttaldywgqgtlvivss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
467,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftdyymhwvrqapgqglewmgwinpksggtdfaqiflgrvtmtrdtsistaymelrglrsddtavyycargsyprdvvvvpaaapfnwldpwgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
468,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlshdgsesyyadsvkgrftisrdnsknslyvqmnslraedtavyycasacnsfncqlgdafdiwgqgtmvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
469,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggrvvqpggslrlscaasgftfhdyamhwvrqapgkglewvslingdgrgryyadsvkgrftisrdnsknslylqmnslrtedtalyycakdmesnwnesdfvdywgqgtlvtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
470,not found,SARS-CoV-2,Homo sapiens (human),qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
471,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
472,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsniylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedsavfycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
473,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpytfgpgtkvgik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
474,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystrtitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
475,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprllvyaassraigipdrfigsgsgtdftltinrlepedfavyfchqygsspwtfgqgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
476,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntypwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
477,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrvsqsvssnylawfqqkpgqaprllifatssraigipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
478,not found,SARS-CoV-2,Homo sapiens (human),,dfqmtqspsslsasvgdrvtitcrasqtittylnwylqkpgkapdlliyaastlqsgvpsrfsgsgsgtdftltidslqpedfatyycqqsyttpytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
479,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqninrylnwyqqkpgqapklliyaasgvqsgvpsrfsgsvsgtdftltisslqpedfatyhrqqsyitpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
480,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
481,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasrsvpsdylawyqqkpgqaprlliydtssratgipdrfsggasgtaftltisrlepedfavyychqygtslrtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
482,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqnianwlawyqqkpgkapklliytasnlesgvpsrfsasgsgteftltisslqpddfatyycqqynsysrlvtfgggtkvesk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
483,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtftcrasqgissylawyqlkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlssypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
484,not found,SARS-CoV-2,Homo sapiens (human),,diqltqsppflsasvgdrvtitcrasqgisrylawyqqkpgkapklliyaastlqsgvpprfsgtgsgteftltisslqpedfatyycqqlntyplafgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
485,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsastgdrvtitcrasqdissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqsedfatyhcqqyysyprtfgqrtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
486,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgignylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedlatyycqqvnsyppectfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
487,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkfgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwppytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
488,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdfftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
489,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdritltcrasqgisnylawyqqkpgkapklliyaastlqggvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
490,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspaflsasvgdrvritcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqltnyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
491,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsispwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisglqpddfatyycqqyngysntfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
492,not found,SARS-CoV-2,Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppvfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
493,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsyspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
494,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvggrvtitcrasqgissslawyqqkpgkapklliygastlrtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
495,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapnlliydasnlesgvpsrfsgsgsgteftltisglqpddfatyycqqyhsyspltfgggtkvefk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
496,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqtvrnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftitisrlepedfavyycqqygrahgafgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
497,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqqpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysspftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
498,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqnrrnwpplltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
499,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnslnwyqqrpgrapkllihaasslqsgvpsrfsgsgsgtdftltiaglqpedfatyycqqsfttpftsgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
500,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgteftltmsslqpedfatyycqqsysshtfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
501,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqtvssiylawfqqkpgqaprlliyaassraigipdrfsgsgsgtdftltisrlepedfavyyclqsgnspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
502,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgrapklliyaasslesgvpsrfsgsgsgtdftlsvsslqpedfatyycqqsyntpqtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
503,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllingassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssqgtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
504,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssyltwyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrtdwppevtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
505,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqrpgqaprlliagtstratgipdrfsgsgsgtdftltisrlepedfavyycqqygasytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
506,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqsliswlawyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfpvtfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
507,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynnypytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
508,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplslsvtpgqpvsisctssqsllhgggktslnwyhqkpgqppqlliygvsnrfsgvpdrfsgsgsgtdftlkisrvqaddvgvyycmqsislpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
509,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsslylawsqqkpgqaprllvfgassraigipdrfsgsgsgtdftliisrlepedfavyychqygsspwtfgqgtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
510,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdtlslspgeratlscrasqsigsrylawyqqkpgqaprllitaassratgipdrisgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
511,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrlpvafgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
512,not found,SARS-CoV-2,Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlngyplfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
513,not found,SARS-CoV-2,Homo sapiens (human),,ekvmtqspatlsmspgeratlscrasqsisnnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqynnwpftfgqgtklemk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
514,not found,SARS-CoV-2,Homo sapiens (human),,dfvmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
515,not found,SARS-CoV-2,Homo sapiens (human),,diqmsqspsslsasvgdrvtitcrasqdiayslnwyqqipgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
516,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsinsylnwfqqkpgkapnlliyaasslqsgvpsrfsgggsgtdftltisrlqpedfatyycqqsystpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
517,not found,SARS-CoV-2,Homo sapiens (human),,dtvmtqsplslpvtpgepapiscrssqsllhsngynyldwylqksgqtpqlliylgshrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmealqtplftfgpgtkvhik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
518,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylvwyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsygytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
519,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrtsqsvntklvwyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqhndwprsfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
520,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsinsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqtyntphtfgqgtkldik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
521,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyhcqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
522,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscranqsvssylawyrqkpgqaprllihdasnratgiparisgsgsgtdftltisslepedfavyycqqrsnwpgftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
523,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
524,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvnsiylawhqqkpgqaprlliygassraigipdrfsdsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
525,not found,SARS-CoV-2,Homo sapiens (human),,etvltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlviygpstratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
526,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqdgvpsrfsgsgsgteftltisslqpedfatyycqqlnnypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
527,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisshlawyqqkpgkapkllifaastlqsgvpsrfsgsgsgtefsltisslqpadfatyfcqhlemfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
528,not found,SARS-CoV-2,Homo sapiens (human),,divltqtplsspvtlgqpasiscrssqglvhsdgntylswlhqrpgqpprvliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqvtqfpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
529,not found,SARS-CoV-2,Homo sapiens (human),,kiqmtqspsslsasvgdrviitcqasqdinkylhwyqqkpgeapklviydasnletgvpsrfsgsgsgtdftftisslqpedlaryycqqydnlpptfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
530,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
531,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlqisrveaedvgvyycmqttqfpdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
532,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtltcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqelnsypffgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
533,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
534,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqvisnslnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
535,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistwlawyqqkpgkvpkllihkasnlhsgvpsrfsgsgsgteftltinslqpedfatyycqqynsystwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
536,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
537,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
538,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrashsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltitslqsediavyycqqynnwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
539,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
540,not found,SARS-CoV-2,Homo sapiens (human),,yiqmtqspsslsasvgdrvtitcrasqnidtylnwyqqtpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyscqqsysspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
541,not found,SARS-CoV-2,Homo sapiens (human),,nivltqspaalsfspgeratlscrasqsvsiflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
542,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasglqsgvpsrfsgsgsgtdftltissllpedfatyycqqsyrtpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
543,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygpssratgipdrfsgsgsgtdftltinrlepedfavyycqqydrspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
544,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsasssylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyychqfgssfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
545,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssrylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
546,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvgsnylawyqqkpgqsprlliyatssraigfpdrfigsgsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
547,not found,SARS-CoV-2,Homo sapiens (human),,evvltqspgtlslspgeratlscrasqglsssslawyqqrpgqaprlliygasnratgisdrfsgsgsgtdftlsvsrlepedfavyycqqysnspltfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
548,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtftcrasqaissklvwyqqkpgkapkvlisdasslqsgapsrfsgsgsgtdftltisslqpedfatyycqqakslpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
549,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrstqsfagsylawyqqkagqaprllihgassrapgipdrfsgsgsgtdftltisrlepedfavyycqqyggsqwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
550,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqlygssprytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
551,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratisckssqtvffisnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
552,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllmygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssvvtfgggttveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
553,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynnwppwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
554,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlcvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
555,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
556,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsvsvgdrvtitcrasqsisnylnwyqqkpgkapnllifaasslqrgvpsrfsgsgsgtdftltisslqpedfaayycqqsystpltfgqgtkvevn,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
557,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstflawyqqkagqaprlliygastrapgipdrfsgsgsgtdftltisrlepedfavyycqqfgssltfgggskveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
558,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsgtylawyqqkpgqaprlliygassrasgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
559,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysrdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
560,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgtapklliysasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysiprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
561,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplslpvtpgepasfscrssqslldsddgntyldwylqkpgqspqlliysvsyrasgvpdrvsgsgsgtdftlkisrveaedvgvyycmqrtefpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
562,not found,SARS-CoV-2,Homo sapiens (human),,qtvviqepsfsvspggtvtltcglssgsvssnyyptwykqtpgqapstliyttntrssgvpdrfsgsilgnkaaltitgaqaddeceyhcalymgsgiwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
563,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsespgqsitisctgtssdvgnynlvswyqhhpgkapklmiyevtkrpsgvsirfsgsksgntasltvsglqtedeadyyccsyagnstlvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
564,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgspgqsvtisctgtssdigsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytsnntfvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
565,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvihedfkrpsgiperfsgsssgtmatltirraqaedeadyycystdnsgnrvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
566,not found,SARS-CoV-2,Homo sapiens (human),,pyeltqppsvsvspgqtaritcsgdalprqfaywyqqkpgqapvlliykdterpsriperfsgsssgttftltisgvqaedeadyycqsaenggtypvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
567,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgttsdvggynyvswyqqhpgkapkvmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
568,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasatpgqrvtiscsgsssnigsnpvnwyqqlpgtapklliynndqrpsrvpdrfsgsksgtsaslaisglqsedeadyycaawddslnglwvfgggtkmtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
569,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgrnsdigsntvnwyqqfpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddrlhgwvfgggtklavl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
570,not found,SARS-CoV-2,Homo sapiens (human),,sfvltqppsvsvapgqtaritcggnniggktvhwyqqkpgqapvlvvhddsdrpsgiperfsgsnsgntatltisrvelgdeadyycqvwdssgghfyvfgagtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
571,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsmsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliynsnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycaawdsslsayvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
572,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnfvywyqqfpgtapkvliyrnslrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsarwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
573,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagnnnfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
574,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnsvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
575,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgnssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
576,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqaasvsgtpgqsitisctgtisnigsynyvswyqqhpgkapklliyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
577,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiyevsnwpsgvsnrfsgsksgntasltisglqaedeadyycssytssitlyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
578,not found,SARS-CoV-2,Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrnyyanwyqqkpgqapvfvingknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
579,not found,SARS-CoV-2,Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapilviygqskrpsgipdrfsgstsgntasltitgaqaedeadyycssrdssgnhlvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
580,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgapgqrvtisctgsssnigagydvhwyqqlpgtppklliygndnrpsgvpdrfsgsksgtsaslaitglqvedeadyycqsydsslsgslfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
581,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigigyavhwyqqlpgtapkllifgtsrrpsgvpdrfsgsrsgtsaslaitglqaedeavyycqsydnsqtdsvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
582,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgppgqsvtisctgtssdvggyhyvswyqqhpgkapklmiygvtrrpsgvpdrfsgsksgntasltvsglqaddeadyycssyagsntvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
583,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsskdmifgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
584,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnpvswyqqlpgtapkllmydndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddtlnghfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
585,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
586,not found,SARS-CoV-2,Homo sapiens (human),,qsvlmqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydnslsdvlfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
587,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
588,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgiapklliygnnirpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
589,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgapgqrvtisctgsssnigsgyvvhwyqhlpntapkllifgnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
590,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvgkrpsgvpdrfsgsksdntasltisglqaedeadyyccsyagspwvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
591,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsittsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsnyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
592,not found,SARS-CoV-2,Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhhvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
593,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtstdvggydyvswyqqhpgkapkvmiygvsnrpsgvssrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
594,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagyvvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqsydsrlfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
595,not found,SARS-CoV-2,Homo sapiens (human),,sfeltqppsvsvspgqtarircsgnalprryaywyqqkpgqapvlviykdserpsgiperfssstsgttvtltisgvqaedeadyycqssdsngsymfgggtkltal,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
596,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvtnrppgvsnrfsgsksgntasltisglqaedeadyycssytststrvfgggtyltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
597,PYLQ7,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VB: Chain E, pYLQ7 T cell receptor beta chain",2022-03-01
598,PYLQ7,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VA: Chain D, pYLQ7 T cell receptor alpha chain",2022-03-01
599,PRLQ3,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VB: Chain E, pRLQ3 T cell receptor beta chain",2022-03-01
600,PRLQ3,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VA: Chain D, pRLQ3 T cell receptor alpha chain",2022-03-01
601,PYLQ7,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VB: Chain B, pYLQ7 T cell receptor beta chain",2022-03-01
602,PYLQ7,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VA: Chain A, pYLQ7 T cell receptor alpha chain",2022-03-01
603,PRLQ3,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VB: Chain E, pRLQ3 T cell receptor beta chain",2022-03-01
604,PRLQ3,"SARS-CoV-2, Spike protein",Homo sapiens (human),,,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.","VA: Chain D, pRLQ3 T cell receptor alpha chain",2022-03-01
605,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscaasgftfrrylmgwarqvpgkglewvsgiysdgstyyadsvkgrftisrdnakntvylqmnslkpedtavyycakdrmdgstwperdfgswgqgtqvtvss,,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.","VH: Chain A, WNb 10",2022-03-01
606,not found,SARS-CoV-2,Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssggntkyadsvkgrftasrdnakntfylqmnslkpedtavyycaaiaatyysgsyyfqcphdgmdywgkgtqvtvss,,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.","VH: Chain C, WNb 2",2022-03-01
607,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.","VH: Chain F, Sybody 23",2022-03-01
608,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.","VH: Chain E, Sybody 23",2022-03-01
609,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.","VH: Chain D, Sybody 23",2022-03-01
610,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggtggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggsggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvss,,"Bracken,C.J. et al.; Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike; bioRxiv (2020); 2020.","VH: Chain D, autonomous human heavy chain variable domain",2022-03-01
611,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.","VH: Chain B, IgG H chain",2022-03-01
612,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.","VH: Chain H, IgG H chain",2022-03-01
613,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.","VL: Chain C, IgG L chain",2022-03-01
614,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.","VL: Chain L, IgG L chain",2022-03-01
615,not found,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvsshhhhhh,,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.","VH: Chain D, nanobody",2022-03-01
616,not found,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvsshhhhhh,,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.","VH: Chain C, nanobody",2022-03-01
617,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardirdssgwanwfdpwgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
618,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmssyywswirqppgkglewigyiynsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarlegegqlvdyygmdvwgqgttvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
619,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqsgrslrlscaasgftfssyamhwvrqapgkglewvavishdgsntyyedsvkgrftisrdnskntlhlqvnslrvedtavyycarakgevryfdwaeqggdywgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
620,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfstyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymglsslrsedtavyycarwvtaygdyvpfdpwgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
621,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycardivgateidywgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
622,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsryaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymevsslrsedtavyycarktyyydssgypeafdiwgqgtmvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
623,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslhlqmnslraedtalyycanlltpprrysgydlredyfeywgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
624,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfspysmnwvrqapgkglewvssisvsniytyyadsvkgrftisrdnaknslylqmnslraedtaiyycardlkkggiqydafdiwgqgtvvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
625,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
626,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
627,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvmviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
628,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdnsgdhgvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
629,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
630,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
631,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
632,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydrnnrpsgipdrfsgsssgntasltitgaqaedeadyychsrdssgnplhvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
633,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvndylawyqqkpgqaprlliydasnratgfparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtrleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
634,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
635,not found,SARS-CoV,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VH: Chain H, IGG Heavy Chain",2022-03-01
636,not found,SARS-CoV,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VH: Chain C, IGG Heavy Chain",2022-03-01
637,not found,SARS-CoV,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VH: Chain A, IGG Heavy Chain",2022-03-01
638,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VL: Chain L, IGG Light Chain",2022-03-01
639,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VL: Chain D, IGG Light Chain",2022-03-01
640,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.","VL: Chain B, IGG Light Chain",2022-03-01
641,not found,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",2022-03-01
642,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgyslievsvhwvrqapgkglewmggfdpenaetiyaqkfqgrvtmtedtstdtaymelsslkyedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
643,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvhlvqsgaevkkpgasvkvsckvsgytlvevsvhwvrqapgkgfewmggfdpenaatiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagplyyyyygmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
644,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
645,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaktiyaqkfqgrvtmtedtstdtaymelsslssedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
646,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapekglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
647,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfynfyygidvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
648,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
649,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
650,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgkglewvaviwydgsnqyyadsvkgrftisrdnskntlylqmnslrvedtavyhcvretvdgmdvwgqgttvtvss,,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VH: anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",2022-03-01
651,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
652,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
653,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
654,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
655,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrlrdqlmglimlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprliiykvsnrfcgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
656,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
657,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
658,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
659,not found,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.","VL: anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-01
660,not found,SARS-CoV-2,Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 440 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 440 from patent US 11034762,2022-03-01
661,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywiswvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgiiqpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 377 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 377 from patent US 11034762,2022-03-01
662,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgstasyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 376 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 376 from patent US 11034762,2022-03-01
663,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 375 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 375 from patent US 11034762,2022-03-01
664,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipvlhtvdyaqrlqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 374 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 374 from patent US 11034762,2022-03-01
665,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 373 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 373 from patent US 11034762,2022-03-01
666,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgynftdyhiqwvrqapgqglewvgmiiprhggtayaqrfqgrvtitadeststaymelsslrsedtavyycaggsglttpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 372 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 372 from patent US 11034762,2022-03-01
667,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtlssyaiswvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistprsvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 371 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 371 from patent US 11034762,2022-03-01
668,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggegistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 370 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 370 from patent US 11034762,2022-03-01
669,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpysgntgyaqkfqgrvtitadeststaymelsslrsedtavyycavlsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 369 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 369 from patent US 11034762,2022-03-01
670,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfstywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 368 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 368 from patent US 11034762,2022-03-01
671,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdstarysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistlydvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 367 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 367 from patent US 11034762,2022-03-01
672,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgqinpsgdstryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 366 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 366 from patent US 11034762,2022-03-01
673,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfisyaiswvrqapgqglewmggiiptlgtynyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 365 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 365 from patent US 11034762,2022-03-01
674,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 364 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 364 from patent US 11034762,2022-03-01
675,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgilepmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 363 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 363 from patent US 11034762,2022-03-01
676,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 362 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 362 from patent US 11034762,2022-03-01
677,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 361 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 361 from patent US 11034762,2022-03-01
678,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 360 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 360 from patent US 11034762,2022-03-01
679,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 359 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 359 from patent US 11034762,2022-03-01
680,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 358 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 358 from patent US 11034762,2022-03-01
681,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsglltpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 357 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 357 from patent US 11034762,2022-03-01
682,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnnglswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycrmgsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 356 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 356 from patent US 11034762,2022-03-01
683,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgwinpnsggtkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpidvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 355 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 355 from patent US 11034762,2022-03-01
684,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 354 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 354 from patent US 11034762,2022-03-01
685,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 353 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 353 from patent US 11034762,2022-03-01
686,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgypftnygiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycatlsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 352 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 352 from patent US 11034762,2022-03-01
687,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetnysqkfqgrvtitadeststaymelsslrsedtavyycaggsglftpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 351 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 351 from patent US 11034762,2022-03-01
688,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttnysqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 350 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 350 from patent US 11034762,2022-03-01
689,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgiyvpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 349 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 349 from patent US 11034762,2022-03-01
690,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 348 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 348 from patent US 11034762,2022-03-01
691,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyyihwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 347 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 347 from patent US 11034762,2022-03-01
692,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysftdyhihwvrqapgqglewmamivprggsttyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 346 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 346 from patent US 11034762,2022-03-01
693,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgyrftdyhlhwvrqapgqglewmggivpfsgttnfaqkfqgrvtitadeststaymelsslrsedtavyycaggsgettpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 345 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 345 from patent US 11034762,2022-03-01
694,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiiptlgtanyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 344 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 344 from patent US 11034762,2022-03-01
695,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfstywigwvrqapgqglewvgwinpnsgatkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 343 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 343 from patent US 11034762,2022-03-01
696,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 342 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 342 from patent US 11034762,2022-03-01
697,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgissdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 341 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 341 from patent US 11034762,2022-03-01
698,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgvltpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 340 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 340 from patent US 11034762,2022-03-01
699,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsglytpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 339 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 339 from patent US 11034762,2022-03-01
700,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfstyafnwvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpgavwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 338 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 338 from patent US 11034762,2022-03-01
701,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyyclpgsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 337 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 337 from patent US 11034762,2022-03-01
702,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 336 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 336 from patent US 11034762,2022-03-01
703,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwmrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 335 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 335 from patent US 11034762,2022-03-01
704,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgminpgggntnyaekfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 334 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 334 from patent US 11034762,2022-03-01
705,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 333 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 333 from patent US 11034762,2022-03-01
706,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaavsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 332 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 332 from patent US 11034762,2022-03-01
707,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfstywigwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 331 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 331 from patent US 11034762,2022-03-01
708,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgsvipvfgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 330 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 330 from patent US 11034762,2022-03-01
709,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnssinwvrqapgqglewmgrinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 329 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 329 from patent US 11034762,2022-03-01
710,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfnshaiswvrqapgqglewmgwinpnsgatnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpvgvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 328 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 328 from patent US 11034762,2022-03-01
711,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 327 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 327 from patent US 11034762,2022-03-01
712,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyhvhwvrqapgqglewvgmiiprhggtayaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 326 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 326 from patent US 11034762,2022-03-01
713,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyihwvrqapgqglewmgwmnpnsgntgyaqnfqgrvtitadeststaymelsslrsedtavyycaggsgistawdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 325 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 325 from patent US 11034762,2022-03-01
714,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywiywvrqapgqglewmgiiypgdgearysqkfygrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 324 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 324 from patent US 11034762,2022-03-01
715,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 323 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 323 from patent US 11034762,2022-03-01
716,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 322 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 322 from patent US 11034762,2022-03-01
717,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnhaiswvrqaygqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 321 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 321 from patent US 11034762,2022-03-01
718,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 320 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 320 from patent US 11034762,2022-03-01
719,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiidpsggstsyaqqfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 319 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 319 from patent US 11034762,2022-03-01
720,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 318 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 318 from patent US 11034762,2022-03-01
721,not found,SARS-CoV-2,Unknown.,,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 441 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 441 from patent US 11034762,2022-03-01
722,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 437 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 437 from patent US 11034762,2022-03-01
723,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywsslresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytapftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 436 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 436 from patent US 11034762,2022-03-01
724,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 435 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 435 from patent US 11034762,2022-03-01
725,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 434 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 434 from patent US 11034762,2022-03-01
726,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 433 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 433 from patent US 11034762,2022-03-01
727,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqhyyntpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 432 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 432 from patent US 11034762,2022-03-01
728,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssrilsyspdnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqsyitpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 431 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 431 from patent US 11034762,2022-03-01
729,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 430 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 430 from patent US 11034762,2022-03-01
730,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywatnresgvpdrfsgsgsgtdftltisslqaedvavyychqyyntpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 429 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 429 from patent US 11034762,2022-03-01
731,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyrsnnlhylawyqqkpgqppklliywastrssgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 428 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 428 from patent US 11034762,2022-03-01
732,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinctssqsvlhssnnlnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 427 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 427 from patent US 11034762,2022-03-01
733,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlhssnnlnyfawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 426 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 426 from patent US 11034762,2022-03-01
734,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 425 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 425 from patent US 11034762,2022-03-01
735,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckstqsvlyssinknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 424 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 424 from patent US 11034762,2022-03-01
736,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 423 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 423 from patent US 11034762,2022-03-01
737,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 422 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 422 from patent US 11034762,2022-03-01
738,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 421 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 421 from patent US 11034762,2022-03-01
739,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 420 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 420 from patent US 11034762,2022-03-01
740,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 419 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 419 from patent US 11034762,2022-03-01
741,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 418 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 418 from patent US 11034762,2022-03-01
742,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 417 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 417 from patent US 11034762,2022-03-01
743,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqtisyssdnknylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 416 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 416 from patent US 11034762,2022-03-01
744,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliyrastrasgvpdrfsgsgsgtdftltisslqaedvavyycqqyystvitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 415 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 415 from patent US 11034762,2022-03-01
745,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 414 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 414 from patent US 11034762,2022-03-01
746,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 413 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 413 from patent US 11034762,2022-03-01
747,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratincrssqsvlyssnnknyfawyqqkpgqppklliywasirgsgvpdrfsgsgsgtdftltisslqaedvavyychqyyttpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 412 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 412 from patent US 11034762,2022-03-01
748,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 411 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 411 from patent US 11034762,2022-03-01
749,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 410 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 410 from patent US 11034762,2022-03-01
750,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 409 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 409 from patent US 11034762,2022-03-01
751,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlhsainknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 408 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 408 from patent US 11034762,2022-03-01
752,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 407 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 407 from patent US 11034762,2022-03-01
753,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 406 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 406 from patent US 11034762,2022-03-01
754,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 405 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 405 from patent US 11034762,2022-03-01
755,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 404 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 404 from patent US 11034762,2022-03-01
756,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvfhssnnknhlawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 403 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 403 from patent US 11034762,2022-03-01
757,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasmresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 402 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 402 from patent US 11034762,2022-03-01
758,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrefgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 401 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 401 from patent US 11034762,2022-03-01
759,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyatpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 400 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 400 from patent US 11034762,2022-03-01
760,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhtipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 399 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 399 from patent US 11034762,2022-03-01
761,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastraagvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 398 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 398 from patent US 11034762,2022-03-01
762,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqrvlyssnnlnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 397 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 397 from patent US 11034762,2022-03-01
763,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaytrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 396 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 396 from patent US 11034762,2022-03-01
764,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasnrepgvpdrfsgsgsgtdftltisslqaedvavyfchqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 395 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 395 from patent US 11034762,2022-03-01
765,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygfpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 394 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 394 from patent US 11034762,2022-03-01
766,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnlnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 393 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 393 from patent US 11034762,2022-03-01
767,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratincrssqtvlyrsnnynylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 392 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 392 from patent US 11034762,2022-03-01
768,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnknnylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 391 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 391 from patent US 11034762,2022-03-01
769,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyyyapwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 390 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 390 from patent US 11034762,2022-03-01
770,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastrasgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 389 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 389 from patent US 11034762,2022-03-01
771,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 388 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 388 from patent US 11034762,2022-03-01
772,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 387 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 387 from patent US 11034762,2022-03-01
773,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastrdfgvpdrfsgsgsgtdftltisslqaedvavyycqqyyalpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 386 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 386 from patent US 11034762,2022-03-01
774,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratirctsslslqdrsnnknyltwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhysapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 385 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 385 from patent US 11034762,2022-03-01
775,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 384 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 384 from patent US 11034762,2022-03-01
776,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaniresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 383 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 383 from patent US 11034762,2022-03-01
777,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 382 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 382 from patent US 11034762,2022-03-01
778,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 381 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 381 from patent US 11034762,2022-03-01
779,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 380 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 380 from patent US 11034762,2022-03-01
780,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 379 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 379 from patent US 11034762,2022-03-01
781,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 378 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 378 from patent US 11034762,2022-03-01
782,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgiinprggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctreakpqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 208 from patent US 11028167,2022-03-01
783,not found,SARS-CoV-2,Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 199 from patent US 11028167,2022-03-01
784,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpngggtyyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 168 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 168 from patent US 11028167,2022-03-01
785,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 167 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 167 from patent US 11028167,2022-03-01
786,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregppqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 166 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 166 from patent US 11028167,2022-03-01
787,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfteyemhwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 165 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 165 from patent US 11028167,2022-03-01
788,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgmvdpnsgntyyaqkfqgrftmtrdtststvymelsslrsedtavyyctregipqllgtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 164 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 164 from patent US 11028167,2022-03-01
789,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfsdyymhwvrqapgqglewmgiidpsggsasyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 163 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 163 from patent US 11028167,2022-03-01
790,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgysftsyeihwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 162 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 162 from patent US 11028167,2022-03-01
791,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvinpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrhldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 161 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 161 from patent US 11028167,2022-03-01
792,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 160 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 160 from patent US 11028167,2022-03-01
793,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgminpsggytnyaqefqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 159 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 159 from patent US 11028167,2022-03-01
794,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpdggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 158 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 158 from patent US 11028167,2022-03-01
795,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgydfinyyihwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 157 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 157 from patent US 11028167,2022-03-01
796,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfasydvnwvrqapgqglewmgiinprsgdanyaqkfqgrvtmtrdtststvymelsslrsedtavyyctrerhpqllmpldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 156 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 156 from patent US 11028167,2022-03-01
797,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsysmhwvrqapgqglewmgaiypgnsdttyaqkfqgrvtmtrdtststvymelsslrsedtavyyctldgipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 155 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 155 from patent US 11028167,2022-03-01
798,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipwwlrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 154 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 154 from patent US 11028167,2022-03-01
799,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfgnyainwvrqapgqglewmgaiypgnsdttynqkfqgrvtmtrdtststvymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 153 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 153 from patent US 11028167,2022-03-01
800,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyrftsyevnwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllwaldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 152 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 152 from patent US 11028167,2022-03-01
801,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 151 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 151 from patent US 11028167,2022-03-01
802,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 150 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 150 from patent US 11028167,2022-03-01
803,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgdiwrlhwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 149 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 149 from patent US 11028167,2022-03-01
804,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgntftgyymhwvrqapgqglewmgaiypggsdtsynqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlawtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 148 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 148 from patent US 11028167,2022-03-01
805,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvvnpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrsqdywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 147 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 147 from patent US 11028167,2022-03-01
806,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftshdinwvrqapgqglewmgminpsggytsyaqnfqgrvtmtrdtststvymelsslrsedtavyyctregipallrtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 146 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 146 from patent US 11028167,2022-03-01
807,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgvinpsgghtnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlagtldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 145 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 145 from patent US 11028167,2022-03-01
808,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgidtylnwyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpediatyycqqydnlpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 209 from patent US 11028167,2022-03-01
809,not found,SARS-CoV-2,Unknown.,,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 200 from patent US 11028167,2022-03-01
810,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysapytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 192 from patent US 11028167,2022-03-01
811,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnplhfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 191 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 191 from patent US 11028167,2022-03-01
812,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyhtsnletgvpsrfsgsgsgtdftltisslqpedfatyycqqsysfpattfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 190 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 190 from patent US 11028167,2022-03-01
813,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 189 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 189 from patent US 11028167,2022-03-01
814,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkggdqt,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 188 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 188 from patent US 11028167,2022-03-01
815,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqvgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlavtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 187 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 187 from patent US 11028167,2022-03-01
816,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 186 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 186 from patent US 11028167,2022-03-01
817,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgswtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 185 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 185 from patent US 11028167,2022-03-01
818,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 184 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 184 from patent US 11028167,2022-03-01
819,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsiyrwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsygnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 183 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 183 from patent US 11028167,2022-03-01
820,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 182 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 182 from patent US 11028167,2022-03-01
821,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqdisdslawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysrlawtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 181 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 181 from patent US 11028167,2022-03-01
822,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlesgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 180 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 180 from patent US 11028167,2022-03-01
823,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygvsslhsgvpsrfsgsgsgtdftltisslqpedfatyyclqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 179 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 179 from patent US 11028167,2022-03-01
824,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpewtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 178 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 178 from patent US 11028167,2022-03-01
825,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqeisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 177 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 177 from patent US 11028167,2022-03-01
826,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 176 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 176 from patent US 11028167,2022-03-01
827,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsirtylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 175 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 175 from patent US 11028167,2022-03-01
828,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 174 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 174 from patent US 11028167,2022-03-01
829,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqeissylswyqqkpgkapklliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqynsypltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 173 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 173 from patent US 11028167,2022-03-01
830,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpediatyycqqfgsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 172 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 172 from patent US 11028167,2022-03-01
831,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 171 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 171 from patent US 11028167,2022-03-01
832,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 170 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 170 from patent US 11028167,2022-03-01
833,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisgylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 169 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 169 from patent US 11028167,2022-03-01
834,not found,SARS-CoV-2,Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 280 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 280 from patent US 11028150,2022-03-01
835,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggsfsrfpiswvrqapgqglewmggiipifgtanyaqrfqgrvtitadeststaymelsslrsedtavyycaletvmgglqvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 232 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 232 from patent US 11028150,2022-03-01
836,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftafyihwvrqapgqglewmggiipisgtanyaqkfqgratitadeststaymelsslrsedtavyycarevvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 231 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 231 from patent US 11028150,2022-03-01
837,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswmrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsnlrsedtavyycardtywggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 230 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 230 from patent US 11028150,2022-03-01
838,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssfaiiwvrqapgqglewmalinpssgttsyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 229 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 229 from patent US 11028150,2022-03-01
839,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgntfsmfainwvrqapgqglewvgvinpigstttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 228 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 228 from patent US 11028150,2022-03-01
840,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 227 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 227 from patent US 11028150,2022-03-01
841,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggmqmwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 226 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 226 from patent US 11028150,2022-03-01
842,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 225 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 225 from patent US 11028150,2022-03-01
843,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfylhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 224 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 224 from patent US 11028150,2022-03-01
844,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyyvhwvrqapgqglewmggilpilgtphyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmtawgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 223 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 223 from patent US 11028150,2022-03-01
845,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggftvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 222 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 222 from patent US 11028150,2022-03-01
846,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgiinpsggstsyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmgvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 221 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 221 from patent US 11028150,2022-03-01
847,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtakyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 220 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 220 from patent US 11028150,2022-03-01
848,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftgfymqwvrqapgqglewmggitpilgtanyaqkfqgrvtitadeststaymelsslrsedtavyycareivmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 219 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 219 from patent US 11028150,2022-03-01
849,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinyeihwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 218 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 218 from patent US 11028150,2022-03-01
850,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnafyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 217 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 217 from patent US 11028150,2022-03-01
851,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfdinwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycgmdtvmggmtswgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 216 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 216 from patent US 11028150,2022-03-01
852,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfhmhwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 215 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 215 from patent US 11028150,2022-03-01
853,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtffggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 214 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 214 from patent US 11028150,2022-03-01
854,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 213 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 213 from patent US 11028150,2022-03-01
855,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgymftefymhwvrqapgqglewmggiipvsgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 212 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 212 from patent US 11028150,2022-03-01
856,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssyyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 211 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 211 from patent US 11028150,2022-03-01
857,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgstfsmfainwvrqapgqglewvgvinprgssttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 210 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 210 from patent US 11028150,2022-03-01
858,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgyaftsyymhwvrqapgqglewmgvidpsegstsnarkfqgrvtitadeststaymelsslrsedtavyycvsdtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 209 from patent US 11028150,2022-03-01
859,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfgnypitwvrqapgqglewmgiiypgdsdaryrpsfqgrvtitadeststaymelsslrsedtavyycardfsmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 208 from patent US 11028150,2022-03-01
860,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaltwvrqapgqglewmglinpsggstsyaqrfqgrvtitadeststaymelsslrsedtavyycardsvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 207 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 207 from patent US 11028150,2022-03-01
861,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgypfssyeinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycadetvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 206 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 206 from patent US 11028150,2022-03-01
862,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 205 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 205 from patent US 11028150,2022-03-01
863,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnytitwvrqapgqglewlgwisayngntdyaqklqgrvtitadeststaymelsslrsedtavyycardalmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 204 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 204 from patent US 11028150,2022-03-01
864,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsfdihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycayetvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 203 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 203 from patent US 11028150,2022-03-01
865,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaitwvrqapgqglewmgvinpgggsttyaqtfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 202 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 202 from patent US 11028150,2022-03-01
866,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsayymhwvrqapgqglewmggitplfgtpsyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggvgvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 201 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 201 from patent US 11028150,2022-03-01
867,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgynfinyylhwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 200 from patent US 11028150,2022-03-01
868,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfnrfamtwvrqapgqglewmgtinpsggstiytqrfqgrvtitadeststaymelsslrsedtavyycghdtvmggmgewgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 199 from patent US 11028150,2022-03-01
869,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgiidpiggttnyaqkfqgrvtitadeststaymelsslrsedtavyycardtvgfgmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 198 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 198 from patent US 11028150,2022-03-01
870,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsrydinwvrqapgqglewmgiinpsggsttyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 197 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 197 from patent US 11028150,2022-03-01
871,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfhinwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 196 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 196 from patent US 11028150,2022-03-01
872,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnnydlhwvrqapgqglewmggiipifdtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmvkwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 195 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 195 from patent US 11028150,2022-03-01
873,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmglidpsggttsyaqkfqgrvtitadeststaymelsslrsedtavyycvwdtvmggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 194 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 194 from patent US 11028150,2022-03-01
874,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtywggmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 193 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 193 from patent US 11028150,2022-03-01
875,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgctftrftmhwvrqapgqglewmggitpifgitnyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmeewgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 192 from patent US 11028150,2022-03-01
876,not found,SARS-CoV-2,Unknown.,,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 281 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 281 from patent US 11028150,2022-03-01
877,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 273 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 273 from patent US 11028150,2022-03-01
878,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 272 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 272 from patent US 11028150,2022-03-01
879,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 271 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 271 from patent US 11028150,2022-03-01
880,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 270 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 270 from patent US 11028150,2022-03-01
881,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwvsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 269 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 269 from patent US 11028150,2022-03-01
882,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdshsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 268 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 268 from patent US 11028150,2022-03-01
883,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 267 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 267 from patent US 11028150,2022-03-01
884,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 266 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 266 from patent US 11028150,2022-03-01
885,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 265 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 265 from patent US 11028150,2022-03-01
886,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 264 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 264 from patent US 11028150,2022-03-01
887,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 263 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 263 from patent US 11028150,2022-03-01
888,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 262 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 262 from patent US 11028150,2022-03-01
889,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 261 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 261 from patent US 11028150,2022-03-01
890,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 260 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 260 from patent US 11028150,2022-03-01
891,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 259 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 259 from patent US 11028150,2022-03-01
892,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdgssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 258 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 258 from patent US 11028150,2022-03-01
893,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsshdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 257 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 257 from patent US 11028150,2022-03-01
894,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 256 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 256 from patent US 11028150,2022-03-01
895,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 255 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 255 from patent US 11028150,2022-03-01
896,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 254 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 254 from patent US 11028150,2022-03-01
897,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 253 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 253 from patent US 11028150,2022-03-01
898,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 252 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 252 from patent US 11028150,2022-03-01
899,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdrssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 251 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 251 from patent US 11028150,2022-03-01
900,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 250 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 250 from patent US 11028150,2022-03-01
901,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwddssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 249 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 249 from patent US 11028150,2022-03-01
902,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 248 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 248 from patent US 11028150,2022-03-01
903,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 247 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 247 from patent US 11028150,2022-03-01
904,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 246 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 246 from patent US 11028150,2022-03-01
905,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 245 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 245 from patent US 11028150,2022-03-01
906,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 244 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 244 from patent US 11028150,2022-03-01
907,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 243 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 243 from patent US 11028150,2022-03-01
908,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveavdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 242 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 242 from patent US 11028150,2022-03-01
909,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnkigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 241 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 241 from patent US 11028150,2022-03-01
910,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqstdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 240 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 240 from patent US 11028150,2022-03-01
911,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 239 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 239 from patent US 11028150,2022-03-01
912,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 238 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 238 from patent US 11028150,2022-03-01
913,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 237 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 237 from patent US 11028150,2022-03-01
914,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrieagdeadyycqvwdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 236 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 236 from patent US 11028150,2022-03-01
915,not found,SARS-CoV-2,Unknown.,,syvltqppsvsvapgktaaritcggnnigsksvhwyqqkpgqapvlviykdgerpsgiperfsgsnsrntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 235 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 235 from patent US 11028150,2022-03-01
916,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 234 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 234 from patent US 11028150,2022-03-01
917,not found,SARS-CoV-2,Unknown.,,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 233 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 233 from patent US 11028150,2022-03-01
918,not found,SARS-CoV-2,Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 497 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 497 from patent US 11053304,2022-03-01
919,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 428 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 428 from patent US 11053304,2022-03-01
920,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 427 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 427 from patent US 11053304,2022-03-01
921,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsvisasggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 426 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 426 from patent US 11053304,2022-03-01
922,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 425 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 425 from patent US 11053304,2022-03-01
923,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafssyalhwvrqapgkglewvsaisgsggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 424 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 424 from patent US 11053304,2022-03-01
924,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 423 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 423 from patent US 11053304,2022-03-01
925,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 422 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 422 from patent US 11053304,2022-03-01
926,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 421 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 421 from patent US 11053304,2022-03-01
927,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 420 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 420 from patent US 11053304,2022-03-01
928,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfpfslygmhwvrqapgkglewvavitsdgrskfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 419 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 419 from patent US 11053304,2022-03-01
929,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgitfnnyamtwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycvtqrdnpvdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 418 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 418 from patent US 11053304,2022-03-01
930,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfddfgmhwyrqapgkglewvsatsgggsityyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 417 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 417 from patent US 11053304,2022-03-01
931,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfkfntyamhwvrqapgkglewvsaisitggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 416 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 416 from patent US 11053304,2022-03-01
932,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 415 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 415 from patent US 11053304,2022-03-01
933,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfrsygmhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnfdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 414 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 414 from patent US 11053304,2022-03-01
934,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 413 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 413 from patent US 11053304,2022-03-01
935,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifndygmhwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 412 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 412 from patent US 11053304,2022-03-01
936,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 411 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 411 from patent US 11053304,2022-03-01
937,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsvitgdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 410 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 410 from patent US 11053304,2022-03-01
938,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisrsgdsayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 409 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 409 from patent US 11053304,2022-03-01
939,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 408 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 408 from patent US 11053304,2022-03-01
940,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfntyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 407 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 407 from patent US 11053304,2022-03-01
941,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 406 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 406 from patent US 11053304,2022-03-01
942,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 405 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 405 from patent US 11053304,2022-03-01
943,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsgissggsgthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 404 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 404 from patent US 11053304,2022-03-01
944,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 403 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 403 from patent US 11053304,2022-03-01
945,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfsrygmhwvrqapgkglewvsgisadggtayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 402 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 402 from patent US 11053304,2022-03-01
946,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygvhwvrqapgkglewvavishdgkkkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnvdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 401 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 401 from patent US 11053304,2022-03-01
947,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsgisgggagtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtyrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 400 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 400 from patent US 11053304,2022-03-01
948,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsgisgsgdrtyyadsvkgrftisrdnskntlylqmnslraedtavyycsmqrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 399 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 399 from patent US 11053304,2022-03-01
949,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfhdyamhwvrqapgkglewvavtsydgntkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 398 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 398 from patent US 11053304,2022-03-01
950,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfgtsavswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 397 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 397 from patent US 11053304,2022-03-01
951,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaysgsggytyfadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 396 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 396 from patent US 11053304,2022-03-01
952,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavvsrsggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 395 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 395 from patent US 11053304,2022-03-01
953,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvaaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 394 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 394 from patent US 11053304,2022-03-01
954,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisassagayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 393 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 393 from patent US 11053304,2022-03-01
955,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsringdgsttgyadsvkgrftisrdnskntlylqmnslraedtavyycvttgdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 392 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 392 from patent US 11053304,2022-03-01
956,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsshtiawvrqapgkglewlshisssgsttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdmsphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 391 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 391 from patent US 11053304,2022-03-01
957,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvaaigasgestyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfplwfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 390 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 390 from patent US 11053304,2022-03-01
958,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstygmhwvrqapgkglewvstisgngvstsyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 389 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 389 from patent US 11053304,2022-03-01
959,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 388 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 388 from patent US 11053304,2022-03-01
960,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftftsygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 387 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 387 from patent US 11053304,2022-03-01
961,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfiftnyalhwvrqapgkglewvsaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 386 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 386 from patent US 11053304,2022-03-01
962,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvavisydgnyqyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 385 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 385 from patent US 11053304,2022-03-01
963,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifssyamnwvrqapgkglewvsgisgsgggayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 384 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 384 from patent US 11053304,2022-03-01
964,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfnnyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 383 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 383 from patent US 11053304,2022-03-01
965,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 382 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 382 from patent US 11053304,2022-03-01
966,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 381 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 381 from patent US 11053304,2022-03-01
967,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 380 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 380 from patent US 11053304,2022-03-01
968,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 379 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 379 from patent US 11053304,2022-03-01
969,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 378 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 378 from patent US 11053304,2022-03-01
970,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsavgdsgrstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 377 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 377 from patent US 11053304,2022-03-01
971,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 376 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 376 from patent US 11053304,2022-03-01
972,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifssfgmhwvrqapgkglewvsaisdsgdatqyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 375 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 375 from patent US 11053304,2022-03-01
973,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsavsttggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 374 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 374 from patent US 11053304,2022-03-01
974,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsaigtggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 373 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 373 from patent US 11053304,2022-03-01
975,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavishdasnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 372 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 372 from patent US 11053304,2022-03-01
976,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfsdhpmhwvrqapgkglewvavitgsgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 371 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 371 from patent US 11053304,2022-03-01
977,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsvisgsgrntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 370 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 370 from patent US 11053304,2022-03-01
978,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 369 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 369 from patent US 11053304,2022-03-01
979,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 368 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 368 from patent US 11053304,2022-03-01
980,not found,SARS-CoV-2,Unknown.,,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 498 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 498 from patent US 11053304,2022-03-01
981,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 490 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 490 from patent US 11053304,2022-03-01
982,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 489 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 489 from patent US 11053304,2022-03-01
983,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssrsllhtnglnyidwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyctqalqtpisfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 488 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 488 from patent US 11053304,2022-03-01
984,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalrtptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 487 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 487 from patent US 11053304,2022-03-01
985,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhrngynyvdwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlrisrveaedvgvyycmqarqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 486 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 486 from patent US 11053304,2022-03-01
986,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrapgvpdrfsgsgsgtdftlkisrveaedvgvyycaqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 485 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 485 from patent US 11053304,2022-03-01
987,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqllislgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 484 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 484 from patent US 11053304,2022-03-01
988,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 483 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 483 from patent US 11053304,2022-03-01
989,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssesllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyciqalqtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 482 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 482 from patent US 11053304,2022-03-01
990,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylssnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqspytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 481 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 481 from patent US 11053304,2022-03-01
991,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqvpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 480 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 480 from patent US 11053304,2022-03-01
992,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 479 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 479 from patent US 11053304,2022-03-01
993,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqaysfpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 478 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 478 from patent US 11053304,2022-03-01
994,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkitrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 477 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 477 from patent US 11053304,2022-03-01
995,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 476 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 476 from patent US 11053304,2022-03-01
996,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsirasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsqqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 475 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 475 from patent US 11053304,2022-03-01
997,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 474 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 474 from patent US 11053304,2022-03-01
998,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 473 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 473 from patent US 11053304,2022-03-01
999,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssksllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaaqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 472 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 472 from patent US 11053304,2022-03-01
1000,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyclqtlqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 471 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 471 from patent US 11053304,2022-03-01
1001,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgtnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppkfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 470 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 470 from patent US 11053304,2022-03-01
1002,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrsshsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqlphtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 469 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 469 from patent US 11053304,2022-03-01
1003,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylaanrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 468 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 468 from patent US 11053304,2022-03-01
1004,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyfgsnrasgvpdrfsgsgsgtdftlkisrvetedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 467 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 467 from patent US 11053304,2022-03-01
1005,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyqgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 466 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 466 from patent US 11053304,2022-03-01
1006,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaqqtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 465 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 465 from patent US 11053304,2022-03-01
1007,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllqsngdnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglhwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 464 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 464 from patent US 11053304,2022-03-01
1008,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 463 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 463 from patent US 11053304,2022-03-01
1009,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 462 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 462 from patent US 11053304,2022-03-01
1010,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsvqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 461 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 461 from patent US 11053304,2022-03-01
1011,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsvrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqgynmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 460 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 460 from patent US 11053304,2022-03-01
1012,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgletpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 459 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 459 from patent US 11053304,2022-03-01
1013,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasisckssqsllhingfnyldwflqkpgqspqlliylgsnrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqslqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 458 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 458 from patent US 11053304,2022-03-01
1014,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 457 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 457 from patent US 11053304,2022-03-01
1015,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhingynyldwflqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 456 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 456 from patent US 11053304,2022-03-01
1016,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngnnyldwylqkpgqspqlliyggsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsytppptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 454 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 454 from patent US 11053304,2022-03-01
1017,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyitpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 453 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 453 from patent US 11053304,2022-03-01
1018,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslldsngfnyldwylqkpgqspqlliylgssrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyntpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 452 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 452 from patent US 11053304,2022-03-01
1019,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 451 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 451 from patent US 11053304,2022-03-01
1020,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvysdgytylnwylqkpgqspqlliyqvsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 450 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 450 from patent US 11053304,2022-03-01
1021,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvhsdgytylnwylqkpgqspqlliyvgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqasqwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 449 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 449 from patent US 11053304,2022-03-01
1022,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllqsngynyldwylqkpgqspqlliylgynrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 448 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 448 from patent US 11053304,2022-03-01
1023,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrpsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtpfsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 447 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 447 from patent US 11053304,2022-03-01
1024,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaiqnrrtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 446 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 446 from patent US 11053304,2022-03-01
1025,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllqsngynymdwylqkpgqspqlliyltsnraagvpdrfsgsgsgtdftlkisrveaedvgvyycqqsygppltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 445 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 445 from patent US 11053304,2022-03-01
1026,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscssrqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycvqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 444 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 444 from patent US 11053304,2022-03-01
1027,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 443 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 443 from patent US 11053304,2022-03-01
1028,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 442 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 442 from patent US 11053304,2022-03-01
1029,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynrlawylqkpgqspqlliylgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 441 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 441 from patent US 11053304,2022-03-01
1030,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngnnymdwylqkpgqspqlliylasqrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 440 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 440 from patent US 11053304,2022-03-01
1031,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 439 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 439 from patent US 11053304,2022-03-01
1032,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 438 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 438 from patent US 11053304,2022-03-01
1033,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngyndldwylqkpgqspqlliyggsngasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 437 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 437 from patent US 11053304,2022-03-01
1034,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalhipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 436 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 436 from patent US 11053304,2022-03-01
1035,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 435 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 435 from patent US 11053304,2022-03-01
1036,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngyiyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlrtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 434 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 434 from patent US 11053304,2022-03-01
1037,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrmeaedvgvyycmqtlqmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 433 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 433 from patent US 11053304,2022-03-01
1038,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllhrngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyyctqslqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 432 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 432 from patent US 11053304,2022-03-01
1039,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaahwpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 431 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 431 from patent US 11053304,2022-03-01
1040,not found,SARS-CoV-2,Unknown.,,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 430 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 430 from patent US 11053304,2022-03-01
1041,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 429 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 429 from patent US 11053304,2022-03-01
1042,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 436 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 436 from patent US 11021532,2022-03-01
1043,not found,SARS-CoV-2,Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 427 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 427 from patent US 11021532,2022-03-01
1044,not found,SARS-CoV-2,Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 419 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 419 from patent US 11021532,2022-03-01
1045,not found,SARS-CoV-2,Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 411 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 411 from patent US 11021532,2022-03-01
1046,not found,SARS-CoV-2,Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 403 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 403 from patent US 11021532,2022-03-01
1047,not found,SARS-CoV-2,Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 395 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 395 from patent US 11021532,2022-03-01
1048,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvyvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 364 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 364 from patent US 11021532,2022-03-01
1049,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgiinpsdgsstyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgysydhdqiyyyygmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 363 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 363 from patent US 11021532,2022-03-01
1050,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgwmnsnsgstgyaqkfqgrvtmtrdtststvymelsslrsedtavyycargwmaydafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 362 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 362 from patent US 11021532,2022-03-01
1051,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycatvtpgygmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 361 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 361 from patent US 11021532,2022-03-01
1052,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 360 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 360 from patent US 11021532,2022-03-01
1053,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 359 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 359 from patent US 11021532,2022-03-01
1054,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisarngntnyaqkfqgrvtmtrdtststvymelsslrsedtavyycttdpvlewfgysiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 358 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 358 from patent US 11021532,2022-03-01
1055,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgsyaiswvrqapgqglewmgwinpktgdtnyaqefqgrvtmtrdtststvymelsslrsedtavyycargssgyyfgwgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 357 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 357 from patent US 11021532,2022-03-01
1056,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgnyihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycakdvqnyygsgssfdywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 356 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 356 from patent US 11021532,2022-03-01
1057,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 355 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 355 from patent US 11021532,2022-03-01
1058,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 354 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 354 from patent US 11021532,2022-03-01
1059,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlmdivvvpwlggmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 353 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 353 from patent US 11021532,2022-03-01
1060,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaktryggnsrsryyyygmdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 352 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 352 from patent US 11021532,2022-03-01
1061,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyymqwvrqapgqglewmgwidphsgatnyahsfqgrvtmtrdtststvymelsslrsedtavyycarleggsywtgyfdlwgrgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 351 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 351 from patent US 11021532,2022-03-01
1062,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyiqwvrqapgqglewmgwinpnsggpnyaqkfqgrvtitadeststaymelsslrsedtavyycarvdygdygrledywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 350 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 350 from patent US 11021532,2022-03-01
1063,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyhmhwvrqapgqglewmgwmnpnsgntsyaqkfqgrvtmtrdtststvymelsslrsedtavyycagmgmgrdgynsrafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 349 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 349 from patent US 11021532,2022-03-01
1064,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinydinwvrqapgqglewmgvinpsagstsyahkfqgrvtmtrdtststvymelsslrsedtavyycasahssswysdwfdpwgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 348 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 348 from patent US 11021532,2022-03-01
1065,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 347 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 347 from patent US 11021532,2022-03-01
1066,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtftsyhmhwvrqapgqglewmgwmnpnsgntgyalkfqgrvtmtrdtststvymelsslrsedtavyycasferfgelvpetfdywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 346 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 346 from patent US 11021532,2022-03-01
1067,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfssyaiswvrqapgqglewmgivnpssgsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarvrgsaaiammdvwgqgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 345 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 345 from patent US 11021532,2022-03-01
1068,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfrstaiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragyssssgyyyygmdvwgkgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 344 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 344 from patent US 11021532,2022-03-01
1069,not found,SARS-CoV-2,Unknown.,evqllesggglvqpggslrlscaasgftfsgsamhwvrqapgkgleyvsaisrnggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgtlitttldywgqgtlvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 343 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 343 from patent US 11021532,2022-03-01
1070,not found,SARS-CoV-2,Unknown.,evqllesggglvqpggslrlscaasgfsfsnydmhwvrqapgkglewvavisydggfklyadsvkgrftisrdnaknslylrmnslrsedtavyycargqvrgsgpqvvvmdvwgkgttvtvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 342 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 342 from patent US 11021532,2022-03-01
1071,not found,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgdtfsnygiswvrqapgqglewmgwmnpnsggtnyaqkfqgrvtmtrdtststvymelsslrsedtavyycaigttvvtpfgywgqgtlvnvss,,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 341 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 341 from patent US 11021532,2022-03-01
1072,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 437 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 437 from patent US 11021532,2022-03-01
1073,not found,SARS-CoV-2,Unknown.,,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 428 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 428 from patent US 11021532,2022-03-01
1074,not found,SARS-CoV-2,Unknown.,,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 420 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 420 from patent US 11021532,2022-03-01
1075,not found,SARS-CoV-2,Unknown.,,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 412 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 412 from patent US 11021532,2022-03-01
1076,not found,SARS-CoV-2,Unknown.,,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 404 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 404 from patent US 11021532,2022-03-01
1077,not found,SARS-CoV-2,Unknown.,,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 396 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 396 from patent US 11021532,2022-03-01
1078,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 388 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 388 from patent US 11021532,2022-03-01
1079,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrvsqgissylnwyqqkpgkapklliyaasilqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpftfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 387 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 387 from patent US 11021532,2022-03-01
1080,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcqasqsiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 386 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 386 from patent US 11021532,2022-03-01
1081,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqtiysylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 385 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 385 from patent US 11021532,2022-03-01
1082,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 384 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 384 from patent US 11021532,2022-03-01
1083,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 383 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 383 from patent US 11021532,2022-03-01
1084,not found,SARS-CoV-2,Unknown.,,divmtqspdslavslgeratinckssqsvfsssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 382 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 382 from patent US 11021532,2022-03-01
1085,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 381 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 381 from patent US 11021532,2022-03-01
1086,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgirnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 380 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 380 from patent US 11021532,2022-03-01
1087,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 379 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 379 from patent US 11021532,2022-03-01
1088,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 378 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 378 from patent US 11021532,2022-03-01
1089,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqaitnylawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyysypptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 377 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 377 from patent US 11021532,2022-03-01
1090,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqhissylnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgygtpytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 376 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 376 from patent US 11021532,2022-03-01
1091,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvssnylawyqqkpgqaprlliyavssratgiparfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 375 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 375 from patent US 11021532,2022-03-01
1092,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsiyswlawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 374 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 374 from patent US 11021532,2022-03-01
1093,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 373 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 373 from patent US 11021532,2022-03-01
1094,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 372 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 372 from patent US 11021532,2022-03-01
1095,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 371 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 371 from patent US 11021532,2022-03-01
1096,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgirndlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 370 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 370 from patent US 11021532,2022-03-01
1097,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqdirnelgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 369 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 369 from patent US 11021532,2022-03-01
1098,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqydtfpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 368 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 368 from patent US 11021532,2022-03-01
1099,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsigyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 367 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 367 from patent US 11021532,2022-03-01
1100,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcqasqgirndlgwyqqkpgkapklliydasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyystppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 366 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 366 from patent US 11021532,2022-03-01
1101,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasesvssrylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqgyknpptfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 365 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 365 from patent US 11021532,2022-03-01
1102,not found,SARS-CoV-2,Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 102 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 102 from patent US 11021531,2022-03-01
1103,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 83 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 83 from patent US 11021531,2022-03-01
1104,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 82 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 82 from patent US 11021531,2022-03-01
1105,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvaiiyeggsphyadsvkgrftisrdnskntlylqmnslraedtavyycardrsgyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 81 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 81 from patent US 11021531,2022-03-01
1106,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymswvrqapgkglewvsaistsgdstfyadsvkgrftisrdnskntlylqmnnlraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 80 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 80 from patent US 11021531,2022-03-01
1107,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 79 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 79 from patent US 11021531,2022-03-01
1108,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsaisgtgdtteyadsvkgrftisrdnskntlylqmnslraedtavyycardrslmldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 78 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 78 from patent US 11021531,2022-03-01
1109,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnhymswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 77 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 77 from patent US 11021531,2022-03-01
1110,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftftnyamtwvrqapgkglewvstmsniggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrrvyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 76 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 76 from patent US 11021531,2022-03-01
1111,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfashamswvrqapgkglewvsgissdgsittyadsvkgrftisrdnskntlylqmnslraedtavyycardrgwyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 75 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 75 from patent US 11021531,2022-03-01
1112,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasglsvtsnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 74 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 74 from patent US 11021531,2022-03-01
1113,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsvvypggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 73 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 73 from patent US 11021531,2022-03-01
1114,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfsdaaihwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsygidywgqgtlvtvss,,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 72 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VH: Sequence 72 from patent US 11021531,2022-03-01
1115,not found,SARS-CoV-2,Unknown.,,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 103 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 103 from patent US 11021531,2022-03-01
1116,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 95 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 95 from patent US 11021531,2022-03-01
1117,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqasstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 94 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 94 from patent US 11021531,2022-03-01
1118,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 93 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 93 from patent US 11021531,2022-03-01
1119,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqfgtsppglsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 92 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 92 from patent US 11021531,2022-03-01
1120,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 91 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 91 from patent US 11021531,2022-03-01
1121,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 90 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 90 from patent US 11021531,2022-03-01
1122,not found,SARS-CoV-2,Unknown.,,eivmtqspatlsvspgeratlscrasqsigtylswyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqslslpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 89 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 89 from patent US 11021531,2022-03-01
1123,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 88 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 88 from patent US 11021531,2022-03-01
1124,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 87 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 87 from patent US 11021531,2022-03-01
1125,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 86 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 86 from patent US 11021531,2022-03-01
1126,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 85 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 85 from patent US 11021531,2022-03-01
1127,not found,SARS-CoV-2,Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 84 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",VL: Sequence 84 from patent US 11021531,2022-03-01
1128,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvsseqkliseedl,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1129,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1130,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1131,not found,SARS-CoV-2,synthetic construct,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1132,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1133,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1134,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1135,not found,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.","VH: anti-SARS-CoV-2 nanobody, partial [synthetic construct]",2022-03-01
1136,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1137,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1138,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1139,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsdtpfywgwirqppgkglewigsmyytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpssifrgtvftpyyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1140,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvnpggslrlscagsgftfsdyymgwirqapgkglevvsyisttgsyikdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgsfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1141,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglsqpggslrlscatsgfavrnncmnwvrqapgkglewvslicgdgityhsdsvkgrfiisrddsenalhlqmnslrvedtavyycvkasppggntgwpffhywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1142,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewlsyishtastiyyadsvkgrftisrdnaknslflqmnsltaedtavyycardrgsgvidpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1143,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggpfsthafswvrqapgqrpewmggimpvfgeskdtqkfkgrvtftadasttttymelrslksddtaiyycvrdsdpytatsshnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1144,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggiiplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1145,not found,SARS-CoV,Homo sapiens (human),evqlvqwgagllkpsetlslrcavyggsfngfywtwirqapgqglewiaeinhsgttnynpslksrvtisidtskkqfslslksvtaadtamyfcargtispivgvptpvvprrgrswfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1146,not found,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgtslrlscaatgftfttypmhwvrqapgkglewvavisydgmnqyyadflkgrftisrdnskntlylqmnslraddtavyycarayggnyqnhfdhwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1147,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpggslrlscadsgnafianpmhwvrqapgkglewlalistdgnnrhyadsvkgrftfsrdnsknslylqmdslrpedtgvyycaresrssgragcfdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1148,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsryamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlflqmsnvrpedtafyycvkdggyydssgpghwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1149,not found,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsissnnlywgwirqppgkglewigsiyysgstyynpslksrviipvdtskdqfslrlssvtaadtavyycarhsqkdivlipaaqspifdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1150,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsshaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftvdestntaymeltslksedtaiyycvrdpdpytatvrhnhywhgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1151,not found,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsinsqywnwirqspgkglewigyvyysgstnynpslksrvtmsvdtsknhfslnlrsvtaadtavyycarglvvryfdgfpsgpiigafdiwnqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1152,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1153,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvyggsfsgyfwswirqspgkglewigeinhsrsmsynpslksritmsvdtsknqfslnlnsvtaadtavyfcargkahrndfwsgyyphwfdpwgqgilvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1154,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfywtwirqppgkglewigeinhsgssnydlslksrvtmsvdtsknqfslklssvtaadtavyycargmispriprttrqrwfdtwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1155,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyvrkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdlwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1156,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggilplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1157,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkmpgssvkvsckvsggrfsdyaiswlrqapleglewmggivphlnrkgysqkfqdrltftaddststaymelsgltsedtavyycardptflntgnhfwyavdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1158,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmlsdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1159,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaaseftfstyamhwvrqapgkglewvalisydginkyyadsvkgrfaisrdnskntlylqvnslraddtavyycvrpysgsytnwfdlwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1160,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscvasgftfsdfymswirqapgkglewvsyisgsgdtiyyadsvkgrftvsrdnaknslflqmsslgaedtamyycarematsfgyyfvldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1161,not found,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgtslrlscavsgfmfknyaihwvrqapgkglewvavisfdgsdisytesvqgrftisrdnsenmlylqmnslraedtamyycarepdgigaagisgywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1162,not found,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsehaqrfqarvkftadeststaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1163,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1164,not found,SARS-CoV,Homo sapiens (human),qvqlvesggevkkpgasvkvsckasgytlssypiswvrqapghglewmgwintyngrtnyeqmlqgrvtmttdtststaymelrslrsddtavyycarvvfrhgqyddssgrlafdiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1165,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvylqmnslrdedtavyfcareldsetyynynsldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1166,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkgpgasvkvsckvsgysfityditwvrqapgqglewmgwistksgdtryaqnvqgrvtmttdtstntaymelrnlksddtalyycarttprgweqwpvleywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1167,not found,SARS-CoV,Homo sapiens (human),qvqlqesgrglvkpsetlsltctvsggsitssryywgwirqppgrnlewigsihysgttsynpslwsrvaisvdtaqnqfslrlnsvtaadtavyycaapapsnheswsgtdwfdpwgqgilvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1168,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1169,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrsnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1170,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlsceasgftfadypmhwvrqapgkglewvavisshgrsqgyaasvkgrftfsrdnsqsslflqlnslrvedtavyfcareaqssgragcldawgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1171,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscgasgftfsdyamswvrqapgkglewvstisgsgdktyyadslkgrftnsrdnskstlylqmtslraedtavyfcakdrycsggscfydafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1172,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1173,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggpfssfaiswvrqapgqglewlggimtvfgpahyaqksrdrisitadeststsylelssltsddtavyycaaeersgtnhnyygldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1174,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggdsvnpggslrlscagsgfsvrdvwmswvrqapgkglewigrikseadggssdyraslkdrfsiwrdaskntlylqvnglqtedtaiyfcswndvgwaftfwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1175,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgdkkyypdsvrgrftisrdnskntlhlqmnslrledtavyycarsyggsystvgywgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1176,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavnggsfnnyywswirqppgkgpewigevvhsgsttynpslksrvtisidmsknqfalklnsvtaadtavyycargftftysdfltgqrtfeywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1177,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpggslrlscvasgfpfgryamhwvrqapgqglewltlisfdssnieysdsvqgrftisrdnsrntlflqmtslrpedtavyfcardlppldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1178,not found,SARS-CoV,Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslntrelgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltltnmdpgdtatyycahtselpprrpyaafdfwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1179,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvkpggslrvscvgsgftfsdhymswirqapgkgleiisyistdgsyindadsvkgrfinsrdnaknsvylqlnslraedtavyycarmgpsgsgsldywgqgslvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1180,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1181,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewmggiiplfgtsesaqrfqarvrftadeststaymelssltsedtavyycvrdsdpytatsrnnhywydmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1182,not found,SARS-CoV,Homo sapiens (human),evqlvqsggglvqpggslrlscaasgftfssysmswvrqapgkglewvsyitrssdniyyaesvkgrftisrdsaknslylhmnslrdedtavyycardpgleysgnyfsyyyyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1183,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvtdnymswvrqapgkglewvsvlysggstyyadavqgrfsisrdnsknalylqmnslraedtavyycargfgngwsyyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1184,not found,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgftfsnynmnwvrqapgkglewvssisgsssyisyadsvkgrftisrdnaknslylqmnslrvedtavyycaradrdydfwsdpplidhwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1185,not found,SARS-CoV,Homo sapiens (human),qvqlvesgaevkrpgasvkvsckasgyafsdyymhwvrqapgqgpewmgwinpnsgdtgypqkfrgwvtmtrdtsvstaymelkrlksddtavyycasgpnyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1186,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlshyaiswvrqapgqglewmggimpvsgtvgyaqkfqgrvkftadeyastaymeltnlrsedsavyfcardpsivdsgphhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1187,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1188,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1189,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1190,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggilpafaasgspgyapifrgratfsadvststayleltnlkpedtavyycardpsilntgnhhwydldlwgqgtevtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1191,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfskfamhwvrqapgkglewvaiisydgshknyadsvkgrftisrdnskntvylqvdslraedtavyycallygsgsyynfvffgwkdgsdawgpgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1192,not found,SARS-CoV,Homo sapiens (human),evqllesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1193,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsdyymswirqapgkglewvsyitgsgrtihyadsvkgrftisrdnaknsvylqmnslraedtavyycarghrflefplnyfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1194,not found,SARS-CoV,Homo sapiens (human),evqlvesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1195,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvkvsckasggtfynsafswlrhapgqgpewmggitpslgrvgyserflarltitadeststvymeltslasedtavyycardasivgtgnhlwygldfwghgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1196,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqhfrgrlsitadesastaymeltglrsedtamyycardpsilntgnhhwydldlwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1197,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsaseftlrshamhwvrqapgkgleyvsgistdgsgrfyadsvkgrftisrdnsknklflqmsslrpedtavyycvrdwgssthydvfdlwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1198,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgatyknsafswarqapgqgfqwmggiiplfgvphyvqmfqgrvtitadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1199,not found,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpifgspgyaeifqgrvtitadeskstvymeltslrsedtavyycardpsildtgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1200,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgfifsghwmswvrqapgkglewvanikqdgrekhyvdsvkgrftisrdnaknsvslqmnslraedtavyycvrqnvaiqyyyyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1201,not found,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfnsyalfwvrqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslktedtsvyycarprsgsyrqaidywglgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1202,not found,SARS-CoV,Homo sapiens (human),evqlvesgaevknpgssvkisckssggtlgdyaiswvrqapglglewlggimplhgttgysqrfrprltitadesartaymeltalssedsaiyycardpsilntgnhhwydldlwgqgtevtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1203,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1204,not found,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsetlslactvsggsisnyywnwvrqppgkglewigniyysgsttfnpslksrvtisvdtsrnqfslklssvtaadtavyycarqssswynpyyfdqwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1205,not found,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfnsytiswvrqapgqglewmggiipildtphyaqkfrgrvtitadkststafmdlssltsedtavyycairrdysdyrdfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1206,not found,SARS-CoV,Homo sapiens (human),qvqllesggglvqpgrslrlsctasgfrfgdytmtwfrqapgkglewvgfirsiayggttehaasvegrfiisrddsksiaylqmnslkaedtgvyfctrgsgmfygsssgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1207,not found,SARS-CoV,Homo sapiens (human),evqlqesgpglvkpsetlsltcavsggsvssdtdywgwirqppgkglewigsihdsertyydpslksrvtisvdtsknqfslrlssvtaadtalyfcasrhldllpigsfdvwgrgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1208,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1209,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqvpgrglewvsgiswnsgtinyadsvmgrftisrdnaknslylqmnslraedtalyycakdgrycsgiscrtgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1210,not found,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsqtlsltctvsngfissgeyywswirqspgkglewigyishsgstyynrslksrvtisldtsrnqfslnlssvtaadtavyycardlakwsygyyysgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1211,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgysstnygfswvrqapgqglewmgwisvhsgnanfaqkfqgritmttdtstttaymelrnlrsddtatyycatsassysryyfgldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1212,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnynmvwvrqapgkglewisyissssstiyyadsvkgrfiisrdnaknslhlqmnslrdedtavyycvrdycnsvscytyyyigmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1213,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggsftsyvlswvrqapgqglewmgrivpnlgvanyaqkfqdrvtitadkstttaylelrslrsedtavyycardlyydnggynyldywgpgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1214,not found,SARS-CoV,Homo sapiens (human),evqlvesgaevrkpgssvkvsckatggtfssygitwvrqapgqglewmgriiptlgrtnyaqkfqgrvtitadkststahmelsslrsedtavyycardlstlqpdaivnfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1215,not found,SARS-CoV,Homo sapiens (human),evqllesgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1216,not found,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvsckasggtfssdaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadestntaymelsslrsedtavyycardgpydsggyhlnhwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1217,not found,SARS-CoV,Homo sapiens (human),evqlvesgaevkkpgasvilsckasgytvtnyyihwvrqapgqglewmgwidpdsgvtnfaekfqgrvtmtrdtsistaymelrwlesddtavyycakdlitvirglgggmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1218,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelgslrsddtavyycarvlagsshewqlthdafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1219,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagvlkpsetlsltcavyggsfrgffwswirqppgkglewigqithsgstnynsslksrltisvdtsknqfslnlssvtaadtaiyycargqggydlrrvgygltswfdpwgqgilvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1220,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1221,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpgkslrlscvasgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgvyycvkdqssgdrllylgyfdlwgpgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1222,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgkslrlscvpsgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgiyycvkdqssgdrllylgyfdlwgpgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1223,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftghyihwvrqapgqglewmgwinpasgdtnyaqkfqgrvtktrdtsittaymelnrlrsddtavyycarggplpwsdldivgtfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1224,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyyvhwvrqvpgqglewmgwispdsgdtiraqnfqgrvtmtrdtsmntaymevnrlrtddtaiyycardlisvirglgggmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1225,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnyamtwvrqapgkglkwvsginpsgdatfytdsvkgqftisrdnsknilylqmnrlraddtaiyycakglsfygsgsdafdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1226,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmkvsckasgvnfrsysfswvrqapgqglewmggvipyfptanyadkfrdrvtitadestgtvyldmsslrsedtavyfcaseyfdgrsyhsfcgldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1227,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckasgysftnywvgwvrqmpakglewmgiiwpddsdtryrpsfqgqvtisvdksistaylhwnslkasdngmyfcaraplascsggrcptynrfdlwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1228,not found,SARS-CoV,Homo sapiens (human),qvqlvesgpglvrpsgtlsvtcavsgdsissdywctwvrqspgkglewigkishsgslnynpslksrvtmsvdksknhfslklasvtaadtavyycarvrigashhnfwsgyytdafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1229,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsgrvywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1230,not found,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvrvsckasggtfrksaiswvrqapgqgfewmggiiptldrrgfaqkfqdrltmtadeftstaymdlsdlrsddtavyycardasfpntgnhfwydfdlwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1231,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscrvsggrfsdyafswlrqapvkglewmggiiprldrkgyshifqdrltftadeststtymelsgltsddtavyycardptflnsgnhfwydvdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1232,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvevsckvsggtfrdyaiswvrqapgqrlewmggimpglgspayaqifgdrvtisadtststaylqvtnlrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1233,not found,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1234,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpgllkpsetlsltctvsnspissnywswirqpagkglewigriditgntnynpslksrvimsvdtsksqfslkmtsvtaadtavyycarsfisfdssghpyyyyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1235,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlslicdvyggsfngfywswirqppgkglewigeishdgstnyspslksrvsisidtskkqfslklrsvtaadtamyycargmtspvvhlyssgrpsrwfdfwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1236,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsnyamnwvrqapgqgpewmgwidtntgnptyaqgfigrfvfsldtsvntaylligsleaedtavyycareehydfssgyfrpaywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1237,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1238,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggifsthaiswvrqapgqrpewmggiipifgeskdtrkfqgrvtftadestttaymelrslksddtaiyycvldsdpytatfshnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1239,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1240,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1241,not found,SARS-CoV,Homo sapiens (human),qvqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1242,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmisdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvstntayleltslnpddtavyycardpsilntgnhhwydldmwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1243,not found,SARS-CoV,Homo sapiens (human),qvtlkesggglvqpggslrlscaasgftvnsygmswvrqapgkglewvsgfksrsdrpdyaesvkgrftisrdtskntvylemiglraedtatyycvrmdwmewmkyyfdswgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1244,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrpewmggimpglgspayaqifrgratisadlststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1245,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggimpglgspayaqifrdratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1246,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1247,not found,SARS-CoV,Homo sapiens (human),evqllesgpgllkpsetlsltctvsgdsvssgnfywswvrrppgkalewiayshytggtnsdpsfmgrvtmsidpsrnqfslrltsvaaadtavyycarttspltysghwplfdywgqgslvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1248,not found,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgidggggssyyadsvrgrftvsrdnsknmlhlqmnslraddtavyfcakgdwiryfdwslpisffdywgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1249,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgadvkkpgasvkvsckasgytftsyymhwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelsslrsedtavyycarvlagsshewqlthdafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1250,not found,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1251,not found,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1252,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnhyywswirqppgkglegigytyysgstnynpslksrvtisvdasknqfslrlssvtaadtavyycargsqidlrgglgatffdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1253,not found,SARS-CoV,Homo sapiens (human),evqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1254,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsitsrdwwswvrqppgkglewigevyhsgstsynpslksrvtisvdksknefslklssvtaadtavyycaragnivvmpaaqyyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1255,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalskvgyagkfqarltfsadelkttvymdlssltsedtavyycardpsflnagnhfyydfdvwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1256,not found,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsafamhwvrqapgkglewvtiisydgsneyyadsvqgrfsisrdnskntlflqmsslrtedtaiyycaraggylsafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1257,not found,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsatlsltctvsggsinnyywtwvrqsagkglewigrintsgstnynaslksrvtmsidtsknefslrlssvtaadtavyycarefgvrfldrslfgamdvwghgatvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1258,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1259,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpvfgspgyaeifqgrltitadesrstaymeltslrsedtavyycardpsilntgphhwydldiwgpgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1260,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgpevkkpgssvrvsckvsggpfssygvswarqapekglewmggvlpifgtvgyvhkfqgrvtitadeststvymalsslrsedtavyycvldttmshphnwygmdvwghgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1261,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftndgfvwvrqapgqvpewmgwisvhtgdtiyaqrfqgrvtmttdtstrtsymelmslrsddtavyycardygdgppdhwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1262,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggslrdyaiswvrqapgqgpewmggimpifgtagyaqkfqgrvkftadesattaymeltglrsedsavyfcardpsilntgnhhwydldiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1263,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvygvsfsdyywswirqppgkglewigeinhsgitnynpslksrvtisvdtsknqfslklssvtaadtavyycarglisytlwlresyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1264,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgasvkisckasgyafrnnyinwirqapgqglewmgiinpsagtstyaqkfqgrvtmtrdtstntvymeitslrsedtatyfcarearrqvtqwfgefwgpynwfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1265,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsrgsisssywswirqppgkglewigfmyysgstnynpslksrvtisldtsknqfslklssvtaadtavyycakaqgiyyrgwsywfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1266,not found,SARS-CoV,Homo sapiens (human),qvqlqqsggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvflqmnslrdedtavyycareldsetyynynsldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1267,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntytmhwvrqapgkgleyvsaissngvvtyyadsvkgrftisrdnskntlylqmsslraedtavyycvkalyssswcpfdywgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1268,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgfilddyavhwvrlapgkglewvsgitwnsgylgyadsvkgrftisrdnaknslylqmnslrpedtalyycaklgtdhpigvdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1269,not found,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdtgrdtyyaasvkgrftisrdnskntvylqmnslraedtavyycantnfldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1270,not found,SARS-CoV,Homo sapiens (human),qvqlqesggglvqpggslrlsceasgfsfsdfvmhwvrqvpgkglewvsrishdgsitsyvdsvkgrftvsrdngkktlylqmnsprtedtavyycardlawtffdywghgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1271,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1272,not found,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsgtlsltcavtgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1273,not found,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1274,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklscrasggtfhtytvnwvrqapgqglewlggiipifgtptyaqrfqgkvsitadsstntvfmeltsltsedtavyyctretgtdefdfwgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1275,not found,SARS-CoV,Homo sapiens (human),evqlqesgpgllkpsetlsltctvsgspiasnywswvrqpagkglewigridtspttdynpslksrvimsvdtstsqfslkmssvtaadtavyyctrsfisfdssghpyyyyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1276,not found,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdsgrdtyyaasvrgrftisrdnskntvylqmnslrvedtavyycantnfldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1277,not found,SARS-CoV,Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslttrrqgvgwlrrppgkalewlaliywdddkryspslksrltitkdtsknhvvlsltnvgpadtatyycahtselpprrpyaafdfwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1278,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1279,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaemkkpgeslkisckgsgysfpnywigwvrqmpgkglewmaimwpsdsdtryspsfqgqvtisadtststvylqwgslkasdtamyycvrqrycsggscflfedafeiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1280,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntyamhwvrqapgkrleyvssitrdgagkfyadsvkgrftisrdnskntlyqqmsslrpedtavyycvregqqwlglyfdhwgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1281,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggnvvqpggslrlscvgsefsitffamqwvrrtpgkglewvalvshdgsnirysdsvkgrfiisrdnakntlylqldsltpedtgiyycardhalqngrpgyfdswgqgsqvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1282,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1283,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfrgfywtwirqppgkglewigevshsgetnynpslksrvtisvdtsknqfslnlisvtaadtsvyycargytapiirevpitfrprwfdpwgqgtpvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1284,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmswvrqapgkglewvsghdggtthyadsvkgrftisrddsmntlslqmnslraedtavyycakerdlpgrggyfdhwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1285,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsnyamywvrqapgkrpeyvsgissnggityyadsvegrftvsrdnskkslylqmsslrpedtavyycvkdlgatvtydvfdvwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1286,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1287,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1288,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscltsgfsfssywmiwvrqapgkglewvaniepdgneeyyvdsvkgrftisrdnaknslylqmnslraedtavyycargpirhfgldafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1289,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1290,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1291,not found,SARS-CoV,Homo sapiens (human),qvtlkesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsqhaqrfqarvkftadestntaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwghgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1292,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfrdyaiswlrqapgqrlewmggimpafgapgyaqifrgratisadvstttayleltslmpddtavyycardpsilntgnhhwydldlwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1293,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftlapygmqwvrqapgkglewvaflshdgshlgyvdsvkgrftisrdnskntlylemnslraedtatyycardnvvqqnadnvgyfdfwgqgslvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1294,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1295,not found,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrvscsasgftfssfamhwvrqapgkgleyvagisdnghttmyadsvkgrftisrdnskntlylqlsslrpedtavyfcvkdnvilpgaivrpqfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1296,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytttfshnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1297,not found,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgtslrlscvasgftfstfamhwvrqapgkglewvalisfdstniryansvrgrftisrdnskntlylevdslriedtgvyycardlppldywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1298,not found,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvaviysdgrneyyadsvkgrftisrdnskntlhlqmnslgaadtavyycardpgpitffdwspdksrksyydyngmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1299,not found,SARS-CoV,Homo sapiens (human),qvqlvesggdlvkpgrslrlsctasgftigdyamtwfrqapgkglecvavirsrafggtteyaasvkgrfivsrddsnsvaflqmnslktedtavyycsrdlrrgyydsnghqqfdlwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1300,not found,SARS-CoV,Homo sapiens (human),evqlqqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1301,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyarkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdmwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1302,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgpglvrpsgtlsltcavsgdsisgdywctwvrqtpgkglewigkishsgsinynpslksritmsvdksknqfslklnsvtaadtamyycarvrvgashhnfwsgyytdafdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1303,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgpelkkpgssvrvsckasggsissyaiswvrqapgqrlewmggvlpmmgrespvqkfkdrvtiaadeststaymelrslsaedtavyycvvdttmadphnwygldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1304,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqlfrgrlsitadesastaymeltgltsddtamyycardpsilntgnhhwydldlwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1305,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfslfhvhwvrqapgqglewmgwinphngdttfaerfqgrvaltrdtsintaymelsrltsddtavyfcardfgvryddsrqlmkycdswgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1306,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvtvsckvsggrfsdyaiswlrqapveglewmggiiphlnkkgysqkfqdritftadeststaymelsgltsedtaiyycardptflntgnhfwyavdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1307,not found,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1308,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1309,not found,SARS-CoV,Homo sapiens (human),pgpactvwaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtqvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1310,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvnpggslrlscvgsgftfsdyymgwirqapgkglevisyisstgsyirdadsvkgrftisrdnaensvylqmnslrgedtavyycarmgpygsgsfdywglgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1311,not found,SARS-CoV,Homo sapiens (human),evqlvesgpelkkpgssvrvsckasggsfsnfavswvrqapgqrlewmggviprfgrseyvqkfqgrvtitvdeaastaymelsslrsedtaiyycvldttsanphnwygmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1312,not found,SARS-CoV,Homo sapiens (human),qvqlvqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslrlrsvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1313,not found,SARS-CoV,Homo sapiens (human),evqlqesgpglvkpsgtlsltcgvsgvsisssswwswvrqppgrglewigeispsgstsynpsfrsrltmsvdksrnqlslklssvtaadtavyycartqsndfwsgyytaafdlwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1314,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssdwcswvrqppgkgpewiaeishsgstnynpslksrvtmsvdrsknqfslnlnsvtaadtavyycaarirgathydfwsgfwagpfdiwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1315,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaemrkpgssvkvsckasggtfsrycfswvrqapgqrlewmggimsilgahyaqkfqgrvtftadestntaymelisltsedtavyycareepsgtyhnyygldvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1316,not found,SARS-CoV,Homo sapiens (human),evqlvesggglsqpggslrlscaasgftvrtycmnwvrqapgkglewvslvcgdnidyypdsvkgrfsisrddskntlllhmdslrvedtavyycaratppgggtgwpyfdfwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1317,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrnnhywyaldvwgpgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1318,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstsamswvrqapgkglewvsrigggggrtkyadsvkgrftisrdnskntlylqmnslraddtavyycakcdlvryfdwlgeennwfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1319,not found,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsgasvtagssywgwirqppgkglewigymfssgntkynpslksrvtisadtsknqfslrlssvtaadtavyfcarvgwvryfdwskpyyyfdlwgrgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1320,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigevnhsgstkynpslksrvtvsvdtsknqfslrlssvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1321,not found,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggsfsgfywswirqppgkglewigeinhsgsanynpslmsrvtismdtskkqfslqlrsvtaadtavyycargqespivgvtgrwfdpwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1322,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1323,not found,SARS-CoV,Homo sapiens (human),evqlvesgaevrtpgssvklsckasggtfsthafswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttvymelrslksddtaiyycvrdsdpytatyrnnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1324,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1325,not found,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgypmhwvrqapgkglewvalisfdgdskyytdsvkarfaisrdnskntlflqmnslrvadtalyycarakggsysnafdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1326,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckisggtfknsafswarqvpgqgfqwmggiipmfgvphsvqmfqgrvtltadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1327,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytatvtsnhywyamdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1328,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpgrslklscvvsgfsfshygmnwvrqapgkglewvavmsydgsdkyyadsvkgrftisrdiskntlylemnslrtedtavyycakkgspycgvdcykgyfdywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1329,not found,SARS-CoV,Homo sapiens (human),evqlvesggglsqpggslrlscaasgfvvknncmnwvrqapgkglewvalicadgityhsdsvtgrftiyrdesdntlhlqmdslriedtavyycvrasppggntgwpffedwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1330,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwmspntgdtgyahkfqgrvrmtsntsistaymelnsltsedtavyycarrgnnfgyyyyytvdvwgqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1331,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmklsckasginfrsysfswvrqapgqglewmggvipyfptanyaekfrgrvtatadestgtvylemsslrsedtavyycaseyfdgrsyhsfcgldvwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1332,not found,SARS-CoV,Homo sapiens (human),evqllesggglsrpggslrlscaasgfiasrncmqwvrqapgkglewvsiicgdeityirdsvkgrftisrddskntlhlemnslraddtavyycaratppggttgwpyidlwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1333,not found,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytfsgydinwvrqatgqglewmgwmnpnsgdtgyahkfqgrvtmtrnssistaymelssltsedtavyfcarekksfgpqyyygsgedwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1334,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscsasgfsfgdyamswfrqapgkglqwvgliktraygaatdyaasvqgrfiisrddsksiaylqmnslktedtavyfcaregtslgyyyyyamdvwghgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1335,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssissssymyyadsmkgrftisrdnaqnslylqmsslraedtavyycardfpgdtavagtgfnywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1336,not found,SARS-CoV,Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsgdsvsssdyhwgwirqppgkglewigsiyyggrshfnpslksrvaifvdtsnnqfslrlnsvtasdtavyfcagrhqellpmgsfdmwaqgttvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1337,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1338,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1339,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1340,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1341,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1342,not found,SARS-CoV,Homo sapiens (human),,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1343,not found,SARS-CoV,Homo sapiens (human),,eivmtqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydssnratgtpdrfsasgsgteftltitrlepedsavyyclqyssattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1344,not found,SARS-CoV,Homo sapiens (human),,ettltqspailsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydasnratgvparfsgsgfgteftltisslqsedfavyycqqynnwppltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1345,not found,SARS-CoV,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqsishylnwyqqkpgkapklliyaasnlqsgvpsrfsgngsgtdftltisslqpedfatyfcqqsystpltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1346,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqvlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1347,not found,SARS-CoV,Homo sapiens (human),,divltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1348,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnigndyvswyqqlpgtapklliyenykrpsgipdrfsgsksgtsatlditglqtgdeadyycgtwdsslsvdnyvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1349,not found,SARS-CoV,Homo sapiens (human),,divltqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytmwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1350,not found,SARS-CoV,Homo sapiens (human),,dirltqspsslsasvgdrvtitcrasqdisswlawyqqksgkapksliyaasslqngvpsrfsgsrsgtdftltisslqpedlgtyycqqydsypvtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1351,not found,SARS-CoV,Homo sapiens (human),,dirvtqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1352,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsatpgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsrlsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1353,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqaasiscrssqavvhsdgntylnwfqqrpgqpprrliykvsnrdsgvpdrfsgsgsgtvftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1354,not found,SARS-CoV,Homo sapiens (human),,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydafnratgvparfsgsgsgtdftltisslepedfavyycqqrtstltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1355,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1356,not found,SARS-CoV,Homo sapiens (human),,divltqspgtlslspgervtlscrasqsissnylawyqqkpgqaprllisdassratgipdrfsgsgsgadftliisrlepedfavyfchqyggspttfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1357,not found,SARS-CoV,Homo sapiens (human),,qpgltqpasvsgspgqsitisctgtsgdvgsdnlvswyqrhpgkapklmiyegskrpsgvshrfsgsnsgntasltisglqaeddadyyccsyagddtvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1358,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasisctssqtvvhtdrntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1359,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1360,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslsvtlgqaasisctcsqsavhsdgttyfnwfhqrpgqsprrliykvsnrdsgvpdrfigsgsgthftlkisrveaedvgvyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1361,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1362,not found,SARS-CoV,Homo sapiens (human),,eivmtqspgtlssspgeratlscrasqsvssrylawyqqkpgqaprlliygtsnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1363,not found,SARS-CoV,Homo sapiens (human),,eivmtqtpsslsasvgdrvtitcrasqsisnyvnwyqqkpgrapnlliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqtystppegptfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1364,not found,SARS-CoV,Homo sapiens (human),,givltqspdslavsvgeratinckssqtvlyssknkhylawyqqkpgqppklltsspstrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1365,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1366,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1367,not found,SARS-CoV,Homo sapiens (human),,eivmtqspsslsasvgdsvtitcrasqsisnylnwyqdkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysdswtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1368,not found,SARS-CoV,Homo sapiens (human),,diqmtqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlrpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1369,not found,SARS-CoV,Homo sapiens (human),,diqvtqspatlsvspgervtlscrasqsisntlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynkwppitfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1370,not found,SARS-CoV,Homo sapiens (human),,eivmtqspaslsasvgdrvtitcragqsistnlcwyqqrqgkapklliyaasslrsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1371,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1372,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslavtlgqpasiscrsslglvhtngntylnwfqqrpgqsprrliyrvsnrdsgvpdrfsgsgsvtdftltisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1373,not found,SARS-CoV,Homo sapiens (human),,dirltqspsslsasvgdrvtitcrasqaiagwlawyqqkpgrapksliyrasslqsgvpsrfsgsgsgtdfsltisnlqpedsatyycqhydsyptafgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1374,not found,SARS-CoV,Homo sapiens (human),,ettltqspsslsasvgdrvnitcrasqsistyltwyqqkpgkapklliygasslhsgvpsrftgvgsgteftlsisslqpedfatyycqqsyntfftfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1375,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1376,not found,SARS-CoV,Homo sapiens (human),,ettltqsplflpvtlgqpasiscrssqrlvhtngntylnwfqqrpghsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1377,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgspgqsvsiscsgtssdfgnynriswyqqtpgtapkviiyevnsrpsgvpdrfsgsksgntasltitglqaedeadyyccsyrsdntyifgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1378,not found,SARS-CoV,Homo sapiens (human),,qsaliqprsvsgspgqsvtisctgtssdvggsnyvswyqqhpgkapkllvydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagtyifgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1379,not found,SARS-CoV,Homo sapiens (human),,qsaliqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssyisdiklvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1380,not found,SARS-CoV,Homo sapiens (human),,dirmtqspsslsasvgdrvtitcrasqgfgnkvawyqqkpgtapklliyetstlqsgvpsrfsgsgsgtefaftisslqpedgatyycqkynrapwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1381,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsgaprqkvtiscsgssaniasngvnwyqqlpgkapklliyyddlvssgvsdrfsgsksgtsaslaisglqsedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1382,not found,SARS-CoV,Homo sapiens (human),,divmtqspgtlslspgeraalscrasqivtrsqlawyqhkpgqpprlliydsssratgtpdrfsgsgsgtdftltisrlepedsavyychqysgsatfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1383,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1384,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqivvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1385,not found,SARS-CoV,Homo sapiens (human),,eivmtqspsslsasvgdrvtitcrasqsisyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfiltisslqpediatyycqhsyssppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1386,not found,SARS-CoV,Homo sapiens (human),,divltqtpsslsasvgdrvtitcrasqtiatylswyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsysipwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1387,not found,SARS-CoV,Homo sapiens (human),,ettltqspatlslspgegatlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdytltisslepedfavyychqrsnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1388,not found,SARS-CoV,Homo sapiens (human),,syvltqppsvsvspgqtaritcsadglpkqysywyqqkpgqapvmviykdterpsgiperfsgsssgttatltisgvqaedeadyycqsadsndsspvfgggtqltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1389,not found,SARS-CoV,Homo sapiens (human),,dirmtqsplslpvtlgqpasiscrssqfvvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1390,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1391,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1392,not found,SARS-CoV,Homo sapiens (human),,diqltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1393,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslpvglgqsasiscrssqwvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1394,not found,SARS-CoV,Homo sapiens (human),,qpvltqpasvsgspgqsitisctgttsdvggydyvswyqqrpgkapkliiydvinrpsgvsnrfsgsksgntasltisglqaddetdyycssytsggtlvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1395,not found,SARS-CoV,Homo sapiens (human),,dirltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1396,not found,SARS-CoV,Homo sapiens (human),,qsvltqpasvsgspgqsitiscavtssdvgsynlvswhqqhpgkapklmiyevnkrpsgvsnrfsgsksgntasltisglqaedeavyyccsyggrstsvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1397,not found,SARS-CoV,Homo sapiens (human),,ettltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1398,not found,SARS-CoV,Homo sapiens (human),,ettltqsplflpvtlgqpasisctssvhvvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtyftlkisrveaedvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1399,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslpvtlgqaasiscksshfivhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftleisgveaedvgvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1400,not found,SARS-CoV,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsiniylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystplitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1401,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvsrgqsasiscrsshsvvhsdgktyvnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgfdftlkisrveaedvgvyfcmqgtdwprsfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1402,not found,SARS-CoV,Homo sapiens (human),,eivmtqsplslpvslgqpasiscrssqsvihtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1403,not found,SARS-CoV,Homo sapiens (human),,ettltqspgtlsvspgeratlscrasqsvisnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltiaslqsedfavyycqqyhhwppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1404,not found,SARS-CoV,Homo sapiens (human),,dirmtqspstlsasvgdrvtitcrasqtigswlawyqqkpgkapnlliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynslytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1405,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslsvtlgqaasiscrpnlglmhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfagsgsgthftleisgveaddvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1406,not found,SARS-CoV,Homo sapiens (human),,divltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1407,not found,SARS-CoV,Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiannyvqwlqqrpgsspttiiyednqrpsgvpdrfsgsidassnsasltisglktedeadyycqsydsssqvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1408,not found,SARS-CoV,Homo sapiens (human),,qpvltqspsasaslggsvkltctltsghstyaiawhqqqpekgprflmklnsdgshnkgdgipdrfsgsssgaeryltisslqsedeadyychtwgtdiqvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1409,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvgtylawyqqkhgqaprllisdvskratgiparfsgsgsgtdftltitslepedfavyycqqrtnwpgatfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1410,not found,SARS-CoV,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqktgkapelliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyrfpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1411,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1412,not found,SARS-CoV,Homo sapiens (human),,eivltqspsslsasvgdrvtitcrasrsissylnwyqqkpgkapnlliydastlqsgvpsrfsgsgsgtdfsltisslqpedfatyyclhtyttprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1413,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsasgtpgqrvtiscsgsysnigtnpanwyqqlpgtapklliynndqrpsgvpdrfsgsksgtsaslaisglqsedetdyycatwddslngvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1414,not found,SARS-CoV,Homo sapiens (human),,dirmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgvtfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1415,not found,SARS-CoV,Homo sapiens (human),,diqltqspsamsasvgdrvtitcrasqgindnlawfqqkpgkvpkrliyaasnlqngvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1416,not found,SARS-CoV,Homo sapiens (human),,qpvltqsssasaslgssvkltctlrsghssyiiawhqqqpgkaprflmkvghsgsynkgsgvpdrfsgsrsgadhyltisnlqpddeadyyceawdnnnlgvfsggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1417,not found,SARS-CoV,Homo sapiens (human),,qpvltqsssasaslgssvkltctlssghssyilawhqqqpgkaprflmkfevggrynkgsgvpdrfsgsssgadryltisnlqsedeadyycetwdsnlkgvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1418,not found,SARS-CoV,Homo sapiens (human),,divmtqtpgtlsvspgeratlscrasqiinrsqlgwyqhkpgqpprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1419,not found,SARS-CoV,Homo sapiens (human),,diqltqspatlslspgeratlscranqsvsnflawyqqkpgqaprhliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1420,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyyclqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1421,not found,SARS-CoV,Homo sapiens (human),,dirvtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1422,not found,SARS-CoV,Homo sapiens (human),,qsvliqpasvsgspgqsitisctgsssdvgsynlvswyqqhpgkapklmiyegykrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagssavvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1423,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtmatltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1424,not found,SARS-CoV,Homo sapiens (human),,divltqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvifgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1425,not found,SARS-CoV,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvtfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1426,not found,SARS-CoV,Homo sapiens (human),,diqvtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkaptlliytasnlqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystpgfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1427,not found,SARS-CoV,Homo sapiens (human),,diqvtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1428,not found,SARS-CoV,Homo sapiens (human),,diqltqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykassletgvpsrfsgsgsgteftltisslqpddfatyycqqyksplsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1429,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqglvhtngnlylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1430,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsvsaapgqkvtiscsgsssniennyvswyqqlpgaapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdfslsagvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1431,not found,SARS-CoV,Homo sapiens (human),,divvtqspgtlslspgeraalscrasqsvgnnylawyqqkpgqaprlliygatsratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1432,not found,SARS-CoV,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1433,not found,SARS-CoV,Homo sapiens (human),,ettltqspvtlpvtlgqpasisctssrwlvhtngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlqisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1434,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkinrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1435,not found,SARS-CoV,Homo sapiens (human),,dirmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1436,not found,SARS-CoV,Homo sapiens (human),,ettltqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1437,not found,SARS-CoV,Homo sapiens (human),,eivltqspgtlslspgdrvtlfcrasqniannhlawyqqkpgqaprvliygasttatdipdrfsgrvsgtdftltisrldpedfavyychqygsspwtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1438,not found,SARS-CoV,Homo sapiens (human),,qpvltqpasvsgspgqsstlscsgtssdvgsydlvswyqqhpgkapklmiyegtkrpsgvsdrfsgstsgntasltisglqaedeanyyccsyagsgtwifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1439,not found,SARS-CoV,Homo sapiens (human),,eivmtqspsslsasvgdrvtitcraghtistylnwyqqkpgkapkilisgasslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1440,not found,SARS-CoV,Homo sapiens (human),,dirvtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1441,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqglvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1442,not found,SARS-CoV,Homo sapiens (human),,eivmtqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1443,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedqadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1444,not found,SARS-CoV,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1445,not found,SARS-CoV,Homo sapiens (human),,diqvtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1446,not found,SARS-CoV,Homo sapiens (human),,ettltqspvtlsvspgeratlscrasqsvisnlawyqqkpgqaprllifgastratgvparfsgsgsgteftltisslqsedfavyycqqynnwpsltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1447,not found,SARS-CoV,Homo sapiens (human),,divltqsplslpvglgqsasiscrssqrvvhtdgntylhwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1448,not found,SARS-CoV,Homo sapiens (human),,diqltqsplslpvglgqsasiscrssqrvvhtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqstdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1449,not found,SARS-CoV,Homo sapiens (human),,divmtqtplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1450,not found,SARS-CoV,Homo sapiens (human),,diqltqspatlsvspgeratlscrasqsvtkhlawyqqkpgqaprlliygastratgvparfsgsgsdtefsltisslqsedfavyycqqyyswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1451,not found,SARS-CoV,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtnsdisnsysvswyqqypgkapklvifdvinrpsgvsnrfsgsksgntasltisglqaddeadyyccsytrtntpvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1452,not found,SARS-CoV,Homo sapiens (human),,dirmtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1453,not found,SARS-CoV,Homo sapiens (human),,qsaliqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1454,not found,SARS-CoV,Homo sapiens (human),,dirltqtplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1455,not found,SARS-CoV,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapkltvydvrnrpsgvsnrfsgsksgntasltisglqaedeahyycssytstntvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1456,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1457,not found,SARS-CoV,Homo sapiens (human),,eivltqspsslsasvgdrvtitcrasqdisnylawyqqkpgkapklliyaastlqsgvplrfsgsgsgtdftltisslqpedfatyyclqlhnyssfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1458,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslpvtlgqpasisctssqdvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedagiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1459,not found,SARS-CoV,Homo sapiens (human),,dirltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsgwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1460,not found,SARS-CoV,Homo sapiens (human),,qpvltqpasvsgspgqsitisctgtssdvgsfnyvswyqqhpgkapklviydvynrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1461,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1462,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvslgqpasiscrssqsvvhtdgntylnwyqqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvavyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1463,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrsshslvhtngntylnwfqqrpgqpprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaddvgiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1464,not found,SARS-CoV,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlfssnnknylawyqqkpglppklliywastrksgvsdrfsgsgsgtdftltisslqaedvavyycqqyyttplftfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1465,not found,SARS-CoV,Homo sapiens (human),,eivmtqtplslpvtlgqpasiscrssqfvshtdgntylnwfqqrpgqsprrliykvskrdsgvpdrfsgsgsgtdftltisrveaedvgvyycmqatewprtfgqgtkveyq,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1466,not found,SARS-CoV,Homo sapiens (human),,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkigqppklliywasiresgvpdrftgsgsgtdftltisslqaedvavyycqqyystpptfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1467,not found,SARS-CoV,Homo sapiens (human),,divltqsplslsvtpgqpasiscrssqslqhtdgktylywylqkpgqspqlliyelfnrfsgvperfsgsgsgtdftlkisrveaedvgiyycmqsiqtpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1468,not found,SARS-CoV,Homo sapiens (human),,qsvvtqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydsdkrpsgiperfsgsksatsatlgitglqtgdeadyycetwddslsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1469,not found,SARS-CoV,Homo sapiens (human),,eivltqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlqpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1470,not found,SARS-CoV,Homo sapiens (human),,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratniparfsgsgsgteftltisslqsedfavyycqqynlwpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1471,not found,SARS-CoV,Homo sapiens (human),,divmtqsplalsvtpgqpasisckssqsllhsdgktyfywylqkpgqsphlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqvpitfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1472,not found,SARS-CoV,Homo sapiens (human),,eivmtqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1473,not found,SARS-CoV,Homo sapiens (human),,qsvltqpsslsaspgasasltctlhsgfnvgdhtinwyqqrpgsppryllkyksdsdkeqgsgvpirfsgskdasanagfllisglrsedeadyycmiwhdnavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1474,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1475,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1476,not found,SARS-CoV,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1477,not found,SARS-CoV,Homo sapiens (human),,dirltqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliyeasnratgvparfsgsgsgtdftlaisslepedfavyycqhrsnwpprytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1478,not found,SARS-CoV,Homo sapiens (human),,eivmtqspgtlslspgervtlscratqsvsnnhlawyqqkpgqaprlliygasttatdipdrfsgrvagtdftltisrldpedfavyychqygsspwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1479,not found,SARS-CoV,Homo sapiens (human),,divltqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1480,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgvprqkvtiscsgstaniasngvnwyqlvpgkaprllisyddlvpsgvsarfsgsksgtsaslaisglqaedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1481,not found,SARS-CoV,Homo sapiens (human),,qpvltqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1482,not found,SARS-CoV,Homo sapiens (human),,eivltqspstlsasvgdrvtitcrasqnvnnwlawyqqkpgkapklliyeastlksgvpsrfsgsgsgteftltisslqpddfatyycqqynsqytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1483,not found,SARS-CoV,Homo sapiens (human),,dirvtqspsslsasvgdrvtitcrasqtinnylnwyqqkpgkapnlliyaastlqngvpsrfsgsgsgtdftltissvqpedfatyycqqtyitptwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1484,not found,SARS-CoV,Homo sapiens (human),,diqltqspatlslspgeratlscraspsvftflawyqqrpgqpprllihdvsnrapgiparfsgsgsgtdftliisslepddsavyfcqqrsdgynfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1485,not found,SARS-CoV,Homo sapiens (human),,eivltqspgtlsvspgeratlscrasqiinrsqlgwyqhkpgqaprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1486,not found,SARS-CoV,Homo sapiens (human),,qpvltqpasvsgspgqsitisctgtssdvgnynvvswyqqhpgkapqlfiyedtkrpsgvsdrfsgsksgitasltisrlqpedeadyyccsyavsgtvlfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1487,not found,SARS-CoV,Homo sapiens (human),,dirltqspdslalslgeratinckssqsvlfssnnnnylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyltpwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1488,not found,SARS-CoV,Homo sapiens (human),,dirvtqspsslsatvgdrvtitcrasqtitkylnwyqqkpgkapklllygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitpgtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1489,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslpvdlgqsasiscrssqtvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1490,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1491,not found,SARS-CoV,Homo sapiens (human),,qpgltqpasvsgspgqsitisctrtsgdvgdynsvswyvswyqqhpgrapklmlydvsnrpsgvsnrfsgsklgdtasltiselqaedeadyycstytststifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1492,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1493,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvdlgqsasiscrssqtavhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrinrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1494,not found,SARS-CoV,Homo sapiens (human),,eivmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1495,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1496,not found,SARS-CoV,Homo sapiens (human),,cirltqspatlslspgeratlscrasqsvtsylawyqqrpgqaprlliydtsnrvtgvpvrfsgsgygtdftltisslepedfavyycqqrgngytfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1497,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1498,not found,SARS-CoV,Homo sapiens (human),,ettltqspasvsasvgdrvtiscrasqgigrwlawyqqkpgrapkllifsasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaesfpftfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1499,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrssqrlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1500,not found,SARS-CoV,Homo sapiens (human),,dirmtqspfslsasvgdrvtitcrasqgfgnrlawyqqkpgrapklliydastlqsgvpsrfsgsgsetdfaltisslqpedvatyycqkhdrdpwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1501,not found,SARS-CoV,Homo sapiens (human),,qpgltqepsltvspggtvtltcgssagavtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeaeyfcflsyrgappvfgggthltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1502,not found,SARS-CoV,Homo sapiens (human),,dirltqspatlslspgeratlscrasqsigyylawfqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqhrtnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1503,not found,SARS-CoV,Homo sapiens (human),,divltqtpatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1504,not found,SARS-CoV,Homo sapiens (human),,diqltqsplslpvtlgqpasisctssqnvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1505,not found,SARS-CoV,Homo sapiens (human),,ettltqspgtlslspgeratlscrasqsvgnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1506,not found,SARS-CoV,Homo sapiens (human),,eivmtqtplslpvtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliyqvshrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1507,not found,SARS-CoV,Homo sapiens (human),,diqmtqsplslpvtlgqaasiscrssqpiphtdgntylnwfhqrpgqsprrlihkvsnrdsgvpdrfsgsgsgldftleisgveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1508,not found,SARS-CoV,Homo sapiens (human),,nfmltqphsvsespgkaviisctrssgniasnfvqwyqqrpgssptpviyedklrpsgvpdrfsgsidrssnsasltisglktedeadyycqsydsgnlvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1509,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslsvtlgqaasisctcsqsavhsdgntyfnwfhqrpgqsprrliykvsnrdsgvperfsgsgsgthftliisrveaedvgvyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1510,not found,SARS-CoV,Homo sapiens (human),,eivltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1511,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1512,not found,SARS-CoV,Homo sapiens (human),,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1513,not found,SARS-CoV,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydsskratgspdrfsasgsgtdftltisglepedtgiyyclqysdattfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1514,not found,SARS-CoV,Homo sapiens (human),,divmtqtplslavtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1515,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsvsaapgqkvtiscsgsssnigdnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdtslsvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1516,not found,SARS-CoV,Homo sapiens (human),,eivltqspgtlslspgeraslscrasqsvsssylawyqhrpgqaprlliydassratgipdrfsgsgsgtdftltisrlesedfavyycqqygnsprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1517,not found,SARS-CoV,Homo sapiens (human),,ettltqspgtlslspgeratlscrasqsigssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsaplytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1518,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslpvtlgqpasiscrssqslvhsngntylnwfqqrpgqsprrliyevsnrdsgvpdrftgsgsgtdftlkisrveaedvgvyycmqgthwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1519,not found,SARS-CoV,Homo sapiens (human),,diqvtqspatvsvspgegaslscrasqsvrsnlawfqqkpgqaprllisdastrasgvparftgsgfgteftltisslqsedfaiyycqqyntwppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1520,not found,SARS-CoV,Homo sapiens (human),,diqltqsplslpvtlgqpasiscrssqhlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1521,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpetapklliyangnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1522,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqlpgtapklliydnnnrpsgvpdrfsgsrsgtsaslaitglqaedegdyfcqsydsslsasfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1523,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnlgnnyvswyqqlpgtapklliydnhkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdsslsvvvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1524,not found,SARS-CoV,Homo sapiens (human),,qpvltqpasvsgspgqsvtisctgtssdvgsysdvgnyvswyqhhpgkapklmiyevrtrpswvstrfsgsksgttasltisglqaedeadyyccsyagaspfvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1525,not found,SARS-CoV,Homo sapiens (human),,etgltqipfslpvtfgqpasiscrfsqrlvhtdgntnlnwflqrpgqfprgliykvfnrdsgvpdrfrgsgsgidftlkisrvevedvgiyygmqgtewlgtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1526,not found,SARS-CoV,Homo sapiens (human),,eivltqsplslpvtlgqpasiscrsslrlvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1527,not found,SARS-CoV,Homo sapiens (human),,dirltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1528,not found,SARS-CoV,Homo sapiens (human),,eivltqspdslavslgeratinckssqsvlyssnnenclawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqycstppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1529,not found,SARS-CoV,Homo sapiens (human),,dirmtqsplslpvtrgqpasiscrsshnvvhsdgktylnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgsdftltisrveaedvgvyycmqgtdwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1530,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqglvhsngntyvnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1531,not found,SARS-CoV,Homo sapiens (human),,eivltqspsslsasvgdrvtitcqasqdirkclnwyqhipgkapkllihdasslesgvpsrfsgsgsgtdfsftinslhpediatyycqqfedlpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1532,not found,SARS-CoV,Homo sapiens (human),,divltqtpatlsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydastratgvparftgsgsgtyftltisslqsedfavyycqqynswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1533,not found,SARS-CoV,Homo sapiens (human),,dirltqspsslsasvgdrvtiacrasqsvsnylnwyqqkpgkapklliyaasslqngvpsrfggsgsgtdftltisslqpedfatyycqqcysypptfghgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1534,not found,SARS-CoV,Homo sapiens (human),,ettltqsplslpvtlgqpasiscrssqglahsngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1535,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlsvspgdgaslscrasqsvgsnlawyqqkpgqaprllisdasaratgvparftgsgsgtdftltisslqsedfavyychqyntwppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1536,not found,SARS-CoV,Homo sapiens (human),,eivmtqspsslsasvgdrvtitcrasqsisnylywyqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpynfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1537,not found,SARS-CoV,Homo sapiens (human),,divltqtpsslsasvgdrvtitcrasqtisyylnwyqqkvgkapqllvyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysvpltlgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1538,not found,SARS-CoV,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqvpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1539,not found,SARS-CoV,Homo sapiens (human),,eivmtqspsslsasigdrvtiscrasqnigsylnwyqqrpgkapnllifvasslqsgvpsrfsgsgsgtdftltisslqaedfatyycqqsyttpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1540,not found,SARS-CoV,Homo sapiens (human),,eivltqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1541,not found,SARS-CoV,Homo sapiens (human),,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
1542,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1543,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1544,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1545,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1546,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
1547,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
1548,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
1549,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
1550,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1551,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1552,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1553,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1554,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmrsvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1555,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlhgdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1556,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1557,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1558,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1559,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1560,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1561,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1562,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1563,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1564,not found,SARS-CoV,Homo sapiens (human),evqlvesggdlvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1565,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1566,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslgaddtavyycardfsghtawagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1567,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssisedgynpyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1568,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1569,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1570,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnnlrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1571,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1572,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1573,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyttyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1574,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsayymnwvrqapgkglewvssissdgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1575,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1576,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfplrgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1577,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysdgdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1578,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1579,not found,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1580,not found,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1581,not found,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
1582,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 828 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 828 from patent US 10975139,2022-03-01
1583,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 824 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 824 from patent US 10975139,2022-03-01
1584,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 810 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 810 from patent US 10975139,2022-03-01
1585,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 808 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 808 from patent US 10975139,2022-03-01
1586,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 804 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 804 from patent US 10975139,2022-03-01
1587,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 796 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 796 from patent US 10975139,2022-03-01
1588,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 794 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 794 from patent US 10975139,2022-03-01
1589,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 790 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 790 from patent US 10975139,2022-03-01
1590,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 780 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 780 from patent US 10975139,2022-03-01
1591,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 778 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 778 from patent US 10975139,2022-03-01
1592,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 774 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 774 from patent US 10975139,2022-03-01
1593,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 764 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 764 from patent US 10975139,2022-03-01
1594,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 762 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 762 from patent US 10975139,2022-03-01
1595,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 759 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 759 from patent US 10975139,2022-03-01
1596,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 757 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 757 from patent US 10975139,2022-03-01
1597,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 753 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 753 from patent US 10975139,2022-03-01
1598,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 751 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 751 from patent US 10975139,2022-03-01
1599,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 747 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 747 from patent US 10975139,2022-03-01
1600,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 737 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 737 from patent US 10975139,2022-03-01
1601,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 735 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 735 from patent US 10975139,2022-03-01
1602,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 731 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 731 from patent US 10975139,2022-03-01
1603,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 723 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 723 from patent US 10975139,2022-03-01
1604,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 721 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 721 from patent US 10975139,2022-03-01
1605,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 717 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 717 from patent US 10975139,2022-03-01
1606,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 708 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 708 from patent US 10975139,2022-03-01
1607,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 706 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 706 from patent US 10975139,2022-03-01
1608,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 704 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 704 from patent US 10975139,2022-03-01
1609,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 702 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 702 from patent US 10975139,2022-03-01
1610,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 700 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 700 from patent US 10975139,2022-03-01
1611,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 698 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 698 from patent US 10975139,2022-03-01
1612,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 696 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 696 from patent US 10975139,2022-03-01
1613,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 692 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 692 from patent US 10975139,2022-03-01
1614,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 678 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 678 from patent US 10975139,2022-03-01
1615,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 674 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 674 from patent US 10975139,2022-03-01
1616,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 658 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 658 from patent US 10975139,2022-03-01
1617,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 654 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 654 from patent US 10975139,2022-03-01
1618,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 640 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 640 from patent US 10975139,2022-03-01
1619,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 636 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 636 from patent US 10975139,2022-03-01
1620,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 624 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 624 from patent US 10975139,2022-03-01
1621,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 620 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 620 from patent US 10975139,2022-03-01
1622,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 608 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 608 from patent US 10975139,2022-03-01
1623,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 604 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 604 from patent US 10975139,2022-03-01
1624,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 594 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 594 from patent US 10975139,2022-03-01
1625,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 592 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 592 from patent US 10975139,2022-03-01
1626,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 588 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 588 from patent US 10975139,2022-03-01
1627,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 574 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 574 from patent US 10975139,2022-03-01
1628,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 572 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 572 from patent US 10975139,2022-03-01
1629,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 570 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 570 from patent US 10975139,2022-03-01
1630,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 568 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 568 from patent US 10975139,2022-03-01
1631,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 566 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 566 from patent US 10975139,2022-03-01
1632,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 562 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 562 from patent US 10975139,2022-03-01
1633,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 548 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 548 from patent US 10975139,2022-03-01
1634,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 546 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 546 from patent US 10975139,2022-03-01
1635,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 544 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 544 from patent US 10975139,2022-03-01
1636,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 542 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 542 from patent US 10975139,2022-03-01
1637,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 540 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 540 from patent US 10975139,2022-03-01
1638,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 536 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 536 from patent US 10975139,2022-03-01
1639,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 524 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 524 from patent US 10975139,2022-03-01
1640,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 520 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 520 from patent US 10975139,2022-03-01
1641,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 510 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 510 from patent US 10975139,2022-03-01
1642,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 506 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 506 from patent US 10975139,2022-03-01
1643,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 495 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 495 from patent US 10975139,2022-03-01
1644,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 491 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 491 from patent US 10975139,2022-03-01
1645,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 480 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 480 from patent US 10975139,2022-03-01
1646,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 476 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 476 from patent US 10975139,2022-03-01
1647,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 468 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 468 from patent US 10975139,2022-03-01
1648,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 464 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 464 from patent US 10975139,2022-03-01
1649,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 451 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 451 from patent US 10975139,2022-03-01
1650,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 447 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 447 from patent US 10975139,2022-03-01
1651,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 432 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 432 from patent US 10975139,2022-03-01
1652,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 430 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 430 from patent US 10975139,2022-03-01
1653,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 428 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 428 from patent US 10975139,2022-03-01
1654,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 426 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 426 from patent US 10975139,2022-03-01
1655,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 424 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 424 from patent US 10975139,2022-03-01
1656,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 420 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 420 from patent US 10975139,2022-03-01
1657,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 409 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 409 from patent US 10975139,2022-03-01
1658,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 405 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 405 from patent US 10975139,2022-03-01
1659,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 396 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 396 from patent US 10975139,2022-03-01
1660,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 392 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 392 from patent US 10975139,2022-03-01
1661,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 381 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 381 from patent US 10975139,2022-03-01
1662,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 377 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 377 from patent US 10975139,2022-03-01
1663,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 366 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 366 from patent US 10975139,2022-03-01
1664,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 364 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 364 from patent US 10975139,2022-03-01
1665,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 362 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 362 from patent US 10975139,2022-03-01
1666,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 360 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 360 from patent US 10975139,2022-03-01
1667,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 358 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 358 from patent US 10975139,2022-03-01
1668,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 356 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 356 from patent US 10975139,2022-03-01
1669,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 354 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 354 from patent US 10975139,2022-03-01
1670,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 352 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 352 from patent US 10975139,2022-03-01
1671,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 350 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 350 from patent US 10975139,2022-03-01
1672,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 348 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 348 from patent US 10975139,2022-03-01
1673,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 346 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 346 from patent US 10975139,2022-03-01
1674,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 342 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 342 from patent US 10975139,2022-03-01
1675,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 333 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 333 from patent US 10975139,2022-03-01
1676,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 329 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 329 from patent US 10975139,2022-03-01
1677,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 316 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 316 from patent US 10975139,2022-03-01
1678,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 312 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 312 from patent US 10975139,2022-03-01
1679,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 302 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 302 from patent US 10975139,2022-03-01
1680,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 298 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 298 from patent US 10975139,2022-03-01
1681,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 284 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 284 from patent US 10975139,2022-03-01
1682,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 280 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 280 from patent US 10975139,2022-03-01
1683,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 268 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 268 from patent US 10975139,2022-03-01
1684,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 264 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 264 from patent US 10975139,2022-03-01
1685,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 252 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 252 from patent US 10975139,2022-03-01
1686,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 248 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 248 from patent US 10975139,2022-03-01
1687,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 238 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 238 from patent US 10975139,2022-03-01
1688,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 234 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 234 from patent US 10975139,2022-03-01
1689,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 220 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 220 from patent US 10975139,2022-03-01
1690,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 216 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 216 from patent US 10975139,2022-03-01
1691,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 202 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 202 from patent US 10975139,2022-03-01
1692,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 198 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 198 from patent US 10975139,2022-03-01
1693,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 185 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 185 from patent US 10975139,2022-03-01
1694,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 183 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 183 from patent US 10975139,2022-03-01
1695,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 179 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 179 from patent US 10975139,2022-03-01
1696,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 167 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 167 from patent US 10975139,2022-03-01
1697,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 165 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 165 from patent US 10975139,2022-03-01
1698,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 163 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 163 from patent US 10975139,2022-03-01
1699,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 161 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 161 from patent US 10975139,2022-03-01
1700,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 159 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 159 from patent US 10975139,2022-03-01
1701,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 157 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 157 from patent US 10975139,2022-03-01
1702,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 153 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 153 from patent US 10975139,2022-03-01
1703,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 137 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 137 from patent US 10975139,2022-03-01
1704,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 133 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 133 from patent US 10975139,2022-03-01
1705,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 119 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 119 from patent US 10975139,2022-03-01
1706,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 115 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 115 from patent US 10975139,2022-03-01
1707,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 99 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 99 from patent US 10975139,2022-03-01
1708,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 95 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 95 from patent US 10975139,2022-03-01
1709,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 83 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 83 from patent US 10975139,2022-03-01
1710,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 79 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 79 from patent US 10975139,2022-03-01
1711,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 65 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 65 from patent US 10975139,2022-03-01
1712,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 63 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 63 from patent US 10975139,2022-03-01
1713,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 59 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 59 from patent US 10975139,2022-03-01
1714,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 44 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 44 from patent US 10975139,2022-03-01
1715,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 42 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 42 from patent US 10975139,2022-03-01
1716,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 38 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 38 from patent US 10975139,2022-03-01
1717,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 22 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 22 from patent US 10975139,2022-03-01
1718,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 18 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 18 from patent US 10975139,2022-03-01
1719,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 2 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 2 from patent US 10975139,2022-03-01
1720,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 826 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 826 from patent US 10975139,2022-03-01
1721,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 818 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 818 from patent US 10975139,2022-03-01
1722,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 806 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 806 from patent US 10975139,2022-03-01
1723,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 800 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 800 from patent US 10975139,2022-03-01
1724,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 792 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 792 from patent US 10975139,2022-03-01
1725,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 786 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 786 from patent US 10975139,2022-03-01
1726,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 776 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 776 from patent US 10975139,2022-03-01
1727,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 770 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 770 from patent US 10975139,2022-03-01
1728,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 749 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 749 from patent US 10975139,2022-03-01
1729,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 741 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 741 from patent US 10975139,2022-03-01
1730,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 733 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 733 from patent US 10975139,2022-03-01
1731,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 727 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 727 from patent US 10975139,2022-03-01
1732,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 719 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 719 from patent US 10975139,2022-03-01
1733,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 713 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 713 from patent US 10975139,2022-03-01
1734,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 694 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 694 from patent US 10975139,2022-03-01
1735,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 686 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 686 from patent US 10975139,2022-03-01
1736,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 676 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 676 from patent US 10975139,2022-03-01
1737,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 666 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 666 from patent US 10975139,2022-03-01
1738,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 656 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 656 from patent US 10975139,2022-03-01
1739,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 646 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 646 from patent US 10975139,2022-03-01
1740,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 638 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 638 from patent US 10975139,2022-03-01
1741,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 630 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 630 from patent US 10975139,2022-03-01
1742,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 622 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 622 from patent US 10975139,2022-03-01
1743,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 614 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 614 from patent US 10975139,2022-03-01
1744,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 606 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 606 from patent US 10975139,2022-03-01
1745,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 600 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 600 from patent US 10975139,2022-03-01
1746,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 590 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 590 from patent US 10975139,2022-03-01
1747,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 580 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 580 from patent US 10975139,2022-03-01
1748,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 564 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 564 from patent US 10975139,2022-03-01
1749,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 556 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 556 from patent US 10975139,2022-03-01
1750,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 538 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 538 from patent US 10975139,2022-03-01
1751,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 530 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 530 from patent US 10975139,2022-03-01
1752,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 522 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 522 from patent US 10975139,2022-03-01
1753,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 514 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 514 from patent US 10975139,2022-03-01
1754,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 508 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 508 from patent US 10975139,2022-03-01
1755,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 503 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 503 from patent US 10975139,2022-03-01
1756,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 493 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 493 from patent US 10975139,2022-03-01
1757,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 487 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 487 from patent US 10975139,2022-03-01
1758,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 478 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 478 from patent US 10975139,2022-03-01
1759,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 472 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 472 from patent US 10975139,2022-03-01
1760,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 466 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 466 from patent US 10975139,2022-03-01
1761,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 457 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 457 from patent US 10975139,2022-03-01
1762,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 449 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 449 from patent US 10975139,2022-03-01
1763,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 440 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 440 from patent US 10975139,2022-03-01
1764,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 422 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 422 from patent US 10975139,2022-03-01
1765,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 416 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 416 from patent US 10975139,2022-03-01
1766,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 407 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 407 from patent US 10975139,2022-03-01
1767,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 401 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 401 from patent US 10975139,2022-03-01
1768,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 394 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 394 from patent US 10975139,2022-03-01
1769,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 387 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 387 from patent US 10975139,2022-03-01
1770,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 379 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 379 from patent US 10975139,2022-03-01
1771,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 372 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 372 from patent US 10975139,2022-03-01
1772,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 344 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 344 from patent US 10975139,2022-03-01
1773,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 338 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 338 from patent US 10975139,2022-03-01
1774,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 331 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 331 from patent US 10975139,2022-03-01
1775,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 323 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 323 from patent US 10975139,2022-03-01
1776,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 314 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 314 from patent US 10975139,2022-03-01
1777,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 306 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 306 from patent US 10975139,2022-03-01
1778,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 300 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 300 from patent US 10975139,2022-03-01
1779,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 290 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 290 from patent US 10975139,2022-03-01
1780,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 282 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 282 from patent US 10975139,2022-03-01
1781,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 276 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 276 from patent US 10975139,2022-03-01
1782,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 266 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 266 from patent US 10975139,2022-03-01
1783,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 260 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 260 from patent US 10975139,2022-03-01
1784,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 250 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 250 from patent US 10975139,2022-03-01
1785,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 242 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 242 from patent US 10975139,2022-03-01
1786,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 236 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 236 from patent US 10975139,2022-03-01
1787,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 228 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 228 from patent US 10975139,2022-03-01
1788,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 218 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 218 from patent US 10975139,2022-03-01
1789,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 210 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 210 from patent US 10975139,2022-03-01
1790,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 200 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 200 from patent US 10975139,2022-03-01
1791,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 191 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 191 from patent US 10975139,2022-03-01
1792,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 181 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 181 from patent US 10975139,2022-03-01
1793,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 175 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 175 from patent US 10975139,2022-03-01
1794,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 155 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 155 from patent US 10975139,2022-03-01
1795,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 145 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 145 from patent US 10975139,2022-03-01
1796,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 135 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 135 from patent US 10975139,2022-03-01
1797,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 127 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 127 from patent US 10975139,2022-03-01
1798,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 117 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 117 from patent US 10975139,2022-03-01
1799,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 107 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 107 from patent US 10975139,2022-03-01
1800,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 97 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 97 from patent US 10975139,2022-03-01
1801,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 89 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 89 from patent US 10975139,2022-03-01
1802,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 81 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 81 from patent US 10975139,2022-03-01
1803,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 73 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 73 from patent US 10975139,2022-03-01
1804,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 61 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 61 from patent US 10975139,2022-03-01
1805,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 51 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 51 from patent US 10975139,2022-03-01
1806,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 40 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 40 from patent US 10975139,2022-03-01
1807,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 30 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 30 from patent US 10975139,2022-03-01
1808,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 20 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 20 from patent US 10975139,2022-03-01
1809,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 10 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 10 from patent US 10975139,2022-03-01
1810,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 828 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 828 from patent US 10954289,2022-03-01
1811,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 824 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 824 from patent US 10954289,2022-03-01
1812,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 810 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 810 from patent US 10954289,2022-03-01
1813,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 808 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 808 from patent US 10954289,2022-03-01
1814,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 804 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 804 from patent US 10954289,2022-03-01
1815,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 796 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 796 from patent US 10954289,2022-03-01
1816,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 794 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 794 from patent US 10954289,2022-03-01
1817,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 790 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 790 from patent US 10954289,2022-03-01
1818,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 780 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 780 from patent US 10954289,2022-03-01
1819,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 778 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 778 from patent US 10954289,2022-03-01
1820,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 774 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 774 from patent US 10954289,2022-03-01
1821,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 764 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 764 from patent US 10954289,2022-03-01
1822,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 762 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 762 from patent US 10954289,2022-03-01
1823,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 759 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 759 from patent US 10954289,2022-03-01
1824,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 757 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 757 from patent US 10954289,2022-03-01
1825,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 753 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 753 from patent US 10954289,2022-03-01
1826,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 751 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 751 from patent US 10954289,2022-03-01
1827,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 747 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 747 from patent US 10954289,2022-03-01
1828,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 737 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 737 from patent US 10954289,2022-03-01
1829,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 735 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 735 from patent US 10954289,2022-03-01
1830,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 731 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 731 from patent US 10954289,2022-03-01
1831,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 723 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 723 from patent US 10954289,2022-03-01
1832,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 721 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 721 from patent US 10954289,2022-03-01
1833,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 717 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 717 from patent US 10954289,2022-03-01
1834,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 708 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 708 from patent US 10954289,2022-03-01
1835,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 706 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 706 from patent US 10954289,2022-03-01
1836,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 704 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 704 from patent US 10954289,2022-03-01
1837,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 702 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 702 from patent US 10954289,2022-03-01
1838,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 700 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 700 from patent US 10954289,2022-03-01
1839,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 698 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 698 from patent US 10954289,2022-03-01
1840,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 696 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 696 from patent US 10954289,2022-03-01
1841,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 692 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 692 from patent US 10954289,2022-03-01
1842,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 678 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 678 from patent US 10954289,2022-03-01
1843,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 674 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 674 from patent US 10954289,2022-03-01
1844,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 658 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 658 from patent US 10954289,2022-03-01
1845,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 654 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 654 from patent US 10954289,2022-03-01
1846,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 640 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 640 from patent US 10954289,2022-03-01
1847,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 636 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 636 from patent US 10954289,2022-03-01
1848,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 624 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 624 from patent US 10954289,2022-03-01
1849,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 620 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 620 from patent US 10954289,2022-03-01
1850,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 608 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 608 from patent US 10954289,2022-03-01
1851,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 604 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 604 from patent US 10954289,2022-03-01
1852,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 594 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 594 from patent US 10954289,2022-03-01
1853,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 592 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 592 from patent US 10954289,2022-03-01
1854,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 588 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 588 from patent US 10954289,2022-03-01
1855,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 574 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 574 from patent US 10954289,2022-03-01
1856,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 572 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 572 from patent US 10954289,2022-03-01
1857,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 570 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 570 from patent US 10954289,2022-03-01
1858,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 568 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 568 from patent US 10954289,2022-03-01
1859,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 566 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 566 from patent US 10954289,2022-03-01
1860,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 562 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 562 from patent US 10954289,2022-03-01
1861,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 548 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 548 from patent US 10954289,2022-03-01
1862,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 546 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 546 from patent US 10954289,2022-03-01
1863,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 544 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 544 from patent US 10954289,2022-03-01
1864,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 542 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 542 from patent US 10954289,2022-03-01
1865,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 540 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 540 from patent US 10954289,2022-03-01
1866,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 536 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 536 from patent US 10954289,2022-03-01
1867,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 524 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 524 from patent US 10954289,2022-03-01
1868,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 520 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 520 from patent US 10954289,2022-03-01
1869,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 510 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 510 from patent US 10954289,2022-03-01
1870,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 506 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 506 from patent US 10954289,2022-03-01
1871,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 495 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 495 from patent US 10954289,2022-03-01
1872,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 491 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 491 from patent US 10954289,2022-03-01
1873,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 480 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 480 from patent US 10954289,2022-03-01
1874,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 476 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 476 from patent US 10954289,2022-03-01
1875,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 468 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 468 from patent US 10954289,2022-03-01
1876,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 464 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 464 from patent US 10954289,2022-03-01
1877,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 451 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 451 from patent US 10954289,2022-03-01
1878,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 447 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 447 from patent US 10954289,2022-03-01
1879,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 432 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 432 from patent US 10954289,2022-03-01
1880,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 430 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 430 from patent US 10954289,2022-03-01
1881,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 428 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 428 from patent US 10954289,2022-03-01
1882,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 426 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 426 from patent US 10954289,2022-03-01
1883,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 424 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 424 from patent US 10954289,2022-03-01
1884,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 420 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 420 from patent US 10954289,2022-03-01
1885,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 409 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 409 from patent US 10954289,2022-03-01
1886,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 405 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 405 from patent US 10954289,2022-03-01
1887,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 396 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 396 from patent US 10954289,2022-03-01
1888,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 392 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 392 from patent US 10954289,2022-03-01
1889,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 381 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 381 from patent US 10954289,2022-03-01
1890,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 377 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 377 from patent US 10954289,2022-03-01
1891,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 366 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 366 from patent US 10954289,2022-03-01
1892,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 364 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 364 from patent US 10954289,2022-03-01
1893,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 362 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 362 from patent US 10954289,2022-03-01
1894,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 360 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 360 from patent US 10954289,2022-03-01
1895,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 358 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 358 from patent US 10954289,2022-03-01
1896,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 356 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 356 from patent US 10954289,2022-03-01
1897,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 354 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 354 from patent US 10954289,2022-03-01
1898,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 352 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 352 from patent US 10954289,2022-03-01
1899,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 350 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 350 from patent US 10954289,2022-03-01
1900,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 348 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 348 from patent US 10954289,2022-03-01
1901,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 346 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 346 from patent US 10954289,2022-03-01
1902,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 342 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 342 from patent US 10954289,2022-03-01
1903,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 333 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 333 from patent US 10954289,2022-03-01
1904,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 329 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 329 from patent US 10954289,2022-03-01
1905,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 316 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 316 from patent US 10954289,2022-03-01
1906,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 312 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 312 from patent US 10954289,2022-03-01
1907,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 302 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 302 from patent US 10954289,2022-03-01
1908,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 298 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 298 from patent US 10954289,2022-03-01
1909,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 284 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 284 from patent US 10954289,2022-03-01
1910,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 280 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 280 from patent US 10954289,2022-03-01
1911,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 268 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 268 from patent US 10954289,2022-03-01
1912,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 264 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 264 from patent US 10954289,2022-03-01
1913,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 252 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 252 from patent US 10954289,2022-03-01
1914,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 248 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 248 from patent US 10954289,2022-03-01
1915,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 238 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 238 from patent US 10954289,2022-03-01
1916,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 234 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 234 from patent US 10954289,2022-03-01
1917,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 220 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 220 from patent US 10954289,2022-03-01
1918,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 216 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 216 from patent US 10954289,2022-03-01
1919,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 202 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 202 from patent US 10954289,2022-03-01
1920,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 198 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 198 from patent US 10954289,2022-03-01
1921,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 185 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 185 from patent US 10954289,2022-03-01
1922,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 183 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 183 from patent US 10954289,2022-03-01
1923,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 179 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 179 from patent US 10954289,2022-03-01
1924,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 167 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 167 from patent US 10954289,2022-03-01
1925,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 165 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 165 from patent US 10954289,2022-03-01
1926,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 163 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 163 from patent US 10954289,2022-03-01
1927,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 161 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 161 from patent US 10954289,2022-03-01
1928,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 159 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 159 from patent US 10954289,2022-03-01
1929,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 157 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 157 from patent US 10954289,2022-03-01
1930,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 153 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 153 from patent US 10954289,2022-03-01
1931,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 137 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 137 from patent US 10954289,2022-03-01
1932,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 133 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 133 from patent US 10954289,2022-03-01
1933,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 119 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 119 from patent US 10954289,2022-03-01
1934,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 115 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 115 from patent US 10954289,2022-03-01
1935,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 99 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 99 from patent US 10954289,2022-03-01
1936,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 95 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 95 from patent US 10954289,2022-03-01
1937,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 83 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 83 from patent US 10954289,2022-03-01
1938,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 79 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 79 from patent US 10954289,2022-03-01
1939,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 65 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 65 from patent US 10954289,2022-03-01
1940,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 63 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 63 from patent US 10954289,2022-03-01
1941,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 59 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 59 from patent US 10954289,2022-03-01
1942,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 44 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 44 from patent US 10954289,2022-03-01
1943,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 42 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 42 from patent US 10954289,2022-03-01
1944,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 38 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 38 from patent US 10954289,2022-03-01
1945,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 22 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 22 from patent US 10954289,2022-03-01
1946,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 18 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 18 from patent US 10954289,2022-03-01
1947,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 2 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VH: Sequence 2 from patent US 10954289,2022-03-01
1948,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 828 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 828 from patent US 10787501,2022-03-01
1949,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 824 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 824 from patent US 10787501,2022-03-01
1950,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 810 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 810 from patent US 10787501,2022-03-01
1951,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 808 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 808 from patent US 10787501,2022-03-01
1952,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 804 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 804 from patent US 10787501,2022-03-01
1953,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 796 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 796 from patent US 10787501,2022-03-01
1954,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 794 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 794 from patent US 10787501,2022-03-01
1955,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 790 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 790 from patent US 10787501,2022-03-01
1956,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 780 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 780 from patent US 10787501,2022-03-01
1957,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 778 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 778 from patent US 10787501,2022-03-01
1958,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 774 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 774 from patent US 10787501,2022-03-01
1959,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 764 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 764 from patent US 10787501,2022-03-01
1960,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 762 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 762 from patent US 10787501,2022-03-01
1961,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 759 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 759 from patent US 10787501,2022-03-01
1962,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 757 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 757 from patent US 10787501,2022-03-01
1963,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 753 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 753 from patent US 10787501,2022-03-01
1964,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 751 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 751 from patent US 10787501,2022-03-01
1965,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 747 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 747 from patent US 10787501,2022-03-01
1966,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 737 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 737 from patent US 10787501,2022-03-01
1967,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 735 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 735 from patent US 10787501,2022-03-01
1968,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 731 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 731 from patent US 10787501,2022-03-01
1969,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 723 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 723 from patent US 10787501,2022-03-01
1970,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 721 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 721 from patent US 10787501,2022-03-01
1971,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 717 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 717 from patent US 10787501,2022-03-01
1972,not found,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 708 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 708 from patent US 10787501,2022-03-01
1973,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 706 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 706 from patent US 10787501,2022-03-01
1974,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 704 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 704 from patent US 10787501,2022-03-01
1975,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 702 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 702 from patent US 10787501,2022-03-01
1976,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 700 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 700 from patent US 10787501,2022-03-01
1977,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 698 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 698 from patent US 10787501,2022-03-01
1978,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 696 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 696 from patent US 10787501,2022-03-01
1979,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 692 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 692 from patent US 10787501,2022-03-01
1980,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 678 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 678 from patent US 10787501,2022-03-01
1981,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 674 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 674 from patent US 10787501,2022-03-01
1982,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 658 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 658 from patent US 10787501,2022-03-01
1983,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 654 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 654 from patent US 10787501,2022-03-01
1984,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 640 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 640 from patent US 10787501,2022-03-01
1985,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 636 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 636 from patent US 10787501,2022-03-01
1986,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 624 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 624 from patent US 10787501,2022-03-01
1987,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 620 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 620 from patent US 10787501,2022-03-01
1988,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 608 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 608 from patent US 10787501,2022-03-01
1989,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 604 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 604 from patent US 10787501,2022-03-01
1990,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 594 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 594 from patent US 10787501,2022-03-01
1991,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 592 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 592 from patent US 10787501,2022-03-01
1992,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 588 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 588 from patent US 10787501,2022-03-01
1993,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 574 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 574 from patent US 10787501,2022-03-01
1994,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 572 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 572 from patent US 10787501,2022-03-01
1995,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 570 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 570 from patent US 10787501,2022-03-01
1996,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 568 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 568 from patent US 10787501,2022-03-01
1997,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 566 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 566 from patent US 10787501,2022-03-01
1998,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 562 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 562 from patent US 10787501,2022-03-01
1999,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 548 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 548 from patent US 10787501,2022-03-01
2000,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 546 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 546 from patent US 10787501,2022-03-01
2001,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 544 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 544 from patent US 10787501,2022-03-01
2002,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 542 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 542 from patent US 10787501,2022-03-01
2003,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 540 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 540 from patent US 10787501,2022-03-01
2004,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 536 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 536 from patent US 10787501,2022-03-01
2005,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 524 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 524 from patent US 10787501,2022-03-01
2006,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 520 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 520 from patent US 10787501,2022-03-01
2007,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 510 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 510 from patent US 10787501,2022-03-01
2008,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 506 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 506 from patent US 10787501,2022-03-01
2009,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 495 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 495 from patent US 10787501,2022-03-01
2010,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 491 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 491 from patent US 10787501,2022-03-01
2011,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 480 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 480 from patent US 10787501,2022-03-01
2012,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 476 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 476 from patent US 10787501,2022-03-01
2013,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 468 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 468 from patent US 10787501,2022-03-01
2014,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 464 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 464 from patent US 10787501,2022-03-01
2015,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 451 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 451 from patent US 10787501,2022-03-01
2016,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 447 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 447 from patent US 10787501,2022-03-01
2017,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 432 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 432 from patent US 10787501,2022-03-01
2018,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 430 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 430 from patent US 10787501,2022-03-01
2019,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 428 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 428 from patent US 10787501,2022-03-01
2020,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 426 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 426 from patent US 10787501,2022-03-01
2021,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 424 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 424 from patent US 10787501,2022-03-01
2022,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 420 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 420 from patent US 10787501,2022-03-01
2023,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 409 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 409 from patent US 10787501,2022-03-01
2024,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 405 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 405 from patent US 10787501,2022-03-01
2025,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 396 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 396 from patent US 10787501,2022-03-01
2026,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 392 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 392 from patent US 10787501,2022-03-01
2027,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 381 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 381 from patent US 10787501,2022-03-01
2028,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 377 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 377 from patent US 10787501,2022-03-01
2029,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 366 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 366 from patent US 10787501,2022-03-01
2030,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 364 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 364 from patent US 10787501,2022-03-01
2031,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 362 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 362 from patent US 10787501,2022-03-01
2032,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 360 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 360 from patent US 10787501,2022-03-01
2033,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 358 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 358 from patent US 10787501,2022-03-01
2034,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 356 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 356 from patent US 10787501,2022-03-01
2035,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 354 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 354 from patent US 10787501,2022-03-01
2036,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 352 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 352 from patent US 10787501,2022-03-01
2037,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 350 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 350 from patent US 10787501,2022-03-01
2038,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 348 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 348 from patent US 10787501,2022-03-01
2039,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 346 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 346 from patent US 10787501,2022-03-01
2040,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 342 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 342 from patent US 10787501,2022-03-01
2041,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 333 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 333 from patent US 10787501,2022-03-01
2042,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 329 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 329 from patent US 10787501,2022-03-01
2043,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 316 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 316 from patent US 10787501,2022-03-01
2044,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 312 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 312 from patent US 10787501,2022-03-01
2045,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 302 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 302 from patent US 10787501,2022-03-01
2046,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 298 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 298 from patent US 10787501,2022-03-01
2047,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 284 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 284 from patent US 10787501,2022-03-01
2048,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 280 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 280 from patent US 10787501,2022-03-01
2049,not found,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 268 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 268 from patent US 10787501,2022-03-01
2050,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 264 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 264 from patent US 10787501,2022-03-01
2051,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 252 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 252 from patent US 10787501,2022-03-01
2052,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 248 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 248 from patent US 10787501,2022-03-01
2053,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 238 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 238 from patent US 10787501,2022-03-01
2054,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 234 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 234 from patent US 10787501,2022-03-01
2055,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 220 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 220 from patent US 10787501,2022-03-01
2056,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 216 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 216 from patent US 10787501,2022-03-01
2057,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 202 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 202 from patent US 10787501,2022-03-01
2058,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 198 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 198 from patent US 10787501,2022-03-01
2059,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 185 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 185 from patent US 10787501,2022-03-01
2060,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 183 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 183 from patent US 10787501,2022-03-01
2061,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 179 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 179 from patent US 10787501,2022-03-01
2062,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 167 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 167 from patent US 10787501,2022-03-01
2063,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 165 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 165 from patent US 10787501,2022-03-01
2064,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 163 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 163 from patent US 10787501,2022-03-01
2065,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 161 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 161 from patent US 10787501,2022-03-01
2066,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 159 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 159 from patent US 10787501,2022-03-01
2067,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 157 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 157 from patent US 10787501,2022-03-01
2068,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 153 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 153 from patent US 10787501,2022-03-01
2069,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 137 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 137 from patent US 10787501,2022-03-01
2070,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 133 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 133 from patent US 10787501,2022-03-01
2071,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 119 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 119 from patent US 10787501,2022-03-01
2072,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 115 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 115 from patent US 10787501,2022-03-01
2073,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 99 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 99 from patent US 10787501,2022-03-01
2074,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 95 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 95 from patent US 10787501,2022-03-01
2075,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 83 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 83 from patent US 10787501,2022-03-01
2076,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 79 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 79 from patent US 10787501,2022-03-01
2077,not found,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 65 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 65 from patent US 10787501,2022-03-01
2078,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 63 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 63 from patent US 10787501,2022-03-01
2079,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 59 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 59 from patent US 10787501,2022-03-01
2080,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 44 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 44 from patent US 10787501,2022-03-01
2081,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 42 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 42 from patent US 10787501,2022-03-01
2082,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 38 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 38 from patent US 10787501,2022-03-01
2083,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 22 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 22 from patent US 10787501,2022-03-01
2084,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 18 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 18 from patent US 10787501,2022-03-01
2085,not found,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 2 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VH: Sequence 2 from patent US 10787501,2022-03-01
2086,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 826 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 826 from patent US 10954289,2022-03-01
2087,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 818 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 818 from patent US 10954289,2022-03-01
2088,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 806 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 806 from patent US 10954289,2022-03-01
2089,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 800 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 800 from patent US 10954289,2022-03-01
2090,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 792 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 792 from patent US 10954289,2022-03-01
2091,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 786 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 786 from patent US 10954289,2022-03-01
2092,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 776 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 776 from patent US 10954289,2022-03-01
2093,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 770 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 770 from patent US 10954289,2022-03-01
2094,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 749 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 749 from patent US 10954289,2022-03-01
2095,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 741 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 741 from patent US 10954289,2022-03-01
2096,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 733 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 733 from patent US 10954289,2022-03-01
2097,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 727 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 727 from patent US 10954289,2022-03-01
2098,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 719 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 719 from patent US 10954289,2022-03-01
2099,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 713 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 713 from patent US 10954289,2022-03-01
2100,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 694 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 694 from patent US 10954289,2022-03-01
2101,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 686 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 686 from patent US 10954289,2022-03-01
2102,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 676 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 676 from patent US 10954289,2022-03-01
2103,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 666 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 666 from patent US 10954289,2022-03-01
2104,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 656 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 656 from patent US 10954289,2022-03-01
2105,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 646 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 646 from patent US 10954289,2022-03-01
2106,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 638 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 638 from patent US 10954289,2022-03-01
2107,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 630 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 630 from patent US 10954289,2022-03-01
2108,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 622 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 622 from patent US 10954289,2022-03-01
2109,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 614 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 614 from patent US 10954289,2022-03-01
2110,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 606 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 606 from patent US 10954289,2022-03-01
2111,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 600 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 600 from patent US 10954289,2022-03-01
2112,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 590 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 590 from patent US 10954289,2022-03-01
2113,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 580 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 580 from patent US 10954289,2022-03-01
2114,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 564 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 564 from patent US 10954289,2022-03-01
2115,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 556 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 556 from patent US 10954289,2022-03-01
2116,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 538 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 538 from patent US 10954289,2022-03-01
2117,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 530 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 530 from patent US 10954289,2022-03-01
2118,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 522 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 522 from patent US 10954289,2022-03-01
2119,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 514 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 514 from patent US 10954289,2022-03-01
2120,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 508 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 508 from patent US 10954289,2022-03-01
2121,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 503 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 503 from patent US 10954289,2022-03-01
2122,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 493 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 493 from patent US 10954289,2022-03-01
2123,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 487 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 487 from patent US 10954289,2022-03-01
2124,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 478 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 478 from patent US 10954289,2022-03-01
2125,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 472 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 472 from patent US 10954289,2022-03-01
2126,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 466 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 466 from patent US 10954289,2022-03-01
2127,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 457 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 457 from patent US 10954289,2022-03-01
2128,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 449 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 449 from patent US 10954289,2022-03-01
2129,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 440 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 440 from patent US 10954289,2022-03-01
2130,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 422 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 422 from patent US 10954289,2022-03-01
2131,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 416 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 416 from patent US 10954289,2022-03-01
2132,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 407 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 407 from patent US 10954289,2022-03-01
2133,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 401 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 401 from patent US 10954289,2022-03-01
2134,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 394 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 394 from patent US 10954289,2022-03-01
2135,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 387 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 387 from patent US 10954289,2022-03-01
2136,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 379 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 379 from patent US 10954289,2022-03-01
2137,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 372 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 372 from patent US 10954289,2022-03-01
2138,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 344 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 344 from patent US 10954289,2022-03-01
2139,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 338 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 338 from patent US 10954289,2022-03-01
2140,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 331 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 331 from patent US 10954289,2022-03-01
2141,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 323 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 323 from patent US 10954289,2022-03-01
2142,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 314 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 314 from patent US 10954289,2022-03-01
2143,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 306 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 306 from patent US 10954289,2022-03-01
2144,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 300 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 300 from patent US 10954289,2022-03-01
2145,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 290 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 290 from patent US 10954289,2022-03-01
2146,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 282 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 282 from patent US 10954289,2022-03-01
2147,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 276 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 276 from patent US 10954289,2022-03-01
2148,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 266 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 266 from patent US 10954289,2022-03-01
2149,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 260 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 260 from patent US 10954289,2022-03-01
2150,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 250 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 250 from patent US 10954289,2022-03-01
2151,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 242 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 242 from patent US 10954289,2022-03-01
2152,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 236 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 236 from patent US 10954289,2022-03-01
2153,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 228 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 228 from patent US 10954289,2022-03-01
2154,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 218 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 218 from patent US 10954289,2022-03-01
2155,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 210 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 210 from patent US 10954289,2022-03-01
2156,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 200 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 200 from patent US 10954289,2022-03-01
2157,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 191 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 191 from patent US 10954289,2022-03-01
2158,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 181 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 181 from patent US 10954289,2022-03-01
2159,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 175 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 175 from patent US 10954289,2022-03-01
2160,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 155 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 155 from patent US 10954289,2022-03-01
2161,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 145 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 145 from patent US 10954289,2022-03-01
2162,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 135 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 135 from patent US 10954289,2022-03-01
2163,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 127 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 127 from patent US 10954289,2022-03-01
2164,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 117 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 117 from patent US 10954289,2022-03-01
2165,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 107 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 107 from patent US 10954289,2022-03-01
2166,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 97 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 97 from patent US 10954289,2022-03-01
2167,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 89 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 89 from patent US 10954289,2022-03-01
2168,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 81 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 81 from patent US 10954289,2022-03-01
2169,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 73 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 73 from patent US 10954289,2022-03-01
2170,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 61 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 61 from patent US 10954289,2022-03-01
2171,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 51 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 51 from patent US 10954289,2022-03-01
2172,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 40 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 40 from patent US 10954289,2022-03-01
2173,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 30 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 30 from patent US 10954289,2022-03-01
2174,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 20 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 20 from patent US 10954289,2022-03-01
2175,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 10 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",VL: Sequence 10 from patent US 10954289,2022-03-01
2176,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 826 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 826 from patent US 10787501,2022-03-01
2177,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 818 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 818 from patent US 10787501,2022-03-01
2178,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 806 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 806 from patent US 10787501,2022-03-01
2179,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 800 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 800 from patent US 10787501,2022-03-01
2180,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 792 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 792 from patent US 10787501,2022-03-01
2181,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 786 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 786 from patent US 10787501,2022-03-01
2182,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 776 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 776 from patent US 10787501,2022-03-01
2183,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 770 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 770 from patent US 10787501,2022-03-01
2184,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 749 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 749 from patent US 10787501,2022-03-01
2185,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 741 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 741 from patent US 10787501,2022-03-01
2186,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 733 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 733 from patent US 10787501,2022-03-01
2187,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 727 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 727 from patent US 10787501,2022-03-01
2188,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 719 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 719 from patent US 10787501,2022-03-01
2189,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 713 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 713 from patent US 10787501,2022-03-01
2190,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 694 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 694 from patent US 10787501,2022-03-01
2191,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 686 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 686 from patent US 10787501,2022-03-01
2192,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 676 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 676 from patent US 10787501,2022-03-01
2193,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 666 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 666 from patent US 10787501,2022-03-01
2194,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 656 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 656 from patent US 10787501,2022-03-01
2195,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 646 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 646 from patent US 10787501,2022-03-01
2196,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 638 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 638 from patent US 10787501,2022-03-01
2197,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 630 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 630 from patent US 10787501,2022-03-01
2198,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 622 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 622 from patent US 10787501,2022-03-01
2199,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 614 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 614 from patent US 10787501,2022-03-01
2200,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 606 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 606 from patent US 10787501,2022-03-01
2201,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 600 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 600 from patent US 10787501,2022-03-01
2202,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 590 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 590 from patent US 10787501,2022-03-01
2203,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 580 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 580 from patent US 10787501,2022-03-01
2204,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 564 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 564 from patent US 10787501,2022-03-01
2205,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 556 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 556 from patent US 10787501,2022-03-01
2206,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 538 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 538 from patent US 10787501,2022-03-01
2207,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 530 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 530 from patent US 10787501,2022-03-01
2208,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 522 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 522 from patent US 10787501,2022-03-01
2209,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 514 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 514 from patent US 10787501,2022-03-01
2210,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 508 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 508 from patent US 10787501,2022-03-01
2211,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 503 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 503 from patent US 10787501,2022-03-01
2212,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 493 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 493 from patent US 10787501,2022-03-01
2213,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 487 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 487 from patent US 10787501,2022-03-01
2214,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 478 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 478 from patent US 10787501,2022-03-01
2215,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 472 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 472 from patent US 10787501,2022-03-01
2216,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 466 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 466 from patent US 10787501,2022-03-01
2217,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 457 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 457 from patent US 10787501,2022-03-01
2218,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 449 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 449 from patent US 10787501,2022-03-01
2219,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 440 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 440 from patent US 10787501,2022-03-01
2220,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 422 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 422 from patent US 10787501,2022-03-01
2221,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 416 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 416 from patent US 10787501,2022-03-01
2222,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 407 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 407 from patent US 10787501,2022-03-01
2223,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 401 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 401 from patent US 10787501,2022-03-01
2224,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 394 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 394 from patent US 10787501,2022-03-01
2225,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 387 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 387 from patent US 10787501,2022-03-01
2226,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 379 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 379 from patent US 10787501,2022-03-01
2227,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 372 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 372 from patent US 10787501,2022-03-01
2228,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 344 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 344 from patent US 10787501,2022-03-01
2229,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 338 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 338 from patent US 10787501,2022-03-01
2230,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 331 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 331 from patent US 10787501,2022-03-01
2231,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 323 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 323 from patent US 10787501,2022-03-01
2232,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 314 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 314 from patent US 10787501,2022-03-01
2233,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 306 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 306 from patent US 10787501,2022-03-01
2234,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 300 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 300 from patent US 10787501,2022-03-01
2235,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 290 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 290 from patent US 10787501,2022-03-01
2236,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 282 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 282 from patent US 10787501,2022-03-01
2237,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 276 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 276 from patent US 10787501,2022-03-01
2238,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 266 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 266 from patent US 10787501,2022-03-01
2239,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 260 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 260 from patent US 10787501,2022-03-01
2240,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 250 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 250 from patent US 10787501,2022-03-01
2241,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 242 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 242 from patent US 10787501,2022-03-01
2242,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 236 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 236 from patent US 10787501,2022-03-01
2243,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 228 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 228 from patent US 10787501,2022-03-01
2244,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 218 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 218 from patent US 10787501,2022-03-01
2245,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 210 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 210 from patent US 10787501,2022-03-01
2246,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 200 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 200 from patent US 10787501,2022-03-01
2247,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 191 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 191 from patent US 10787501,2022-03-01
2248,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 181 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 181 from patent US 10787501,2022-03-01
2249,not found,"SARS-CoV-2, Spike protein",Unknown.,,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 175 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 175 from patent US 10787501,2022-03-01
2250,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 155 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 155 from patent US 10787501,2022-03-01
2251,not found,"SARS-CoV-2, Spike protein",Unknown.,,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 145 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 145 from patent US 10787501,2022-03-01
2252,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 135 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 135 from patent US 10787501,2022-03-01
2253,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 127 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 127 from patent US 10787501,2022-03-01
2254,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 117 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 117 from patent US 10787501,2022-03-01
2255,not found,"SARS-CoV-2, Spike protein",Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 107 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 107 from patent US 10787501,2022-03-01
2256,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 97 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 97 from patent US 10787501,2022-03-01
2257,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 89 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 89 from patent US 10787501,2022-03-01
2258,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 81 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 81 from patent US 10787501,2022-03-01
2259,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 73 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 73 from patent US 10787501,2022-03-01
2260,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 61 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 61 from patent US 10787501,2022-03-01
2261,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 51 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 51 from patent US 10787501,2022-03-01
2262,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 40 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 40 from patent US 10787501,2022-03-01
2263,not found,"SARS-CoV-2, Spike protein",Unknown.,,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 30 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 30 from patent US 10787501,2022-03-01
2264,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 20 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 20 from patent US 10787501,2022-03-01
2265,not found,"SARS-CoV-2, Spike protein",Unknown.,,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 10 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",VL: Sequence 10 from patent US 10787501,2022-03-01
2266,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2267,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqdntamsyyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2268,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2269,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2270,not found,SARS-CoV-2,Homo sapiens (human),ecrllesggglvqpggslrlscaasgftfsiypmtwvrqapgkglewvsaitagggstyytdsvkgrftisrdnskntlylqmnslraedtaiyycakngdcdstscppdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2271,not found,SARS-CoV-2,Homo sapiens (human),eaqllesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardivvatartagdyyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2272,not found,SARS-CoV-2,Homo sapiens (human),qcrlvesggglvkpggslrlscaasgftfsdfymswirqapgkglewisyisrsggtiyyadsvkgrftisrdnaknslylqmnslraedtavyycargvsgydygsrfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2273,not found,SARS-CoV-2,Homo sapiens (human),qvqlqexgpglvkpsqtlsltctvxggsissgdxywswxrqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslkxssvtaadtavyycarvdcggdcypdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2274,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvkpggslrlscaasgfrfsntwmnwvrqapgrglewvgriktlgeggitdyaapvkgrftisrddskqtlylqmnslkiedtavyycttdlptafdsyygmaawgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2275,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftftnarmtwvrqapgkglewvgriktktqggtidygapvrgrftisrddlkntldlqmnslktedtavyycaaiddgldhwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2276,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdfyanyspsfqghvtisadksistaylqwsslkasdtamyycarqtgycsstscyaggpfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2277,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgsglvkpsqtlsltcavsggsissggyswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsknqfslklssvtaadtavyycarspydssgaidywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2278,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhtdcsggscylggafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2279,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyyccffdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2280,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggetyvryyfdfwgqgglvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2281,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdmtpyydilteaygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2282,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftftnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylemnslktedtavyycttrrycsstrcylgewsyfdcwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2283,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycasgwylswfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2284,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvsdyglfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2285,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgpyydssgyfdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2286,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarggdlfgellgatgyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2287,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycatcsggschpyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2288,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardfsrggydspsgyyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2289,not found,SARS-CoV-2,Homo sapiens (human),evqlvefggglvqpgrslrlscaafgftfddyamhwvrqapgkglewvsgiswnsgsigyadfvkgrftisrdnaknslylqmnslraedtalyycaksriaaavfyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2290,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssytmnwvrqapgkglewvsyitsdsstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarnkamddywgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2291,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscavsgftfssswmfwvrqapgkglvwvsrisadgytatyaesvegrftisrdnakntlylqmnslraedtalyycarglthdywgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2292,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaadlnyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2293,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2294,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2295,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaktmmgyyyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2296,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarangdydlpyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2297,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycatdadniatgfwsgyyseyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2298,not found,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycareardpfyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2299,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshwmhwvrqapgkglvwvsriigdgseityadsvkgrftisrdnvkntlyleinslraedtavyyclrghvsgstrhfdywgqgtlltvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2300,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyycardlfpeyssswyrplyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2301,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",2022-03-01
2302,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssytiyyadsvkgrftisrdnaknslylqmnslrdedtavyycardpsdssswypiywyfdlwgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2303,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarspyydfwsgyhyyfdywgqgtlvavss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2304,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2305,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2306,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaralssyydfwsaplswdrdnyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2307,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctasggsiasnsyywgwirqspgkgldwigsiyysgitysnsslksrvtisvdtsknqfslklssvtaadtavyhcaryssgwahddgfdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2308,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevrkpgasvkvsckasgytfsnyaiiwvrqapgqglewmgwisayngktdyseklqdrvtmttdtstntaymelknlrsddtavyycardmffrewfgelihyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2309,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsinngdyywswirqhpgkglewigyiyysgntyynpslksrvtisldtsknqfslklssvtaadtalyycargplgyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2310,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnyaihwvrqapgkglewvafisydgsikyytdsvkgrftisrdsskntlflqmnnlrpedtavyyctrgavagnnafdvwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2311,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyyctagfmaqgliitsifdfwgqgtqvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2312,not found,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyycttgfmaqgliitsifdfwgqgtqvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2313,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyidnsgstyynpslksrvtisvdtsknqfslnlrsvtaadaavyycarerdlaaagidswgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2314,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltctvsggsvnsdsyywswirqppgkglewigyiyysgstncnpslksrltisadtsknqfslklnsvtaadtavyycarveapeggsdywgqgtlvtvsp,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2315,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsdtlsltctvsggsissssyywgwirqppgkglewigsisysgstyynpslksrvtisgdtsknqlslklssvtaadtavyycarhtyyydssgylalapdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2316,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarsreskdwsygggfyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2317,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggnlvqpggslrlscvvsgftfssysmnwvrqapgkglewvsvisgsgdttyyadsvkgrftisrdnskntlylqmnslraedtaiyycakdcdyeiltgyhsncfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2318,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsrggsyhdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2319,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggnyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2320,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsggsissssyywgwirqppgkglewigiiyfsgspyynpslksrvtisvdtsknqfslrlssvtaadtalyycarhnyltryyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2321,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfdnyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdwggvyygsgtyytnwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2322,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigslyysgstyynpslksrvsisvdtsknqfslklssvtaadtavyycatlyyvwgsyrglegnfdnwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2323,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpgvllwfgellspwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2324,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarawgsyysafdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2325,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgvyydfwsgyyggdnggfwldywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2326,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgytlielsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtgymelsslrsedtavyycvtgppysgsywfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2327,not found,SARS-CoV-2,Homo sapiens (human),evqlqesgpglvkpsqtlsltctvsgdsisrgsyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycaregsfwywfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2328,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardysycsstscytsifdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2329,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqspgkglewigeinhsgstnyspslksrvtisldtsknqlslkvtsvtaadtgvyfcardsrtsgwhkiyyyyamdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2330,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltcavsgasisssgyywgwirqppgkglewignifyigsthynpslksrvtisldtsknqlslklrsvtaadtavyycarptndyggfyfdywgqgilvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2331,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaaafsnyeyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2332,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardskeyyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2333,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscvvsgftfsnysmnwvrqapgkglewvssissvssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvlrryydfwsgyypdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2334,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyfsgatkynpslnrrvtmsvdtsknqfslklqsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2335,not found,SARS-CoV-2,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsisssdyywgwirqppgkglewigsmyysgstyynpslnsrvtisvdtsknqfslnlnsvtaadtavyycarargycsivgcytslyyfdylgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2336,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrfaisrdnaknslylqmnslraedtalyycardivpyssswlyyygmdvwgqgttvsvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2337,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisnyywswirqppgkglewigyifysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwpdafdmwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2338,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssywswirqtpgkglewigyidysgstnynpslksritmsvdtsknqfslklssvtaadtavyycarspnfdwllntggyygldvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2339,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrsvrlscaasgftfsscamywvrqapgkglewvavisydvinkyyedsvkgrftisrdnskntlylqmnslraedtavyycasqppairafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2340,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgggvvqpgrslrlscassgftfstyamhwvrqapgkglewvafisydgskkyyadslkgrftisrdnskntlylqtnslraedtavyycakvrrwlqfpetdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2341,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvrvsckasggpfsnyaifwvrqapgqglewmggiipvfgttnyaqkfqgrvtitadeststaymemsslrsedtavfycaglvastpwpdfwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2342,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglelvsyisssgsiiyyadsvkgrftisrdnaknslslqmnslraedtavyycardaniwfgelrglstgymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2343,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardshiyrhdswetaitifgvviidafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2344,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakrenrllwfgelllghdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2345,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrsltlscaasgftfssygvhwvrqapgkglewvslisyegsitqyadpvrgrftisrdnskntlylqmnslktedtavyycargavagndafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2346,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisgnsgntkyaqkvqgrvtmttdtststaymelrslrsddtamyycardiiellwfgdyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2347,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaakmglwfgelwwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2348,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",2022-03-01
2349,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2350,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaslqwsslkasdtamyycarqkrdgttwafdywgqgtlvtass,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2351,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnykyslksrvtisvdtsknqfslklssvtaadtavyycarekggtewefndafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2352,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvstnymswvrqapgkglewvsviysggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycastnsgsyshvfdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2353,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglgqpggslrlscaasgftfsnyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakagavgyydsngyyydvdyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2354,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrltitaddststaymelsslksedtavyycarfraydssgygpdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2355,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslklscaasgftfnsyamtwvrqapgkglewlstisgsggrtyyadsvkgrfaisrdnskntvflqmstlraedtavyfcardfyglesfypgidswgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2356,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhiaglewlfraaavlnwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2357,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycagtyydfwsgstnyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2358,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvhhcsggscygyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2359,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycaredsygsgstgafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2360,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlsgifgvviipgffdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2361,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardptavtgpfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2362,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvprppwddfwsgylyyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2363,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpseslslaffvyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargggysygaidywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2364,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2365,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptvttvtnwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2366,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilditnyaqkfqgrvtitadkststaymelsslrsedtavyycarglwrssiaglhvpygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2367,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2368,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgnslrlscvasgfkfsssamhwvrqapgkglewvaiiwfhgntkfygdfvkgrftvsrdnsnntlhlqmnslraedtavyhcarassdyggafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2369,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraltgnyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2370,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggiipifgtanyaqnfqgrvtitadeststaymelsslrsedtavyycarvsyydssgyytdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2371,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2372,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadsvkgrftisrdsskntlylqmnslraedtavyycarggvgyqllfgndwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2373,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptifgvvlqiprfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2374,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpelvkpsetlsltcsvsggsissyywswirqppgkglewigyiyysgstnynpslsgstnynpslksrvtvsvdtsknqfslkvssvtaadtavyycargfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2375,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigniyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarqlwgyydssgyyafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2376,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymelsslrsedtavfycvsriaaaadfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2377,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrlydyvwgsyrfghtwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2378,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntldlqmnslraedtavyycarayggnyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2379,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfisygiswvrqapgqglewmgwisgyngntnyaqkfqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2380,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraysydssgyspdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2381,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardrrgsgwswdyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2382,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtstnqfslklssvtaadtavyycarrvhydiltgfyggalitrafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2383,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissrssytnyadsvkgrftisrdnaknslylqmnslraedtavyycargydssgyhyslwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2384,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsgissnggstyyadsvkgritisrdnskktlylqmsslraedtavyycvksssrgyywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2385,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasarfitmvrgviniyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2386,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftnfgiswvrqapglglewmgwistyngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarasgpyllglywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2387,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycatnsnypywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2388,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsncwmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarmgntawyfdlwgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2389,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrftfstyamhwvrqapgkglewvtvisydgdnkyyadsvkgrftisrdnskntlylqmnslrtedtavyyctragsgsylsyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2390,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarissydssgysmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2391,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctmvwqqlhdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2392,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadestntaymelssltsedtavyycakigdydssgyyfdywaqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2393,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarayggsyfygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2394,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssnayywgwirqppgkglewigsvnyrgstyyiptlksritisvntsknqfslkltsvtaadtavyycarrgvalvtityfdfwgqgalvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2395,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglefigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqevvlvrpynyngmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2396,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaagfifssyamnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlnlqmnslraedtavyycargngyiiidywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2397,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgkidpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarqfggellgwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2398,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisstsnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvspnydfwsgyypdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2399,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsfamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsggyscfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2400,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycaseivsfigssedywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2401,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckafgytftknginwvrqapgqglewmgwispnngytnfaqkfqgratmtsdtststaymelrslrsddtavyycarvrvdydssgydayyyhldvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2402,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmardtsistaymelsrlrsddtavyycardqvspycggdcpdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2403,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntlylqmnslrvedtavyycarpgggsyygpfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2404,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2405,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvstistnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvlgycsstscqhfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2406,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfafiwvrqapgqglewmggiipifgtakytqkfqgrvtitadeststaymelsslrsedtavyycarvsyydssgfytdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2407,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggifssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasysgfddyghyrnywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2408,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfalhwvrqapgkglewvavvsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarsmggnyadyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2409,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylemnslraedtavyycastsdsgsyyihwyfdlwgrgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2410,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylhmnslraedtavyycarpnsgsyhsyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2411,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssrsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycasnpaadpntyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2412,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsissstwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycarsasnyfgyyyygmdvwgqgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2413,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaagyydsinwgqgtlvtvps,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2414,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscgasgfifssyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpysgtyfsafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2415,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgnsftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhrnydiltgyryyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2416,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlflqmnslrtedtavyycaramggnyfhafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2417,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnnaqkfqgrvtltadestsaaymelsslrsedtavyycariepyastgytfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2418,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycvrvalydssgyspdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2419,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigniyytgstyynpslksrvtisvdtsknhfslrlssvtaadtavyycarhnrfwsedtpfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2420,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglaqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadslkgrftisrdnskstlylqmnslraedtavyycakgpmwqwlvrlslvgdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2421,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2422,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssdnyywswirqppgkglewigyiyysgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargfvatyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2423,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfsvssnymnwvrqaprkglewvsviysggstyyadsvkgrftisrdnskntlylqmntlraedtavyycargygdsqrwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2424,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpgqvkpsetlsltctvsgysissgyfwgwvrqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycardhgsydfwsgysrdafdiwgqgtmvtfss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2425,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvscktsgyiftdyfmhwvrqapgqglewmgwinpnsgganyaqkfqgrvtmtrdtsittvymelsrlriddtamyycareaslnrsryyssggtvyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2426,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvglsswyfeywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2427,not found,SARS-CoV-2,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsirsyshywgwirqppgkglewigtiyysgstyynpslksritisvdtsksqfslklssvtaadtavyfcastiptyddiltgyqfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2428,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydgsnkyyadsvrgrftisrdnskntlylqmnslraedtavyycarggggyntffdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2429,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdgavatgpgyfyfymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2430,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgfpfrnyamhwvrqapgkglehisvissrgdttyyansvkgrftisrdnsqntlylqmdslraddmavyycarvqsgfsygygfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2431,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisadtsknqfslklssvtaadtavyycarapgatyssgwyyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2432,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2433,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydginkyyadsvkgrftssrdnskntlylqmnslraedtavyfcarmysgsylgyfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2434,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgdsissyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklssvtaadtavyycanlgynsgwyggyfeywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2435,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsrysmnwvrqapgkglewvssissstsfiyyadsvrgrftisrdnaknslylqmnslraedtavyycarwiggdssgyypdafdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2436,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgpglvkpsetlsltctvsgdsisnyywswirqppekglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtamyycardfslwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2437,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgftfsnygmhwvrqapgkglewvavilydgsnryyadsvkgrftvsrdnskntlylqmnslraedtavyycakgggpycgggscwahyfdywgqgtlvsvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2438,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvaggsissgtyywswirqpagkglewigriytsgsanynpslksrvtisvdtsknqfslrlssvtaedtavyycareysssyyyfyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2439,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgnyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtalyycardayydflsgyiptynwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2440,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlsctasgftfgdyamiwfrqapgkglewvgfirskayggtteyaasmkgrftisrddsksiaylqmnslktedtavyyctrdldyydssgyyptyidywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2441,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsyyalswvrqapgkglewvsatygsgsntyyadsvkgrftisrdnskntlylqmsnlraddtavyycakdqrnaydsfdfwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2442,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgqglewvavisydgsnkyyadsvrgrftisrdnskntlylqmntlraedtavyycargptysymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2443,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdksknmvylqmnslraedtalyycakdleyytsgsyslfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2444,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgfyggslnnyfwswirqppgkglewigdinhsgstnynpslksrvtvsvdtsknqfslnlnsvtaadtavyycarglflvyygsglggfdywgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2445,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssygmswvrqapgkglewvsginnhggstyygdsvkgrftisrdnskntlylqmnslraedtavyycaksdtamvpynwfdpwgqgtlvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2446,not found,SARS-CoV-2,Homo sapiens (human),qvqlqgsgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhptfsgyeyyfdhwgqgtlitvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2447,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssyalswvrqapgkglewvsaisgsggsiyyadsvkgrftisrdnskstlylqmnslkaedtavyycakddstsayyyyyymdvwgkgttvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2448,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyigssgssihyadsvkgrftisrdnaknslylqmnslraedtavyycardgsygdyvrgywgqgalvivss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2449,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2450,not found,SARS-CoV-2,Homo sapiens (human),,qavvtqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2451,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2452,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigshpvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsgrvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2453,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqepsltvspggtvtltcgsstgavtsghwpywfqqkpgqtprtliydtsnkqswtparfsgsllggkaaltlsgaqpedeaeyyclllysdgrvfgggtkltvq,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2454,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2455,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2456,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2457,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2458,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2459,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqepsltvspggtvtltcasstgvvtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeadyyclitysgrevfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2460,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyravvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2461,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2462,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqepslavspggtvtltcasstgtvtsgsypnwfqqkpgqppraliydtsnkhswtparfsgfllggkatlalsgaqpedeaeyycllynggvwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-01
2463,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvrtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2464,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppatfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2465,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvssnflawyqrkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2466,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplflvatatgvhseivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2467,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2468,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspstlsasvgdrvtitcrasqsvsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsywtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2469,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2470,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvwtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2471,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2472,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlfsfnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqynstpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2473,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2474,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2475,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2476,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpmtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2477,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2478,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrlmykvskrdsgvpdrfsgsgsgtdftlkisrveaedagiyycmqgthwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2479,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2480,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2481,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdslavslgeratinckssqtvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2482,not found,SARS-CoV-2,Homo sapiens (human),,eilmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgrtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2483,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2484,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2485,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltvsslepedfavyycqqrsnwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
2486,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2487,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdsslsawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2488,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssniesntvqwyqqlpgtapkliihnnskrpsgvpdrfsasksgtsaslaisglqsqddgdyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2489,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvapgktasiicggnnignknvhwyqqkpgqapvlvisydsgrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdlmvfgggtkltal,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2490,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2491,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsylsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2492,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2493,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtasitcsgdklgnryacwyqqkpgqspvlviyqnnkrpsgiperfsgsnsgnsatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2494,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2495,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqprsvsgspglsvtisctgsssdvggynyvswyqqhpgkapklmiydvsrrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytyvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2496,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtasitcsgdklgdkyaswyqqksgqspvlviyqdsrrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2497,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2498,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasatpgqrvtiscsgsssnigsnyvywyqqfpgtapklliygnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddspsvhwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2499,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvapgktaritcggnnigtksvhwyqqkpgqapvlviyydtdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggakltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2500,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2501,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsmsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydngkrpsgipdrfsasksgtsatlgitglqtgdeadyycgtwdsslstwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2502,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycsssassttlhgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2503,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsmsvspgqtasitcsgdklgnkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsestatltisgtlamdeadyycqawdsstegvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2504,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsvspgqtasiicsgdklgdkyacwyqqkpgqspllviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyfcqawdsstavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2505,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2506,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtnsdvgaynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-01
2507,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslesedfvvyycqqrsnwpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2508,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspssvsasvgdrvtitcrasqdisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfppptfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2509,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpgtlslspgeratlscrasqsvsnnylawyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnswtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2510,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqssstpsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2511,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2512,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpftfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2513,not found,SARS-CoV-2,Homo sapiens (human),,airmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsasgagtdftlkisrveaedvgvyycmqatqfpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2514,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrviitcrasqsiagylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2515,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2516,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2517,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2518,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2519,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpqtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2520,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2521,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2522,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyycqqydnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2523,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpsslstsvgdrvtitcrtsqsigsflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystpytfgqgtkmeik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2524,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasiratgiparfsgsgsgtdftltisslepedfavyycqyrsnwpprltfgggtrveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2525,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkagqaprlliygastratgiparfsgsgsgteftltisslqsedfaiyycqqynnwpprtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2526,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2527,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2528,not found,SARS-CoV-2,Homo sapiens (human),,airmtqsplslpvtlgqpasiscrssqslvysdgntyliwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlnisrveaedvgvyycmqgthwpltfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2529,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2530,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-01
2531,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2532,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2533,not found,SARS-CoV-2,Homo sapiens (human),,syeltqpssvsvfpgqtaritcsgdvlekkyarwfqqkpgqapllviykdserpsgiperffgsssgttvtltisgaqvedeadyycysaadnnrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2534,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2535,not found,SARS-CoV-2,Homo sapiens (human),,syeltqplsvsvalgqtaritcggnnigsknvhwyqqkpgqapvlviyrdsnrpsgiperfsgsnsgntatltisraqagdeadyfcqvwdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2536,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigtnyvywyqqlpgtapklliyrntqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaswddshvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2537,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2538,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaevfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2539,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapqlliydnnkrpsripdrfsgsksgtsatlgitglqtgdeavyycgtwdsslsavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2540,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedesdyycssyttsstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2541,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeaayyccsyvgsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2542,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeahyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2543,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytnsrtldvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2544,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstllfgggtklrs,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2545,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2546,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqatdeadyycqawdsstgvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2547,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyswvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2548,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtitctgsssnigsgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeahyycqsydssvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2549,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitlsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistlvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2550,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmkfnsdgthskgdgipdrfsgsssgaersltisslqsedeadyycqtwgtggvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2551,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyccystdssdnhrrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2552,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigrntvnwfqqlpgtapklliysnyqrpsgvpdrlsgsksgtsaslairglqsedeadyycaawddslhgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2553,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2554,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltlsglqaedeadyycssytssstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2555,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2556,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyyccshagsstsyifgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2557,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2558,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2559,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2560,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysaprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2561,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2562,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2563,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgkratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqxygsspntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2564,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2565,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwvtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2566,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyslltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2567,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappgftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2568,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2569,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvslgeratlscrasqsvtsslawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqynnwppwtfgqgtkvevt,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2570,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2571,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2572,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2573,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2574,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2575,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsissylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpplltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2576,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2577,not found,SARS-CoV-2,Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2578,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2579,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2580,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlhtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2581,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2582,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsyrpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2583,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygsspplftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2584,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2585,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2586,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2587,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2588,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisslqsedfavyychqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2589,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlsvspgeratlscrasqsvssklawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2590,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2591,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2592,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrynwppeltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2593,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvtnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpntfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2594,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlviydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2595,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssqlawyqqkpgqaprllisdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2596,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyytyswtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2597,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqlqpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2598,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2599,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqrkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavfycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2600,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppritfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2601,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwppgitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2602,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2603,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2604,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2605,not found,SARS-CoV-2,Homo sapiens (human),,digmtqspstlsasvgdrvtitcrasqsisswlawyqhkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysftfgpgtkvdpk,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2606,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqynsyprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2607,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletrvpsrfsgsgsgtdftftisslqpediatyycqhyttfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2608,not found,SARS-CoV-2,Homo sapiens (human),,airmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyfcqqyystpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2609,not found,SARS-CoV-2,Homo sapiens (human),,eivltqsplslpvtpgepasiscrssqsllhingynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2610,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2611,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2612,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2613,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdfiltirrlepedfavyycqqygsslytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2614,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspvslsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2615,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliystssravgipdrfsgggsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2616,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslstsvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpttfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2617,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyvasnletgvpsrfsgsgfgtdftftisslqpediatyycqqfdnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2618,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcqasqdisnylncyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqynnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2619,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpaqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslss,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2620,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqdissalawyqqkpgktpkiliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlska,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2621,not found,SARS-CoV-2,Homo sapiens (human),,eixltqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgtparfsgsgsgteftltisslqsedfavyycqqynywppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2622,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvnnylawyqqkpgqaprlliydashratdiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2623,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyynsytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsst,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2624,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2625,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvtextartap,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
2626,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgsssdvggydfvswyqqhpgkapkvviydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2627,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2628,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstsyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2629,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgapgqrvtisctgsgsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgpvvigggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltp,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2630,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvlfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwksh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2631,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynvvswyqqhpgkapqlmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstswvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwks,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
2632,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2633,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyycarhvqwlvlyyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2634,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartrggsyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2635,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaemkepgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqdrvtitadeststaylelsslrsedtavyycaresttifgvviltsygmdvwgqgttitiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2636,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgggliqpggslrlscaasvfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrddskntlylqmnslraedtavyycarsrggpldywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2637,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkepgasvkvsckasgytftsygiswvrqapgqglewmgwisaydgntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregsdyydssgfhdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2638,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkgltwighisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycarqlwlrapfdywgqgalvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2639,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpgrslrltcaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrpedtalyycakddssswyfysraklgqyyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2640,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgsglvkpsqtlsltcavsggsidsggdswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsnnqfslklssvtaadtavyycarhsgydlggafdiwgqgtmvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2641,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewlggfdpedaetiyaqkfqgrvtmtedtstdtaymglssltsedtavyycatgvavagtqknysyyygldvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2642,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvasgggvvqpgrslrlscaasgfiitsygmhwvrqapgkglewvaaiwydgsnkyyadsvkgrftisrdnskntlylqmnspraedtavyycarddptpdgdafdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2643,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfstysmnwvrqapgkglewvssisssstdihyadsmkgrftisrdnaknslylqmnslraedtavyycardfhrgwydhsayifdfwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2644,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsviswhsgsidyadsvkgrftisrdnaknslylqmnslraedtalyhcakgtgysygyavdggfdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2645,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyisssgstkyygdsvkgrftisrdnaknslylqlnslrdedtavyycartiysydssgyygteryfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2646,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftnswiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdsamyycarlgswyvyyyyyaldvwgqgplvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2647,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgfyihwvrqapgqglewmgwinpnsggsncaqkfqgrvtmtrdtsistaymevsrlrsddtavyycarysnyyyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2648,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygesfsgyywswirqppgkglewigeiihsgstnynpplksrvtisvdtsksqfslklssvtaadtavyycaremsvavvdhwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2649,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsctasgytftvcyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvarhyydrsgnlhsadyfqhwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2650,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsggtdyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycaslsaagplndvfdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2651,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitspgsaiyyadsvkgrftisrdnaknslylqmnslraedtalyyctrdgvipprfdywgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2652,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymnwvrqapgkglewvsliysggttyyadavkgrftisrdnskntlylqmnslraedtavyycargfgdrrldywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2653,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydgstkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdrgtliegmdvwgkgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2654,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpggslrlscaasglifshygmhwvrqapgkglewvafirndgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggyyyessgwfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2655,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshamnwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaksmfgydssgyfygedfdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2656,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggstsssfhywgwirqppgkglewigniyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlgsgsyytadywgqgtrvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2657,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfisyamhwvrqapgkglewvavisydgnnkyysdsvkgrftisrdnskntlhlqmnslraedtavyycakdlsggysywdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2658,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtftsydvnwvrqatgqglewmgwmdpnsgntgyaqnfqgrvtmtrstsigtaymelsslrsedtavyycarskergyynrtgyyypgdwfdpwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2659,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisnnyaywgwirqppgkglewignlyysgstyynpslksrvtisvdtsenqfslrlssvtaadtavyycarlpygydyveafdiwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2660,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvafisydgsnqystdpvkgrftfardnskdtlylqmnslrgddtavyycaksrggnyfdafdmwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2661,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvtanymswvrqapgkglewvstiysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycarergakafdpwgqgalvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2662,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgrglewvavisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakpysgsywsyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2663,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissygkywswirqhpgkglewigyiyysgstqynpslksrvtisvdtsknqfslklnsvtaadtavyycardsaaghfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2664,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgnthyaqkfqervtitrdmststaymelsslrsedtavyycaapyctttrchdgfdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2665,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrltifrdnskntlylqmnslraedtavyycaregadrsgwwgsfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2666,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardrfgrindywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2667,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckafgysftsfnlnwvrqapgqglewmgwisayngntsyaqkfqgrvtmttdtstttvymelrslrsddtavyycaralenyydrngnyyvgafdywgqgslvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2668,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsrtscqdgfdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2669,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsiywmhwvrqapgkglvwvsrinsdgsstsnadsvkgrftisrdnakntlylqmnslraedtavyycardhvvaatpgmdvwgqgttitvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2670,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfvaedgetiyaqkfqgrvsmtedtstdtaymelsslrsedtavyycatdrarldyfasgsyyghfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2671,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfmfssynmnwvrqapgkglewvssisssssyiyyedsvkgrftisrdnaknslylqmislsaedtavyycarmayfdssgyypnafdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2672,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifssydmhwvrqatgkglewvsgignagdthypgavkgrftisrenaknslylqmnslragdtavyycarahrgyydrsgyyhnpdafdiwgqgttvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2673,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgysftsygiswvrqapgqglewmgwisafnnnanyvqkfqgrvtmttdtststaylelrslrsddaavyycardddnydttgyylywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2674,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtfrsysiswvrqapgqglewmgriipilgipnyaqkfqgrvtitadkstntaymelsslrsedtavyycarespycssttclsdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2675,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglewigsmyysgntyynpplqsrvtisvdtsknqvslslssvtaadtalyycarhpdicdfwsgypgwfdpwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2676,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgltfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegwgysygsyyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2677,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycastprgdsygggaywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2678,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggalvqpggslrlsceasefivsrnymnwvrqapgkglewvsviysggstfyadsvkgrfiisrdnskntlylqmnslraedtavyycarelvgyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2679,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyytdsvkgrftisrdnskntlylqmnslrpedravyycakdaadsritmfgvviishfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2680,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewassissnssciyyadsvkgrftisrdnaknslylqmnslraedtavyycasgehnyyyyygmdvwgqgttvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2681,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqqsgaevkkpgasvkdsckasgytftsygiswvrqapgqglewvgwisayngntnyglklqgrvtmttdtststaymelrslrsddtavyycarahpfydsggysdywgqgslvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2682,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrltcaasgfifssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyyctkadyydfwsgyqktyyyymdvwgkgttvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2683,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgltvsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycarniyddafdvwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2684,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2685,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnggiidyadsvkgrftisrdnaknslylhmrslraedtafyycakdigpfeaarpggnyyyyamdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2686,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvtsnnyywgwirqppgeglewigsiyytgstfynpslksrvtisvdasknqfslklssvtaadtavyyctrqlvlvrgyfdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2687,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgpglvkpsqtlsltctvsggsissgsyfwswirqpagkglewigriftsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargpdivvvpaadprnwfdpwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2688,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvetgggliqpggslrlscatsgftvssnymtwvrqapgkglewvstiysggstyyadsvkgrfsisrdsskntlylqmnslraedtavyycargpyphfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2689,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyycakdiksfgifgvvtafdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2690,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2691,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaresygmdvwgqgttitvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2692,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifddyaihwvrqgpgkglewvsgiswnsgsigygdsvkgrftisrdnaknslylqmnslraedtafyycakggrraamllnyfdywgqgtlvtvsa,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2693,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvrgrftisrdnaknslflqmnslraedtalyycardpfsrwerpegwfdpwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2694,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgrifpilgianyaqkfqnrvtitadrststafmelsslrsedtavyycardqdsgyiwwfdpwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2695,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2696,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlteismhwvrqapgkglewmggfdpeegetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsevvvpgairhkaayyynymdvwgkgttvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2697,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstnamhwvrqapgkglewvalisydgsnkyyavsakgrfiisrdnskntlhlqmsslraedtavyycvkglggnyyyfgfwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2698,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmvgqycsggncylgyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2699,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissttsytnyadsakgrftisrdnaknslylqmnslraedtavyycardvayyydsgsyyyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2700,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmmgqycsggdcysgyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2701,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsfiypggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycarsygdyyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2702,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlslsctvsggsispyywswirqlpgkglewigyiyytgstnynpslkgrvtmsadmsknqfslnlssvtaadtamyycargydfwsrgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2703,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgitwnsgtigyadsvkgrftiskdnaknslylqmnrlraedtafyycakdltgwgltfggvitnwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2704,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslksedtavyycateehpfagraklhhldywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2705,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftiyymhwvrqapgqglewmgiinpgggsrsyaqrfqgrvtmtrdtststvymelsslrsedtavyycargrycsssscyigldywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2706,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqprgslrlscaasgftfstywmtwvrqapgkglewvanigqdgseryfvdsvkgrftisrdnannslylqmnslraedsavyycardytddygdyggyfdlwgrgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2707,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgdsissshwwswvrqppgkglewigeiyhsgstnynpslksrvtisveksknqfslklssvtaadtavyycarrrlgpssnnsgyfywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2708,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifsnyrmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardsvpryyyhyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2709,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfniyvmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycakgrsgsyfnpldywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2710,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgtnkyyadsvngrftisrdnskntlylqmdslragdtavyycarpnsgsyssyldywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2711,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvhpggslrlscaasgftfssywmswvrqapgkglewvanikedgrekyyvdyvkgrftisrdnaknslylqmnslraedtavyycardsvhyyydssgyhysygmdvwgqgttvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2712,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcaahggsfsgynwswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqlslklssvtaadtavyycarggtigttgiydiltgydpffdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2713,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgnwndvlshyyyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2714,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlsctgsgftfgdyamswfrqapgkglewvgfirsedhggtteyaasvkgrftisrddsksiaylqmnslktedtavyycsrpltyyydssgyyypyyfdywgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2715,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgwggynthfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2716,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftiywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrtltttygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2717,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakshsgsyfssgdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2718,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarenydfwsgyfngwfdpwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2719,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrhdskntlylqmnslktedtavyycttasnpdywgqgtrvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2720,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardtrgrgghdafdiwgqgtmvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2721,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygthwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpdsgsywgafdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2722,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdladgetiyaqefqgrvtmtedtstdtaymalsslrsedtavyycatgpltiavagqwfdpwgqgtlvtiss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2723,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftiprdnskntlylqmnslraedtavyycakggsgyryyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2724,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksafgsyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2725,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqvgatsgidywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2726,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycashpyydssgyypnygmdawgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2727,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnrlrdedtavyycardrcgdcygpyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2728,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaarsyyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2729,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptivvvavnptfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2730,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyygdsvkgrftisrdnskntlylqmnslraedtavyycardfregafdiwgqgtmvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2731,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmhwvrqapgkglvwvsriniygsstsyadsvkgrftisrdnakntlylqmnslraedtavyycardlhydssgwdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2732,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsgtlsltcavsggfisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrycsggscgyfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2733,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycaraqyssgwylrfdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2734,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargaasvlrflewlldywgqgalvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2735,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevknpgasvkvsctasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycalvgatdywgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2736,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycakafkgnyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2737,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardrppivvvttyyyygmdvwgqgttvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2738,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgpglvkssqtlpltctvsgasinsnnyywnwirqpagkglewigrihssgntnyspslrsrltisvdtsknqfsleltsvtaadtavyycarddwttaldcwgqgtlvtvss,,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
2739,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipdwtfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2740,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynsvswyqhhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagrytlvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2741,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftptisslqpedfatyycqqsystppytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2742,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsirswlawyqqkpgkapkvliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynyysvtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2743,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipxwtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2744,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyvtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2745,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgisgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2746,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvnnylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedlavyycqqcsnwppsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2747,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmisevskrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagsnnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2748,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2749,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qlvltqppsvsvapgqtaritcggnsigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwhissdhlwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2750,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysftfgpgtkkdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2751,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssnigsytvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2752,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspatlslspgeratlscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2753,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvsrnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynngrgtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2754,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqtplslpvtpgepasiscrsgqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2755,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeatyycnsytssstyvlfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2756,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnflnwyqekpgkapkllisdasnletgvpsrfsgsgsgtdftftitslqpediatyycqqydnllitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2757,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qlvltqpptvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperisgsssgtmatltisgaqvedgadyycysidssgnhyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2758,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsslsasvgdrvtitcqasqdiskylnwyqrkpgtaptlliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2759,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqfgewftfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2760,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qlvltqppsvseaprqrvtiscsgsssnignnpvnwyqqlpgkapkpliyyddllpsgvsdrfsgsrsatsaslaisglqsedeadyyctawdgslngyvfgsgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2761,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqksgqaprlliygassratgipdrfsgsgsgtdftltisrlqpedfavyycqqygsspmytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2762,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipptfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2763,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgteftftitslqpediatyycqqydtlpptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2764,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgggsgtdftltisslepedfavyycqqrsnwrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2765,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslgpedfavyycqqrsnwpptwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2766,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspsslsasvgdgvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgggsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2767,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2768,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspsslsasvgdrvtitcqasqdirnylnwyqqtpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyychqydnlpqsfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2769,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlhssnnknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyhcqqyystpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2770,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgagtyftftisslqpediatyycqqydnlpplftfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2771,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsllftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2772,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspdslavslgeratinckssqsvlhnsknksylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyggrwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2773,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlpgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2774,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspgtlslspgeratlscrashnissthlvwyqqkpgqaprlliygasnratgipdrfsgggsgtdftltisrlepedfavyfcqqfgsspqtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2775,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspgtlslspgeratlscrasqsvssshlawyqqksgqaprlfiygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2776,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspeqtasitcsgdklgdkyacwyqqkagqspvlviyedgkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdrttavfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2777,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgirsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlntyaltfgggtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2778,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2779,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqpasvsgspgqsitisctgtssdvgvydyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2780,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspstlsasvgdrvtitcrasqsisrwlawyqqipgkapnlliyqtsslqsgvpsrfsgsgsgteftltisslqpddfatyycqqyysypltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2781,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqfpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssridvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2782,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qavvtqppsvsgapgqrvtisctgsssnigagydihwyqqlpgtapklliynnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2783,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyhqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2784,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qlvltqspsasaslgasvkltctlssghssnaiawhqqqpekgprylmklnidgshrkgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgpnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2785,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsflsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgygsgteftltisslqpedfatyycqhlnsyprytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2786,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsafvgdrvtiicrasqsisswlawyqqkpgkapklliykasslesgvpstfsgsgsgteftltisslqpddfatyfcqqynsypytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2787,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslavtpgepasiscrssqsllhsdgynyldwylqkpgqspqlltylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2788,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqqpgkapklllyaasrlasgvpsrfsgsgsgtdytltisslqpedfatyycqqyysapptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2789,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2790,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspsslsasvgdrvtitcrasqgvssylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2791,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2792,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qtvvtqapsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnvvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2793,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qavvtqprsvsgspgqsvtisctgtssdvgaynfvswyqqhpgkapklmtydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsfyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2794,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgegatlscrasqsvgrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2795,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqsediatyycqqydnlpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2796,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqpwrltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2797,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2798,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsisstylawyqqkpgqaprllihgassratgisdrisgsgsgtdfiltisrlepedfavyycqqygsspgtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2799,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspatlsvslgeratlscrasqsvssnlawyqqkpgraprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2800,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspssvsasvgdrvtitcrasqgissglawyrqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpytfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2801,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qtvvtqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2802,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2803,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgqapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpadfatyycqqsysifrtsgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2804,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgegatlscrasqsvssylawyqrkpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqersswppafgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2805,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsslsasegdrvtitcqasqdinnylnwyqqkpgkapklliydasnleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlppafgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2806,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwprtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2807,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsrtdftftisslqpddiatyycqqydkppvtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2808,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlssspgeratlscrasqgvsssylawyqqklgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhsrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2809,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2810,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvapgqtaritcggnniggksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2811,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpedfatyfcqqyddlpytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2812,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftistlqpediatyycqqydnllsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2813,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsastgdrvtitcrasqgirtylvwyqqkpgqapnlliyaasslqsgvpsrfsgsgsgtdftltisglqsedfatyycqqyysypltfgggtkvevk,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2814,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsissnlawhqqkpgqaprllisdastratgiparfsgsgsgteftltidslqsediavyycqqynnwpptitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2815,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,slsqlvltqgrlgpgqtaritcegnniggksvlwyqqkpgqapvlvvyddsdrpsgiperfsasnsgntatltisrveagdeadyycqvwdtssdhagvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2816,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspstvsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisrlqpddfatyycqqynsylfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2817,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftlttsslqpddfatyycqqystyspltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2818,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylktfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2819,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsvsgapgqrvtisctgsssnigadydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssdsslsgsrvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2820,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2821,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnryplytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2822,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2823,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapelpiyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2824,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nivmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2825,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2826,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2827,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2828,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssftfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2829,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliymgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspynlgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2830,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2831,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsaphtfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2832,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedegdyycystdssgnkrvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2833,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlarfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2834,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2835,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2836,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytfgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2837,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsytltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2838,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2839,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2840,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssqytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2841,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2842,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2843,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqsissylnwyqqepgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2844,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltissmqsedfavyycqqynnwppgdtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2845,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2846,not found,not determined,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VH: Chain G, Cyno antibody heavy chain",2022-03-01
2847,not found,not determined,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VH: Chain E, Cyno antibody heavy chain",2022-03-01
2848,not found,not determined,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VH: Chain H, Cyno antibody heavy chain",2022-03-01
2849,not found,not determined,Macaca fascicularis (crab-eating macaque),,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VL: Chain F, Cyno antibody light chain",2022-03-01
2850,not found,not determined,Macaca fascicularis (crab-eating macaque),,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VL: Chain D, Cyno antibody light chain",2022-03-01
2851,not found,not determined,Macaca fascicularis (crab-eating macaque),,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VL: Chain L, Cyno antibody light chain",2022-03-01
2852,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqsplslpvslgqsasiscrssqslvhtdgitylswfqqrpgqsprrllykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgtywpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.","VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
2853,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsfssywmswvrqapgkglewvgnikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdpywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2854,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsistaylqisslkaedtavyycarvgpssswpswgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2855,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggwysskwyyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2856,not found,SARS-CoV-2,Homo sapiens (human),qvhlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifdianyaqkfqgrvtmtadkstttaymeltslrsedtamyycarteysydsgssraysmdvwgkgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2857,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsavgtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycargfdtttgfyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2858,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakaagggysyiywggdywgqgtlvtsph,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2859,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgrglewigsiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycariprhlgqdhyyyvmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2860,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkplewlaliywdddkryspslksrltitkdtsknqvvlrmtnmdpvdtatyycahspdhryfdvltgyfnserfyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2861,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsfstyywswirqppgkglewighisysgsthynpslkgrvtisldtsknqfslnlssvtaadtavyycarggyyygpprdfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2862,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdllfssqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2863,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwddakyystsletrltiskdtsnnqvvltltnmdpvdtatyycarevagavhldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2864,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyfcardgsavagpmsyfdywgqgtpvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2865,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasghtftsylihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardppsgnydnidewtrsenhynygmdawgqgttvtvlt,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2866,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2867,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnynpsltsrvtlsvdtsknqfslklssvtaadtavyycareyfvslpaaqtlyyygidvwgqwttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2868,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgisdsggspyyadsvkgrftisrdnskntlylqmnslrvedtavyycaesssltgnfnywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2869,not found,SARS-CoV-2,Homo sapiens (human),qvrlvesgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvallsydgtnkyyadsvkgrftisrdnskstlflqmhslraedtavyfcakgggyisawstryyamdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2870,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyqsgstyynlslksrvtilvdtsknqlslklssvtaadtavyycarvgvatilgvdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2871,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqhpgkglewigyifysgstyynpslksrviisvdtsknqfslklssvtaadtavyycarvsrytmvrgvifdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2872,not found,SARS-CoV-2,Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgtnekyadsvkgrftisrdnskntlylqvnslraedtavyycakngysyayprqyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2873,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaseiivssnymswvrqapgmglewvsvvysggstfyadsvkgrftisrhnskntlylqmnslrtedtavyycareapnsrgsgtnfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2874,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrydmhwvrqttgkslewvsaigtagdtyypdsvkgrfiisrenansslylqmnslragdtavyycargsdtvttafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2875,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasrgtfssyaiswvrqapgqglewmggiipifttpnyaqnfqgrvtitadkststaymelnsltsedtavyycavlplhssynwyyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2876,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsifamswvrqapgkglewvsgingsgdntyyadsvkgrftisrdnsrntlylqmnslrpedtavyycakqtdygvgwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2877,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckrsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasqaaagyyyymdvwgkgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2878,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstyynpslksrvtisvdksknqfslklssvtaadtavyycarvqglidywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2879,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgplgmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2880,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgkslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgnigyadsvkgrftisrdnandslflqmnslraedtalyycakdirsgdyvgvfdywgqgalvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2881,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrvscaasgfavsnnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmkslraedtavyycardlvvagidywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2882,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvqpggslrlscaasgitvssnymnwvrqapgkglewisviysggstyyadsvkgrftisrdnskntlflqmnslraedtavyycardldiagafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2883,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfstydmhwvrqvtgkglewvsalgtsgdtyyadsvkgrftisrenaknslylqmnslragdtavyycvrgdhssgwygtyyyymdvwgkgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2884,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygitwvrqapgqglewmgwisvyngnthyaqklqgrvtmttgtststaymelrslrsddtavyycavldycsggssssgyynygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2885,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqnlqgrvtmttdtststaymelrslrsddtavyycaregagliiaydywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2886,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvtviwydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakggnygdylrgfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2887,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryrpsfqgqvtisadksistaylqwsslkasdtamyycalavgrgiptsyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2888,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasissyfwswirqppgkgldwigyiyyngstnynpslksrvtisvdtsknqfslklssvtaadtavyfcastywdssgyyygvdywghgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2889,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarekirsiaaagtvyyygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2890,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaglfwyggyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2891,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgsstyyadsvkgrftisrdtskntlylqmnslraedtavyycarglqyyydtsgyykdsyyygvdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2892,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsyyvhwvrqapghglewmaiinpdagstsfaqrfqgrltmttdtststvymglnslrsedtavyycargglvpavmpaldywgqgalvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2893,not found,SARS-CoV-2,Homo sapiens (human),qvqliqsgaevkkpgasvkvscttsgytftsyflhwvrqapgqglewmgiinpsdgtttyaqkfqgrvtmtrdtstgtvsmelsslryedtavyycardgalysnsptefdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2894,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsintaymelsrltsddtavyycardslfsrvdwyfdlwgrgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2895,not found,SARS-CoV-2,Homo sapiens (human),qvllqesgpglvkpsqtlsltctvsggsisngsyywswirqhpgkglewigyiyysgstyynpslrsrvtisldtsmnqfslklssvtaadtavyycariyrgtmvvvfsdlhwyfdlwgrgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2896,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevrkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpeansttyaqkfqgrvtmtsdtststvyldlsslrsedtavyycartgflipskgggmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2897,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgselkkpgasvkvsckasgysftdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqistlkaedtavyycastvgrgsgtyyygnyysysmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2898,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksittaylqwsslkasdtaiyycarlpphfgsgsyygnafdiwglgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2899,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdpvdtatyycariqrgiaadywgqgilvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2900,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaaskftfsnyamnwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakgellwfgellenwfdpwgqgtrvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2901,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2902,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddddryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslpskysysygsfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2903,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsiifsggttyyadsvkgrftisrdnsrntlylqmsslraedtavyycaetgwdgmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2904,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkgldwigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardyggnsnyfhywgqgtlvtvsp,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2905,not found,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvatisydgsdkfyadsvkgrftisrdnsrntlyvqmnslrpedtalyycakggwygdirvdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2906,not found,SARS-CoV-2,Homo sapiens (human),dvqlvesggglvqpggslrlscaasefivssnymswvrqapgrglewisviysggstfyadsvkgrftisrdsskntlylqmnslraedtavyycardlplhgdyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2907,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkgldwvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarelgpvggtdqwgqgtlvsvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2908,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkasetlsltctvsggsissssyywgwirqppgkglewigsihdsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaryygpgtyydafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2909,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfysihwvrqapgkglewvavisydgsykfyadsvkgrftisrdnskdtvylqmnslraedtavyycardwvhygsgsyppdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2910,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgdsfpsywiewvrqmpgkglewmgliypgdsdtryspsfqgqvtisadksistaylqlsslkasdtamyfcarhpvlrgnidywgqgtlvivss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2911,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivsrnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlenggldvwgqgttvtvfs,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2912,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggflqpggslrlscaasgftfssddmhwvrqvtgkglewvsaigtsgdtyysgsvkgrftisrenaknslylqmnslrvgdtavyycargslrggilsgyafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2913,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewvsyisssgatiyyadsvkgrftisrdnaknslylqmtslraedtavyycaspllshnygsgsyynvywyfelwgrgtlvsvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2914,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsiityywswirqppgkglewigyidysgstnynpslksrvtisvdtsknqfslelssvtaadtavyycartlgayydiltgfrtpggwfapwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2915,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisasgdstyyadfvkgrftisrdnskntvylqmnslraedtaiyycakepsfglwfgelsgwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2916,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2917,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2918,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaviywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahttwyyygsgwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2919,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2920,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycaritphlvydywsqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2921,not found,SARS-CoV-2,Homo sapiens (human),qvqivqsgaevkkpgasvkvsckasgytftsyaihwvrqapgqrlewmgwintgngntkysqnfqdrvtitrdtsattaymelssltpedtavyycaragwelnywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2922,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasrftfsnyamtwvrqapgkglewvsaisgsagsiyyadsvkgrftisrdnskntlylqmnslraddtavyfcakgqrgspdffdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2923,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2924,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftrywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarieyyndssgyyqfwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2925,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfsnawmswvrqapgkglewvgrikfttdggtsdyaapvrgrftisrddskntlylqmnslrtedtavyycsttndygdysanywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2926,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2927,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissfywswirqpagkglewigrmsasgstnynpslksrvtmsvdtsenqislklgsvtaadtavyycageqhivttiidywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2928,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycakdptslycsggscynnwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2929,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstfyadsvkgrftisrlsskntlylqmnslrvedtavyycargpypssswawgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2930,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasmtvsckasgytfstyyihwvrqapgqglewmgiinpsagstsyaqkfqgrvtmttdtststvymelsslrsedtavyycardysritmirgagdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2931,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsskyyadsvkgrstisrdnskntlylqmnslraedtavyycakrggtycsggicyggyfdywgqgmlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2932,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2933,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycareeaagtkldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2934,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmcvswirqppgkalewlaridwddekyystslqtrltiskdtsknqvvltmtnmdpvdtatyycarmipipaldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2935,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmsvswirqppgkalewlaridwdddkyystslktrlsiskdtsknqvvltmtnvdpvdtatyyctrtatvvkdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2936,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssfamswvrqapgkglewvsvisssgdytsyadsvkgrftisrdnskntlylqmnslraedtavyycakdvgsrliydvfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2937,not found,SARS-CoV-2,Homo sapiens (human),rgpgngvwaevkkpgssvkvscktsggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasfgslwdlrdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2938,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlslictvsggsitsyywtwirqppgkglewigyiyyngssnynpslesrvtisvdasknqfslklssvtaadtavyycatdyydssgyrygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2939,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfnsygiswvrqapgqglewmgwissyngntnyaqklqgrvtmttdtststaymelrsltsddtavyycatddpdivlvpaamsldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2940,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2941,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycakdgsgsyynsgaldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2942,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscagsgftfshygmhwvrqapgkglewvavilydgsnnyyadsvkgrftvsrdnskntlylqmnslrtedtavyycgkgagpycgggscyptkvdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2943,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggalvqpggslrlscaasgftfssydmhwvrqatakglewvstigtagdtyypgsvkgrftisrenaknslylqmnnlragdtavyycarvgydssgyywyldlwgrgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2944,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvnwirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycartrlgitafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2945,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviyngvttyyadsvkgrftisrdiskntvylqmnslraedtavyycaragwlrgrfdpwgqgtlvivss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2946,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslqisckgsgysfisnwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylrwsslkasdtamyycarigdwigfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2947,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardleergamdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2948,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2949,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslriscaasgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmntlrvedtavyycardavgsyyygmevwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2950,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvrptqtltltctfagfslrthgmcvswirqppgkalewlaridwdgdkyystslktrltiskdtskdqvvltmtnmdpvdtatyycarflvggfkawfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2951,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycakmlwlrgwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2952,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgdtfsshyihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvylelsslrsedtavyycardqafivatlgpdywgqgilvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2953,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamnwvrqapgkglewvslisgdgdspsysgsvkgrftisrdnsknslylqmislrtedtalyycarespkltgyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2954,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfsnydmhwvrqatgkglewvsvigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarayydtsgyynyfdhwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2955,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymnwvrqapgkglewvsviysgdnthyadsvkgrftisrdnskntlylqmnslraedtavyycargygsgsygwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2956,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqmsslgvedtavyycakggfgyasgwyyldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2957,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglvgttltfdywgqgslvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2958,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasagtfssyavswvrqapgqglewmgriipivsitkyaqkfqgrvtmtadkststaymelsslrsedtavyycargrytygtegyfdnwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2959,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglgmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2960,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardpmrpgmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2961,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytlhwvrqapgkglewvavissdgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppgnmgsmaqhlvllvvfdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2962,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyafswvrqapgqglewmggiipifgtsnyaqkfqgrvtisadessstaymelsslrsedtavyycargpayvsgtyywnafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2963,not found,SARS-CoV-2,Homo sapiens (human),emqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyissstnsiyyagsvqgrftisrgnaknslylqmnslraedtavyycargrddygdyrggdfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2964,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscegsgysfisywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsistaylqwsslkasdtamyycvrsdgdyvighdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2965,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatdggggsyyyahyyygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2966,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdlssgwdlfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2967,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvisnymswvrqapgkglewvsviyrggstyfadsvkgrftisrdnskntlylqmnslraedtavyycarlasdgsgsyldyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2968,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgyrftnywtvwvrqmpgkglewmgiiypgdseirysppfqgqvtisadksistaylqwsslkasdtamyycarhpsnfydsggdyyamdvwgqgtpvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2969,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswssgsivyadsvkgrftvsrdnaknslylqmnslrvedtafyycakdmvagphyygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2970,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslrtrltiskdtsknlvvltmtnmdpvdtatyycalgragtmdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2971,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtalyycarvgyygsgsyplywyfdlwgrgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2972,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2973,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywitwvrqmpgkglecmgridpsdsyskyspsfqghvtisadksistaflqwsslkasdtamyycarlpfcdsascgrahyyygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2974,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlsrywmswvrqapgkglewvanikqdgsekkyvdsvkgrftisrdntknslylqmnslraedtavyycarlmyyygnfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2975,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasglivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlniaggfdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2976,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsavgvgwirqppgkalewlaliywnddkryspslknrltitkdpsknqvvltmtnmdpvdtatyycahrlapdydfltgyyngddafdvwgpgtmvtiss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2977,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvsvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahsmvrgvlfgadfdywgqgtlvavss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2978,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysiswvrqapgqglewmgriipilgvaddaqkfqgrvtitadkststaymelsslrsedtavyycareagttdwyfdlwgrgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2979,not found,SARS-CoV-2,Homo sapiens (human),rilltqsgaevkkpgasakvsckvsgyslsespmhwvrqapgkglewmggfdpedgeiinvqkfkgrvtmtedtssdtaymeltsltsedtavyfcaitslarglkgyfdswgqgtllivss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2980,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrwdgvgfdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2981,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnywmtwvrqapgkglewvanikldgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycarsphyyggfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2982,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywtwirqapgkglewigyiynsgstnynpslrgrvtisvdtsknqfslnlssvtaadtavyycardqgyssgwndafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2983,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfissyywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycarrsmgycsggncysgfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2984,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2985,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryglhwvrqapgkglewvgvilydgsdehyadsvkgrftisrdnskntldlqmnslrpedtavyycakqaspycsggscysgnfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2986,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissntfywgwirqppgkglewigsihytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarfitdgyssgsdswgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2987,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgiyywswirqppgkglewigyvfysgstnynpslksrvtisvdtsknqfslklrsvtaadtavyycamtyydyiwgrvdpqfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2988,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisstshywgwirqppgkglewigsihysgstyynpslksrvtisvdtskkqfslklrsvtaadtavyycarfitdgyssgsdswgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2989,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2990,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsdntnyaqkfqervtitrdmstrtaymelsslrsedtavyycaadrmrivggkgyyygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2991,not found,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalqwlaridwdddkyystslktrltiskdtsknqvvltvtnvdpvdtgtyycarvqvaaagspydywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2992,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsgkhyadsvkgqftisrdnskntlylqmnslraedtavyycardgvdfgmvtlfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2993,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2994,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqapgkglewvsgiswnsgsfgyadsvkgrftisrdnaknslylqmnslrpedtalyycakdigcsstscsyyhyygmdvwglgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2995,not found,SARS-CoV-2,Homo sapiens (human),evmlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycarfrygdypdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2996,not found,SARS-CoV-2,Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlflqmnslrpedtavyycardgravagtdwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2997,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycgvpycsssscyryygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2998,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
2999,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygrsfsgnswswirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycargwtvpplwvlnwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3000,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipilgvanyaqkfqgrvtitadkststaymelsslrsedtavyycaregttiteyfqqwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3001,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddnkryspslksrltitkdtsknqvvltmttmdpvdtatyycahrplfsgpfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3002,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvrpsetlsltctvsggsissssyfwgwirqppgkglewigsiyysgtthynpslksritisvdtsknqfslkltsvtaadtavyycatlewlrapfdnwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3003,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsggtnfvqkfqgrvtmtrdtsistaymelsrlksddtavyycargtppdsvvvpaaihpynwfdpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3004,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasevtvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardglvgatlafdfwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3005,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3006,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakd,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3007,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3008,not found,SARS-CoV-2,Homo sapiens (human),vqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsgiysggstyyadsvkgrftisrdkskntlylqmnslraedtavyycardggysaytlfysdfafdiwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3009,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgifnpgagttnypqkfqgrvtmtrdtststvymelsslrsedtavyycardgspwgndydiygmdvwgqgttvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3010,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftlsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkgplffwsgyytdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3011,not found,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3012,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfiryyywtwirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslnlssvtaadtavyycarrgkygsgspddafdvwgqgtmvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3013,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsyaihwvrqtpgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycardgrifylsfyfdywgqgtlvtvss,,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",2022-03-01
3014,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdgvtitcrasqgisnslawyqqkpgkapklllyaastvesgvpsrfsgrgsgtdytltissllpedfatyycqqyysaprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3015,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3016,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspvslpvtpgepasmscrssqsllhsngyiyldwyvqkpgqspqllfylgsnrapgvpvrfsasgsgtdftlkisrveaedvgvyycmqalqmgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3017,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqtisnylnwyqqkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqthstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3018,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqkpgkapklllyaasrlqsgvpsrfsgsgsgtdytltisslqpedfavyycqqdynfpwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3019,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3020,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyagifvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3021,not found,SARS-CoV-2,Homo sapiens (human),,rsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapkvliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3022,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqgvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspqytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3023,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqkpgtapklllyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqyysdpprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3024,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslpasvgdrvtitcrasqsirryinwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedsaiyycqqsfstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3025,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqppsslsasvgdrvtitcrasqdisnslawyqqkpgkapklllyaasrlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyysiprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3026,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvrsflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpyltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3027,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeraalscrasqgvtstylawyqqkpgqaprlliygvstratgipdrfsgsgsgtdftltisrlepedfavyychqydsspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3028,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspvtlsvspgeratlscrasqsvssnlawyqqkpgqgprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqyknwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3029,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdtawvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3030,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgnapklmiydvnnrpsgvsdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3031,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktviisctrssgsiasnyvqwyqqrpgsapttviyedslrpsgvphrfsgsidsssnsasltisglmtedeadyycqsydsswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3032,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitlsctgtssdvgsydlvswyqhhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyycclyaghstyvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3033,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisndlnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqhydnlkvtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3034,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3035,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpgltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3036,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissleaedfavyycqqrsnwppgmytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3037,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnfsltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3038,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsynilwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3039,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgignslawyqqkpgkapklllyaastlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyystpprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3040,not found,SARS-CoV-2,Homo sapiens (human),,divltqspgtlslspgeratlscrasqsvsssslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygssplfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3041,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgipasfsgsgsgteftltisslqsedfavyycqqyndwppmytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3042,not found,SARS-CoV-2,Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqllnsdsptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3043,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsfpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3044,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpediatyycqqsyssppwtfgqgakveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3045,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgerttlscrasqsvrgsylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3046,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdfqsvtpkekvtitcrasqsiasslhwyqqkpdqspkllikyasqsfsgvpsrfsgsgsgtdftltinslepedaatyychqssslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3047,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftfaisslqpediatyycqqyhnvppafgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3048,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatfycqqyhnlpitfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3049,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgthftltisslqpedfatyycqqansfrltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3050,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtefthtisslqsedfavyycqqynnwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3051,not found,SARS-CoV-2,Homo sapiens (human),,vltqppsvsgapgqrvtisctgsssnigagagydvhwyqqfpgtapklliygnnnrpsgvpdrfsgsksgtsasltitglqaedeadyycqsydrslsvlyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3052,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3053,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3054,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycttwdasrggwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3055,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgntvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3056,not found,SARS-CoV-2,Homo sapiens (human),,syvvtqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvmyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssadhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3057,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspeqsitisctgtssdvgvynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssslqifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3058,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadfyctsytgsstsvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3059,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrsnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddsltgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3060,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqtissylnwfqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3061,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqadsfpwtfgqgtrveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3062,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3063,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsinyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysapytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3064,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3065,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdiskylswyqqkpgkapklliydasnletgvpsrfsgsgsgadftftisslqpediatyycqqydtlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3066,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgttftftisslqpadiatyycqhynnlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3067,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3068,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkqgkapnlliyaasslqsgvpsrfsgsgsgtdftltitslqvedfatyycqqshstpytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3069,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasmsgspgqsitisctgttsdvgaynyvswyqqhpgkapklmisnvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3070,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsgspgqsvtiscagtssdvgsynrvswyqqppgtaprlmiyevgnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3071,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctasssnigadydvhwyqqlpgtvpklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslrgsvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3072,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgiskwvawyqqkpgkapkiliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3073,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdtvtitcrasqiinsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3074,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqqlgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3075,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscragqsvsssylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3076,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqslsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3077,not found,SARS-CoV-2,Homo sapiens (human),,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3078,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgktasitcggnnigsksvhwyqqrpgqapvlviyydtdrpsgiperfsgsnsvntatltisrveagdeadyycqvwdsssdhplfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3079,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnnvnwyqqlpgtapkvliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnghvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3080,not found,SARS-CoV-2,Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyscnsrdssgnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3081,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapksliyvasslqsgvpsrfsgsgsgtnftltisslqpedfatyycqqsysiprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3082,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysfwafgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3083,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydssslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3084,not found,SARS-CoV-2,Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfngsgsgtdftltisslqpedfatyycqqfnnflltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3085,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3086,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3087,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqksgkapklliydasnletgvpsrfsgsgsgadftftisslqpedigtyycqqsdnvpvtfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3088,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqplsasgtpgqrvtiscsgkssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3089,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3090,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvterpsgvsnrfsgsksgntasltisglqaedeadyycssftssstpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3091,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaqvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3092,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtvsctgsssnigagydvqwyqhlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdwgvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3093,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapkffmysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3094,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrtsqsirvylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3095,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslstsvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtnftltisslqpedfatfycqqsystphtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3096,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqtisrylnwyqqrpgkapklliyiasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3097,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkllmyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystppysfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3098,not found,SARS-CoV-2,Homo sapiens (human),,esvltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsrtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3099,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsaslgdrvtitcrasqgisgwlawyqqkpgkapmlliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqansfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3100,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqhedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3101,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3102,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqktgkapkpliydasileagvpsrfsgsgsgtdftftitslqpediatyycqqydnlppytfgqgtnleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3103,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnclnwyqqkpgkaptlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllwtfgpgtkmeik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3104,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcraslsigrylnwyqqkpgkapkllisaastlqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsyttplftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3105,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqniktylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3106,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdeadyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3107,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdesdyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3108,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsslwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3109,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqninkylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3110,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3111,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgiapelliydnnkrpsgipgrfsgsrsgtsatlditglqtgdeadyycgtwdtslnvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3112,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssdsasltisglktedeadyycqsydtsnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3113,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsfsvspggtvtltcglssgsvstsyyaswyqqtpgqaprtliystntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgiwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3114,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgqtagitcggddigsknvhwyqqkpgqapvlvvyddhdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3115,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3116,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3117,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqkpgkapklliydasdletgvpsrfsgsgsgtdftftisslqpediatyycqqygnlppiafgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3118,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgdsylnwfqqrpgqsprrliykvsnwdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3119,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyhcqqynnlytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3120,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3121,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfiftisslqpediatyycqqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3122,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttlaltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3123,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3124,not found,SARS-CoV-2,Homo sapiens (human),,qivltqspatlslspgeratlscrasqsvttylawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgpgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3125,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssniggntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3126,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsfsvspggtvtltcglssgsvptsyfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgivvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3127,not found,SARS-CoV-2,Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatlsisrveagdeagyycqvwdtsgdplvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3128,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigadydvhwyqqfpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3129,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssnvgnydlvswyqqhpgkapklmiyevnkrpsgvsdrfsgsksgntasltisglqaedeadfyccsyagssswvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3130,not found,SARS-CoV-2,Homo sapiens (human),,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3131,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpgdfatyycqqsysppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3132,not found,SARS-CoV-2,Homo sapiens (human),,diqmtpspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgteftltisslqpedfatyfcqqsysappwtfgqgtrveir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3133,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3134,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpetfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3135,not found,SARS-CoV-2,Homo sapiens (human),,airitqspsslsastgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisrlhsedfatyycqqyygyptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3136,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnidpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3137,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqpedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3138,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvseaprqrvtiscsgsssnighnavnwyqqipgkapklliyyddlvpsgvsdrfsgsksgtsaslaisglqsedeaeyycaawddslngpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3139,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3140,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvniscsgsssnlgnnfvywyqqlpgtapkllsyldsrrpsgvpdrfsgsksgtsasldisglrsedeadyycaawddslsgvifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3141,not found,SARS-CoV-2,Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydknnrpsdipdrfsgsssgntasltitgaqaedeadyycnsrdssinhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3142,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsvasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsyhnsvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3143,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyhccsyagsrfwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3144,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapelliyaasslqsgvpsrfsgsesgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3145,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyychqyassprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3146,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqanqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdnvpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3147,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspvslpvtlgqpasiscrssqslvhsdgntylnwfqqrpgqsprrliykvsyrhsgvpdrfsgsgsgtdftleisrveaedvgvyycmqgthwpmytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3148,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvggvyycmqgthwpptfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3149,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsvssylnwyqqnpgkapklliyaastlqsgvpsrfsgsgsgtdftltistlqpedfatyfcqqsystprltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3150,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqhisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqakgfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3151,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsitswlawyqqkpgkapklliykastlergvpsrfsgsgsgpeftltisslqpddfatyycqqynsyspgdtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3152,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3153,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3154,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrrdftfgpgtrvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3155,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3156,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisiylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediaiyycqqydnlpsftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3157,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpvdiatyychqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3158,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypqatfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3159,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpawtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3160,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlviylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3161,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssltgsvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3162,not found,SARS-CoV-2,Homo sapiens (human),,sfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttliyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsstiifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3163,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3164,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtlsctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgnfvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3165,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3166,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3167,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtnftltisslqpedfathycqqsystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3168,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplslsvtpgqpasiscksrqsllhsdgktylywylqkpgqspqlliydvssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgihlptfgqgtrldik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3169,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcragqnissylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3170,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftlnisslqaedvavyycqqyystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3171,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3172,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsigynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3173,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3174,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvnsnyltwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqsdnspftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
3175,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgglipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycanfigdgynyeedymdvwgkgttvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3176,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasakvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqrfqgrvtmtedastdtaymelsslrsedtavyycttvgfpdyydssvylrhfdywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3177,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgftftnyyihwvrqapgqglewmgiinpsggstiyaqkfqgrvtmtrdtstrtvymelsslrsedtavyycadllldywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3178,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgkslrlscadsgftfssyamhwvrqapgkglewvavisfdgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwlnwafdywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3179,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkdrftisrdnskntlylqmnslraedtavyycvrdlysygmdvwgqgttvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3180,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgyslielsmhwvrqapgkglewmggfdpedvetiyaqnlqgrvtmtedtstdtaymelsslrsedtavyycatffavrgalnwfdswgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3181,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggitpifhtanyaqkfqgrvtitadeststvymelsslssedtavyycaretgdqgvtapfdlwgrgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3182,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlfcaasgftfsdyymswfrqapgkglewvsyisssgsniyyadsvkgrftvsrdnaknslylqmnslraedtavyfcargrlwgwfdpwgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3183,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqtpgkglewmggfdpadaetiyaqklqgrvtmtedtstdtaymelsslrsedtavyycatalpitmvrgvqyyyygmdvwgpgttvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3184,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslraadtavyycatgtydfwsdnhyldywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3185,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgpsvkvsckasggtfssytinwvrqapgqglewmgriipmlgiakyaqkfqgrvtitadkststaymelsslrsedtavyycargivgatpgyfdywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3186,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsinymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaapllwadsyymdvwgkgttvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3187,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntdyvqkfqgrvtitrdmststaymelsslrsedtavyycaapycssttchdgfdiwgqgtmvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3188,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssas,,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3189,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgpgtkvdikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3190,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyprtfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3191,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3192,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsslsasvgdrvtitcragqsissylnwyqqkpgkapklliylastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3193,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3194,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3195,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqlrgnwppwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3196,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3197,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgiyycmqvtqfpytfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3198,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypsttfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3199,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspaalsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgswsgteftltisslqsedlavyycqqynnwltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3200,not found,SARS-CoV-2,Homo sapiens (human),,aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqrgvpsrfsgsgsgteftltisslqpedfatyyclqhnsylwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3201,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3202,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3203,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 71 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 71 from patent US 10851155,2022-03-01
3204,not found,SARS-CoV,Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 70 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 70 from patent US 10851155,2022-03-01
3205,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 69 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 69 from patent US 10851155,2022-03-01
3206,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 68 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 68 from patent US 10851155,2022-03-01
3207,not found,SARS-CoV,Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 26 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 26 from patent US 10851155,2022-03-01
3208,not found,SARS-CoV,Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 22 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 22 from patent US 10851155,2022-03-01
3209,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 18 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 18 from patent US 10851155,2022-03-01
3210,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 14 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 14 from patent US 10851155,2022-03-01
3211,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 10 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 10 from patent US 10851155,2022-03-01
3212,not found,SARS-CoV,Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 6 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 6 from patent US 10851155,2022-03-01
3213,not found,SARS-CoV,Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 2 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VH: Sequence 2 from patent US 10851155,2022-03-01
3214,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 71 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 71 from patent US 10131704,2022-03-01
3215,not found,SARS-CoV,Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 70 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 70 from patent US 10131704,2022-03-01
3216,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 69 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 69 from patent US 10131704,2022-03-01
3217,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 68 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 68 from patent US 10131704,2022-03-01
3218,not found,SARS-CoV,Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 26 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 26 from patent US 10131704,2022-03-01
3219,not found,SARS-CoV,Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 22 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 22 from patent US 10131704,2022-03-01
3220,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 18 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 18 from patent US 10131704,2022-03-01
3221,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 14 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 14 from patent US 10131704,2022-03-01
3222,not found,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 10 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 10 from patent US 10131704,2022-03-01
3223,not found,SARS-CoV,Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 6 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 6 from patent US 10131704,2022-03-01
3224,not found,SARS-CoV,Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 2 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VH: Sequence 2 from patent US 10131704,2022-03-01
3225,not found,SARS-CoV,Unknown.,,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 77 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 77 from patent US 10851155,2022-03-01
3226,not found,SARS-CoV,Unknown.,,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 76 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 76 from patent US 10851155,2022-03-01
3227,not found,SARS-CoV,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 75 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 75 from patent US 10851155,2022-03-01
3228,not found,SARS-CoV,Unknown.,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 74 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 74 from patent US 10851155,2022-03-01
3229,not found,SARS-CoV,Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 73 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 73 from patent US 10851155,2022-03-01
3230,not found,SARS-CoV,Unknown.,,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 72 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 72 from patent US 10851155,2022-03-01
3231,not found,SARS-CoV,Unknown.,,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 28 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 28 from patent US 10851155,2022-03-01
3232,not found,SARS-CoV,Unknown.,,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 24 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 24 from patent US 10851155,2022-03-01
3233,not found,SARS-CoV,Unknown.,,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 20 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 20 from patent US 10851155,2022-03-01
3234,not found,SARS-CoV,Unknown.,,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 16 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 16 from patent US 10851155,2022-03-01
3235,not found,SARS-CoV,Unknown.,,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 12 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 12 from patent US 10851155,2022-03-01
3236,not found,SARS-CoV,Unknown.,,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 8 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 8 from patent US 10851155,2022-03-01
3237,not found,SARS-CoV,Unknown.,,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 4 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",VL: Sequence 4 from patent US 10851155,2022-03-01
3238,not found,SARS-CoV,Unknown.,,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 77 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 77 from patent US 10131704,2022-03-01
3239,not found,SARS-CoV,Unknown.,,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 76 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 76 from patent US 10131704,2022-03-01
3240,not found,SARS-CoV,Unknown.,,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 75 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 75 from patent US 10131704,2022-03-01
3241,not found,SARS-CoV,Unknown.,,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 74 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 74 from patent US 10131704,2022-03-01
3242,not found,SARS-CoV,Unknown.,,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 73 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 73 from patent US 10131704,2022-03-01
3243,not found,SARS-CoV,Unknown.,,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 72 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 72 from patent US 10131704,2022-03-01
3244,not found,SARS-CoV,Unknown.,,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 28 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 28 from patent US 10131704,2022-03-01
3245,not found,SARS-CoV,Unknown.,,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 24 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 24 from patent US 10131704,2022-03-01
3246,not found,SARS-CoV,Unknown.,,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 20 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 20 from patent US 10131704,2022-03-01
3247,not found,SARS-CoV,Unknown.,,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 16 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 16 from patent US 10131704,2022-03-01
3248,not found,SARS-CoV,Unknown.,,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 12 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 12 from patent US 10131704,2022-03-01
3249,not found,SARS-CoV,Unknown.,,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 8 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 8 from patent US 10131704,2022-03-01
3250,not found,SARS-CoV,Unknown.,,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 4 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",VL: Sequence 4 from patent US 10131704,2022-03-01
3251,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 96 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",VH: Sequence 96 from patent US 10822379,2022-03-01
3252,not found,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 8 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",VH: Sequence 8 from patent US 10822379,2022-03-01
3253,not found,SARS-CoV-2,Unknown.,,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 16 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",VL: Sequence 16 from patent US 10822379,2022-03-01
3254,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3255,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrhssgwdnwyfdlwgrgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3256,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3257,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3258,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3259,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvgplmvrgviipwgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3260,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgspsggwytldywgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3261,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3262,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpglvkpsetlsltctvsggsissyywswirqppgkglewigniyysgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycareqfsggdyegfdfwgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3263,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelgslrsedtavyycaragwsvsplkynwfdpwgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3264,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraaygpyygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3265,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlrgptgwtfdywgqgtlvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3266,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttegamvrrviygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3267,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3268,not found,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdawgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3269,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrssgyhdysyygmdvwgqgttvtvss,,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VH: anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
3270,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygngnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3271,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdssliarlfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3272,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslnvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3273,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3274,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvsiscsgstssigrntvswfqqlpgtapklliyrdnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycsawhdtlngvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3275,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsisnigsahvswyqqvpgtapklliydnserpsgiparfsafkygtsatlditglqtgdeadyycaswdislsagifgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-01
3276,not found,SARS-CoV-2,Homo sapiens (human),,envltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystllgtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3277,not found,SARS-CoV-2,Homo sapiens (human),,envltqspatlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3278,not found,SARS-CoV-2,Homo sapiens (human),,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpwtfgqgtkvei,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3279,not found,SARS-CoV-2,Homo sapiens (human),,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrwtfgqgtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3280,not found,SARS-CoV-2,Homo sapiens (human),,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnpitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3281,not found,SARS-CoV-2,Homo sapiens (human),,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspiftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3282,not found,SARS-CoV-2,Homo sapiens (human),,envltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwkitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3283,not found,SARS-CoV-2,Homo sapiens (human),,envltqspgtlslspgeratlscrarqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3284,not found,SARS-CoV-2,Homo sapiens (human),,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplltfgggtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3285,not found,SARS-CoV-2,Homo sapiens (human),,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.","VL: anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-01
3286,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3287,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3288,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3289,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3290,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3291,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3292,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3293,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3294,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VH: anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
3295,not found,SARS-CoV-2,Homo sapiens (human),,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3296,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3297,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
3298,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3299,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3300,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3301,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3302,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
3303,not found,SARS-CoV-2,Homo sapiens (human),,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.","VL: anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
3304,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtlvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3305,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3306,not found,SARS-CoV-2,Lama glama (llama),dvqlqesgggsveaggslrlscaasgvtldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtadyycaavpstyysgtyyynchpgamhywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3307,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftisrdnakntvylqmnslkpddtavyycaaalseggytidgsswcyhsvygmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3308,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscitnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycasfpstyysgsyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3309,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsggstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3310,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtlvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3311,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3312,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3313,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvacisssdgttyyadsvkgrftisrdnakntvylqmnslkpedtavyycatrpltyysgsyyttcsdygmdywgkgtlvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3314,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyytigwfrqapgkeregvscisssddstyyadsvkgrftisrdnakntvylqmnslkpedtavyycatapgtyykgsyypmchyygmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3315,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyysgtyyynchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3316,not found,SARS-CoV-2,Lama glama (llama),dvqlqesggdlvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyyngsyyytchpggmdywgkgtqvtvss,,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",2022-03-01
3317,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3318,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3319,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvaaisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsilygggmdvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3320,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyyctragwelrldafdiwgqgtmvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3321,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3322,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfyygmdvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3323,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3324,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3325,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisnyywswirqspgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsakhwlappgdyyyymdvwgkgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3326,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3327,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3328,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgwavagssdvwyyyygmdvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3329,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqllqsgaevkkpgasvkvsckasgysftsyymhwvrqapgqglewmgiinpsgggttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpgggsyqefdywgqgtlvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3330,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3331,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3332,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3333,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3334,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3335,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VH: immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3336,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3337,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlqvtfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3338,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3339,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrssyaswyqqkpgqapilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgilfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3340,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3341,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3342,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3343,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3344,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgqapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3345,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypcfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3346,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3347,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3348,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3349,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3350,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsalaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3351,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3352,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3353,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3354,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.","VL: immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3355,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3356,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiafagsvkgrftisrdnaknslylqmnslraedtalyycakdqgysygnyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3357,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvscmasgytftsyymhwvrqapgqglewmgiispsgggtsyaqkfqgrvtltrdtststvymelsslrsedtavyycarwydstgsidywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3358,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3359,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfatyalnwvrqapgqglewmgwvntntgsptyaqgftgrfvfsfdtsvstaylqirtlkaedtavyycavyyydsgspgwfdpwgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3360,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyamtwvrqapgkglewvsaissgsgstyyadsvkgrftisrdnskntvylqmnslraedtaiyycakankysssefdfwgqgtlvtiss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3361,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfigyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistvymelsrlrsddtavyycarempaamgyyyygmdvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3362,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtvsadksistaylqwsslkasdtamyycarvnyydssgypsfhfdywgqgtlvtvs,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3363,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3364,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscsasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrtgnyyygmdvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3365,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqgdcsttscaydywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3366,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgfaqnmvlltpywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3367,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymdlsslrsedtavyycatafsifgvvppdywgqgtlvtvs,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3368,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslrgedtavyycakdqayydiltgylnppknyyyygmdvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3369,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgsgsgsypnyyyyygmdvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3370,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarlhcggdcyldywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3371,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglegvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssgsyyyyyygmdvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3372,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnknyadsvkgrftisrdnskntldlqmnslraedtavyycardpfpgavagtgylqywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3373,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmsslraedtaiyycardrrrryctngvcyrpeeidywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3374,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfnyysmnwvrqapgkglewissistsssfvyyadsvkgrftisrdnaktslylqmnslraedtavyfcarggycsdgscyvqdrliyyysgldvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3375,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardpygyssiwdgqgghwgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3376,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtavyycargprysgtyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3377,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3378,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyfmhwvrqapgqglewmgwispdsgganyaqtfqgrvtmtrdtstttahmelsrlrsddtavyycargprysgthfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3379,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqnfqgrvtmtrdtsistgymelsrlrsddtamyycargprysgtyfdywgqgvlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3380,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3381,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvtcktsgyifsgyymhwvrqvpgqglewmgwispdsgatnyaqkfqgrvtmtrdtsittsyveltwlksddtavyycargprysgtyfdfwgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3382,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittgymelsglrsddtavyycargprysgtyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3383,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtamyycargprysgtyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3384,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispnsggtnyaqkfqgwvtmtrdtsvstaymelsrlrfddtavyycateswvygsgsyssgafdiwgqgtmvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3385,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3386,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsvfysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdlyfdywgqgtlvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3387,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3388,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3389,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqppsvsvapgktaritcggnnigsksvywyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpyvfgsgtkvtvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3390,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypiltfgggtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3391,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqeagkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3392,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqtassylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3393,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgaapklliyrndqrpsgvpdrfsgsksgtsvslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3394,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstfvfvfgtgtkvivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3395,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqepsltvspggtvtltcvsstgavtsgyypnwfqqkpgqapraliystskkhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggaqrwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3396,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3397,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3398,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssgtylvvfgggtklavl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3399,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3400,not found,SARS-CoV-2,Homo sapiens (human),,qavvtqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3401,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasstpgqrvtiscsgsssnigsnyvywyqqlpgtapklliytnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgrvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3402,not found,SARS-CoV-2,Homo sapiens (human),,syeltqspsvsvapgqtaritcggnnigsksvhwyqrkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdnnsdhlvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3403,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiannyvkwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnheeiwvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3404,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddtdrpsgiperfsgsssgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3405,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3406,not found,SARS-CoV-2,Homo sapiens (human),,qavltqppsvsgapgqrvtisctgsssnieagydvhwyqqlpgtapklliyvnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3407,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvfycmqgthwpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3408,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnfatgvpsrfsgtgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3409,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsgstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3410,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3411,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsltisctgtssdvggynyvswyqqhpdkapklmiydvnnrpsgvsnrfsgsksgstasltisglqaedeadyycssyagsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3412,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3413,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynhvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3414,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqpasvsgspgqsltisctgtssdiggfnyvswyqqhpgkapklmifdvskrpsgvpnrfsgsksgntasltisglqaedegdyycssytissaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3415,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqptsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytvsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3416,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssytssstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3417,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgspgqsvtisctgtssdvggydyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvpglqaedeadyyctsyagsnnfvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3418,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3419,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsetdftltisrlepeefavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3420,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3421,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3422,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3423,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3424,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3425,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqkfqervtitrdvststaymelsslrsedtavyycaaprcsggscydgfdiwgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3426,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkisckasgyifinyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtslstaylqissleaedtavyycakigsrnslgvwgqgtlvtvsa,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3427,not found,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3428,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggilgyadsvkgrftisrdnaknslylqmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3429,not found,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3430,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggildyadsvkgrftisrdnaknslylhmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3431,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssntryytdsvmgrftisrdnaknslflqmnslraedtavyycasskgfcsggscsdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3432,not found,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3433,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrytiiwvrqapgqglewmgriipildianyaqkfqgrvtitadkststaymelsslrsedtavyycareggldyfgsrnsgwtytwfdpwgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3434,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycatgarfgespfdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3435,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgrglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycatgarfgespfdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3436,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfrnyamtwvrqapgkglewvsgisdsgdrtynadsvkgrfsisrdnskntlhlqmnslraedtavyycalasgsyfgganywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3437,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtglyycakdinydsggyhknyfdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3438,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqgrvtitrdmstrtaymelsslrsedtamyycaapycsstrcydafdiwgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3439,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyffdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3440,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardfgdfffdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3441,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaatgftfrrygmhwvrqapgkglewvagilfdgsnkyyvdsvkgrftisrdssrntlylqlnslrredtavyycakggdyewelleswgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3442,not found,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcssticydgfdiwgqgtmvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3443,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgrnkyyvdsvkgrftisrdnskntlylqisslraedtavyycaraarrpvvtdtmayymdvwgkgttvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3444,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3445,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3446,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarattdcsstscwsldfwsgyytggrekifdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3447,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdapirtaymelsglgsddtavyycarasvatitdfdywgqgtlvavss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3448,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdasirtaymelsrlgsddtalyycarasvstitdfdywgqgtlvavss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3449,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksivylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3450,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3451,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3452,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3453,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3454,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrashsvdrsylawyqqkpglaprlliygassratgipdrfsgsgsgtdftltisrlepedfalyycqhfgtssvtfgrgtrleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3455,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3456,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtkvdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3457,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3458,not found,SARS-CoV-2,Homo sapiens (human),,diqmiqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtivdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3459,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfvvyychqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3460,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3461,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapnlliyaasslqsgvpprfsgsgsgtdftltisslqpedfatyycqqsystlysfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3462,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3463,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3464,not found,SARS-CoV-2,Homo sapiens (human),,qavvtqepsltvspggtvtltcgsstgpvtsdhypywfqqkpgqapttliydtnnkhswtparfsgsllggkaaltlsgaqpedeaeyycllsytgarvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3465,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdratitcrasqsissylnwyqekpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3466,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkvei,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3467,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllisgassraagipdrfsgsgsgtdftltinrlepedfavyycqqygssprtfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3468,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3469,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstvsasvgdrvtitcrasqsidnwlawyqekpgkapkvliykasslesgvpsrfsgrgsgteftltisslqpgdfatyycqhyhsfpltfgggtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3470,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3471,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscraslslssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptwtfgqgtkaeik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3472,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3473,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3474,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3475,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtsgdigsynlvswyqqypgkapkliiyeaskrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3476,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtsgdvgsynlvswyqqhpgkapklviyeatkrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3477,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3478,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3479,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3480,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppaltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3481,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3482,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3483,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3484,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3485,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3486,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3487,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3488,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3489,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3490,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstywmtwvrqapgkglewvanikqdgsekyyvdsvkyrftisrdnaknslylqmnslraedtavyycarvgssswyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3491,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3492,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3493,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydmnwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarggiyylvrgfiigyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3494,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3495,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3496,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3497,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdnigyadsvkgrftisrdiaknslylqmnslraedtalyycakgiyydifmplldwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3498,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3499,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaityyydssgywwddwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3500,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3501,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3502,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3503,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscatsgftfssfalhwvrqapgkglewvtvisddgnnkyyvdsvkgrftisrdnskntlflqmnslrvedtaiyycarasynsnwsigeyfrdwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3504,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtvisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksyngnyydafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3505,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigrvyiyssgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargaasfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3506,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgsyywswirqpagkglewigriytsgsttynpslksrvtisvntsknqfslnlssvtaadtavyycarvggispyyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3507,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwvnpnsghtgyaqkfqgrvtmtrntsvstaymelsslrsedtavfycargrvgyvgsgsrgyyyyydmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3508,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiylsgttnynpsltsrvtisvdksknqfslklnsvtaadtaiyycarptagaggafdiwgqgtvvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3509,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyviswvrqapgqglqwmggiipifgkpnyaqkfqgrvtitadeststaymelsslrsedtavyycargwfgellkgtywfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3510,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgssyyspslksrvtisadtsknqfslnlrsvtaadtavyycasgppymatfsyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3511,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3512,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdlvqpggslrltcaasgftfsshwmtwvrqapgkglewvanikedgrekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarvvvevatnkgihgvdyyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3513,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgynkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3514,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3515,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscadsaftfssfwmswvrqapgkglewvanikqdgsekfyldsvkgrftisrdnaknslylqmnslraedtavyycarlgrsswnfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3516,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylemnslraedtavyycarprggsyqtcfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3517,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtlisydggnkyyadsvkgrftisrdnskntlylqmnslraedaavyfcarghtgnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3518,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqleesgpglvkpsetlsltctvsggsisshywswirqppgkglewigyiqdsgstnynpslksrvtisvdtsknqfslrlssvttadtavyycvrgamawfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3519,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgfsfrnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3520,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigriftsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarggllwfggagnymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3521,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3522,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3523,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlylqmnslraedtavyycarprsgsyyayfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3524,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarelmsvgwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3525,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygmhwvrqapgqrlewmgwinvgngntkysqrfqgrvtitrdtsastaymelsslrsedtavyycamgpsafswldpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3526,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmtwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslslqmnslrvedtavyycvrlgvsswyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3527,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3528,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltcavsgasissgsyywswirqpagkglewigriytsgntnynpslksrvtisvdtsknqfslklssvtaadtavyycatgyigtyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3529,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiyhsgttnynpslrsrvtisvdksknqlslklnsvtaadtaiyycarptagaggafdtwgqgtmvtvsa,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3530,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3531,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3532,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3533,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfilsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3534,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnpkntlylqmnslraedtavyycardtatyvllwsgdfnldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3535,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrhamhwvrqapgkglewvavisydgsnkyyadsvkgrfaisrdnskntlylqmnslrpedtavyycardpsplvlitsidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3536,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsiywmswvrqapgkglqwvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlggsswhfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3537,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyyailwfrqapgkglewvaiisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycarpqsggyyapldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3538,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3539,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardvggysgydlgfdyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3540,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvelvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3541,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3542,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvnsgsyysyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3543,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgsalkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycargrsyglslgywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3544,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtsvstaylqisslkaedtavyycarglvgridpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3545,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3546,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtskkqfslklssvtaadtavyycageevrgvklyyyyamdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3547,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3548,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgttnyaqklqgrvtisadeststaymevsslrsedtavyycarvsgygdygaysdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3549,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3550,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslraedtavfycargdgdvynfllvrnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3551,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3552,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsfisgtgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqarvqdyiwgsyrsygmdvwglgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3553,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3554,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkgldwvavisydgsnryyaasvkgrftisrdnskntlylqmnslrtedtavyfcargdgyrsqfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3555,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngnsnygkkfqgrvtmtadtststaymelrslrsddtavyycardlpikvvvpaadynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3556,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3557,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3558,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3559,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaylqisslkaedtavyycararllgycsstscytigwgafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3560,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3561,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3562,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyfvdsvkgrftisrdnaknslylqmnslraedaavyycarlvttvttanglyyysyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3563,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3564,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfafsnyaihwvrqapgkglewvavisydgnnkdyadsvkgrftisrdnskntlylqmnslraedtavyycarvpvmvrgvyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3565,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdltivvipaapnfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3566,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgfifgdyamgwvrqapgkglewvgfirgkaydgtteyaasvkgrftisrddskyiahlqmnslktedtavyycirdydfwggyyyhplrafdiwgrgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3567,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavissdgsnkyyagsvkgrftisrdnskntlylqmnslraedtavyycakdmveplfshyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3568,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgtyywswirqpagkglewigrfytsgstnynpslksrvtisvdasknqfslklssvtaadtavyycararpdyyyyyamdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3569,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvqvsceasgytfttyymhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymdlsslrsedtavyycardrlgdgsylgggyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3570,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3571,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggavqpgrslrlscaasgftfstyamywvrqapgkglewvavisydgsnryyadsvkgrftisrdnskntlylqmnslrpedtavyycardrsgnyrdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3572,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsvyyigstyynpslksrvtmsvdtsknqfslklssvtaadtavyycarapfqlldkyyffyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3573,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3574,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydeinkyyadsvkgrftisrdnskttldlqmnslraedtavyycaragggsyrgpfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3575,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraddtavyycakgrgnyltffdswgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3576,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfyaihwvrqapgqglewaaaissdgtykyyadsvkgrftisrdnskntsylqmnslraedtavyycaralnkgfdpwgqgtlltvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3577,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvsp,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3578,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3579,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggrlvlpggslrlscaasgftfsvyemnwvrqapgkglewlsyigtsgspiyyadsvkgrftvsrdnaknslylqmnslrvedtalyycardrgwnygldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3580,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3581,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3582,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3583,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsgnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnspraedtavyycardpsayydiltgysgdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3584,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysagstyyadsvkgrfsisrdkskntlylqmnslraedtavyycakeggsgslryyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3585,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3586,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgpplvepkqtltltctfsgfslttsgeavgwirqppgkalewlaliywdddkhyspslrnrltitrdtsknqvvltltnvdpadtgtyycahravilnfdhwgqgflvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3587,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrvscaasgftfsshgmhwvrqapgkglewvsviwydgsnkyyadsvkgrftisrdnskntlslqmnslraedtavyycaresadissrldywgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3588,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsppasyynpstgyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3589,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftrhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycvreygsghplpiwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3590,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsdywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarltfggsgsyyfyyngmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3591,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyviswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardqgptyyygsgsphygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3592,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3593,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmsslraedtavyycakegewelrgnaldiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3594,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctvsgfslstsgvgvgcirqppgkalewlaliywdddkryspslksrltitrdtsknqvvltmtnmdpvdtgtyfcvhrhvsgafdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3595,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstygmhwvrqapgkglewvavisydgsnkynadsvkgrftisrdnskntlylqmnslrvedtavyycaiygyyyygldvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3596,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3597,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qgqlvqsggdvvqpgkslrlscaasgftftnyamhwvrqapgkglewvavisndgsnekyvdsvkgrfslsrdnskntvyldmhslrpedtaiyycardrsnlerlvmtfggiiagafdiwgqgarvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3598,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3599,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarglislfrgaifhyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3600,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgrikgktdggttdyaapvkgrftiskddskntlylqmsslntedtavywcttltyyydssaylndafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3601,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgkglewigtihysgisyynpslksrvtisvdtsnnkfslelssvtaadtavyfcarrtyydlwsaysstayycmdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3602,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisndgrnkyyadsvkgrltisrdnskntlylqmnslraedtavyycarpsnwyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3603,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycardggnayssgwyryyyhmdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3604,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfhnyaiswvrqapgqglewmggfipilgttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvegegvdsyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3605,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqiqqwgagvlkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslklssvtaadtavyycargppvttffvfsllfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3606,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgftfssygmhwvrqapgkglewvaviwydgnnkfyvdsvkgrftisrdnskntlymemnslraedtavyycarkgplwrfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3607,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapdkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwpnqafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3608,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3609,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckaseytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpgkaaafdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3610,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqgtyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3611,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavvsydgsnkyytdsvkgrftisrdnskntlflqmiglreedtavyycaqgrggyyspfddwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3612,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntngvavgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrgiltedafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3613,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgnkkycadsvkgrctisrdnskntlylqmnslraedtavyycaregpfgdreasgafdvwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3614,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisgdnskntlylqmnslrvddtavyycardpgsrysggwydyyyamdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3615,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssnywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardprvvvtarmynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3616,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwtwvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrwgdyfdssgaydswgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3617,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssylmhwvrqapgkglewvaviwangnryyadsvkgrftisrdiskntlylqmnslraedtamyycardycngvtcnsnywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3618,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttatvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3619,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsgsyygwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3620,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlacaasgftfssygmhwvrqapgkglewvavisydgnnkyyadslkgrftisrddskntlylqmnslraedtavyycakdrtavflffglgdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3621,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwfdgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycaregdfwsgyytgwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3622,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3623,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3624,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3625,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaradpyqllgqhyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3626,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtalyycarearyfdwifegsdyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3627,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3628,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklnsvtaadtavyycasrwgdyfdssgaydswgqgtlltvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3629,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvadisydgsekyyadsvkgrftiyrdnskntlylqmnslraedtavyycakdfggdntamveyffdfwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3630,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3631,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyfcakvgwelsidafdlwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3632,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviyydgsnkyyadsvkgrftisrdnskntlylqihslraedtavyycaregqmaattgidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3633,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3634,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evalvesggglvkpggslrlscaasgfifsnawmtwvrqapgkglewvgrikskseggtpeyaapvkgrfiisrddstnslhlqmnylriedtavyycttggyssyaasdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3635,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3636,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3637,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahnrfqycssttcytllpfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3638,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvrdlalfevviqqgvwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3639,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrrggigieygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3640,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfssywmhwvrqapgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylqmnslraedtavyycareveqlahmvdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3641,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycardlagvpaalgcwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3642,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3643,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfptywigwvrqmpgkglewmgiiypgdsdtrygpsfqgqvtisadksistaylqwsslkasdtamyycarrdtdfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3644,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evrllesggglvqpggslrlscaasgftfsdyamnwvrqapgkglewvsaisatggstfyadsvkgrfsisrdnsknslvlqmnslraedtavyycakpygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3645,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgqglewvagiwydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycagssgegglyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3646,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfdsygvhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlyvqmnslrtedtavyycardsggnygdsyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3647,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaflhigslkaedtavyycardqdsgyptyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3648,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamswvrqapgkglewvsgisisggstyyaasvkgrftisrdnskntlylqmnslraedtavyycakdsrsgiagvdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3649,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3650,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3651,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3652,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycargwyfdywgqgtlvtvsa,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3653,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggslssyywswirqppgkglewigyiydsggasrstnynpslksrvtisvdtsrnqlslklssvtaadtavyycardqrqfqllgrfgwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3654,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgssnynpslksrvtisvdtsknqfslklssvtaadtavyycargwgwgavagraeyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3655,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3656,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycareandsgsfyngpfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3657,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3658,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evrllesggglvqpggslrlscaasgftftsyamswvrqapgkglqwvstisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdpasgivgpthfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3659,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaavkkpgssvkvsckasggtfssyaiswvrqapgqglewmggivpifgtanyaqkfqgrvtitadestttaymelnslrsedtavyycaredyygsgslvdpyyyyrmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3660,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3661,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3662,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissgtyycgwirqppgkglewigstyyggstlynpslrgrvtisvdtsknqfslklssvtaadtavyycarrgnyydsknwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3663,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3664,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamnwvrqapgkglewvsaisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgsgivgatgfdfwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3665,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsygmswvrqapgkglewvsaisisggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakllgsgitldndafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3666,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyscaslwfgdlysfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3667,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3668,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifsgdeksystslksrltiskdtsksqvvltmtnmdpldtatyycarttwgtwiqawyfdiwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3669,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3670,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggpisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklnsvtaadtavyycarhdgsgemdtitwgpiyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3671,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfssyamhwvrqapgkglewvalisydgnnkyyadsakgrftisrdnskntlylqmnslrsedtavyycardlgrgldpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3672,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsirsssyywgwirqppgkglewiasiyysgstyynsslksrvtisvdtsknqfslkvnsmtaadtavyycailwrgsswadrhyyyysmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3673,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllqsggglvqpggslrlscaasgftfrnyamswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakneritmlvvvtlfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3674,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3675,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvhpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnrlraedtavyycaqmgplgstssaadywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3676,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsinsgnyywswirqpagkglewigrmftsgstnynpsltsrvtmsidtsknqfslnlnsvtaadtamyycarghvaawescyywgqgilvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3677,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3678,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3679,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3680,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3681,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3682,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3683,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3684,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3685,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3686,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3687,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedgetvyaqkfqgrvtmtedtssdtaymelsslrsedtavyycatsfpirgdpsyyyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3688,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsihwvrqapgkglewmggfdpedvetiyaqkfqgrvtmtedtstdtaymelssltsedravyycatqpaaiggtppyywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3689,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqnfqgrvtmtedtstdtaymelsslrsedtalyycaaapavmtagwfdpwgqgtlvsvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3690,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3691,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3692,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3693,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrlptpqllpsfenwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3694,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgseltkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintdtgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardpsycsstrcytvgwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3695,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntsgvgvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahrppsyhgwcyfdywgqgnlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3696,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavilydgsnryyadsvkgrftisrdnskntlylqmnslraedtavyycakqgglycsgtncwggyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3697,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvgiisydasdktyaesvkgrftisrdnskntlylqmnslraedtavyycakvsatyyyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3698,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywvgwvrqmpgkglewmgiiypgdsdtrdspsfqgqvtisadksistaylqwsslkasdtamyycarlgseskidyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3699,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglecvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpirdgvwglnendywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3700,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvymelsslrsedtamyycardvfwvpaassfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3701,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstkrvgvgwirqppgkalewlaliywdddqryspslksrltitkdtsknqvvltmtnmdpvdtatyycahsgppdlspvlsqgwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3702,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgitiyyadsvkgrftisrdnaknslylqmnslraedtavyyctgvvaapaeyfqhwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3703,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3704,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwlrqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvggyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3705,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevktpgasvkvsckasgytftsydinwvrqatgqgpewmgwmnpnsgntgyahkfqgrvtmtrntsistaymelsslrsedtavyycargpsiltgfynpldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3706,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3707,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftsydinwvrqatgqglewmgwmnpnsghtgyaqkfqgrvtmtrntsistaymelsslryedtavyycargygltyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3708,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3709,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfssyylhwvrqapgqglqwmgisnpsggsttyaqkfqgrvtmtgdtststvymelsslrsedtavyycargglvpaarnafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3710,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiqpgdsdtryspsfqgqvtmsadkststaylqwsslkasdtamyycardliiestiaarpgyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3711,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtagdtyypdsvkgrftisrenaknslflqmnslragdtavyycarvdfdiltgyysnwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3712,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvrlvqsgaevkkpgssvkvsckasggtfsdyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeftitaymelsslrsedtavyycarlsgsgwlgyamdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3713,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3714,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvalisydgrneyyadsvkgrftisrdnskntlylqmnslragdsavyycardlayhpyrdygdddyyyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3715,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3716,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyfadsvkgrftisrdnskntlylqmnslraedtavyycardqgtvvthfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3717,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhggstdynpslksrvtisvdksknqfslkltsvtaadtavyycarvdhvnvrdywgpgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3718,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavfycakdlppyasgwyeggfdywgrgtqvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3719,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3720,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3721,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3722,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpggslrlsceasgfifssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvndgrpnpleyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3723,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqsggslrlscaasgftfstygmhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntvylqmnslrtedtamyycakgdgsylmdyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3724,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargltgssaykdeiyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3725,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3726,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifwndensystslktrltiskdtsksqvvlnmtnmdpvdtatyycartewllsdnwfdswgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3727,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgilvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3728,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarggdsgydlgawyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3729,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3730,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3731,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfrsydmhwvrqvtgkglewvstigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvfetkvirggryyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3732,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapgqglewmgilnpgagstsyaqkfqgrvtmtsdtstntvymqlsslksedtavyycardqqivphadgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3733,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3734,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvssitsllgyyfdswgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3735,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3736,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsssdlhwvrqatgkglewvsaigtagdtyylgsvkgrftisrengknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3737,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3738,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyylhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtstsavymelrslrsedtavyycarendygdyveprdyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3739,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3740,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycardlgdgynlrvpayfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3741,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3742,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdlvkpgrslrlscsasgftfgdytmswfrqapgkglewvafirskayggtteyaasvigrftisrddsksiaylqmnslksedtavyycsrvrgsfygsvgknygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3743,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3744,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktaggtsssyaiswvrqapgqglewmgriipilgvaiyaqkfqgrvtitadkststaymelnslrsedtavyyctttqggdygdnlyyldywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3745,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3746,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgilvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3747,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3748,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqvvesggglvqpgrslrlscaasgftfedyamhwvrqapgkglewvsgvswnsgiigyadsvkgrftisrdnaknslylqmnslraedtalyycakldvggydfvsghyyafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3749,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3750,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3751,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmhwvrqvpgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylemnslraqdtavyycagspwlrgdidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3752,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvqsgaevkkpgasvklsckasgytftnyllhwvrqapgqglewmgnvnpsrgtatypqklddrvtmtsdksastiymelsglrsedtaiyycarersgtyffdywgqgtlltvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3753,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkrpgasmnisckasgynfnnnyiywvrqapgqglewmgvvnptgggtayaqgfqdrvtitsdtprntvylgvtglhsedtavyfcarggewrivpggrdyfdywgqgtlvtvsa,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3754,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3755,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3756,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3757,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3758,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3759,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3760,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissrsstikyadsvkgrftisrdnaknslylqmnslrdedtavyycarvdyygsgsvywyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3761,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3762,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyaesvkgrftisrdnskntlylqmnslraedtavyycardlhqdwvvvvaanvygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3763,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3764,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargtlipahrgafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3765,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrsltlscaasgftfddytmhwvrqapgkglewvsgidwnggtigyadsvkgrftisrdnaknslylqmnslraedtalyycakagyyayvwgsyrfeyfdnwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3766,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3767,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3768,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqvvesggglvqpgrslrlscvssgfifddyvmhwvrqrpgkglewvagitynggilgygdsvkgrfiiardnvrgflslqmgdlrtedtalyycardycssttcpaetyyymdvwgkgtavtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3769,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdliqpggslrlscaasgltvssnymswvrqapgkglewvsiiysggstyyadsvkgrfsisrdnsnntlylqmnslraedtavyfcarhipawgykwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3770,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarddnspqgsgwyfyyyyamdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3771,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqvvqsgpglvkpsetlsltctvsgdpvintnyywgwirqppgkglewigtlsysggthynpslssrvtiavdsskkrfsltlrsvtaadtaiyycarhpvdgynygysdlwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3772,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3773,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3774,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtdss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3775,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqagaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargaavpaagefdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3776,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftgyvvhwvrqapgqdlewmgwintgygntkysqkfqgrvtiswdtsattaymelsnlksedkavyycasmtrmseqtyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3777,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3778,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3779,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgryywswirqhpgkglewigfvyysgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaretysayemppyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3780,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgtlvtvst,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3781,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfssytiswvrqapgqglewmgriipilavanyaqkfqgrvtitadkststaymelsslrsedtavyycardhsgyydstslmspffdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3782,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlpltctvsggsissssyywgwirqppgkglqwigniyysgstyynsslksrvtisvdtsknqfslklssvtaadtavyycarqsrgysyawsfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3783,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3784,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmspnsgntgyaqkfqgrvtmtrdtsistaymelnslrsedtavyycarmrsgwpthgrpddhwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3785,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgeslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrfiisrhnskntlylqmnslraedtavyycardlnehgldvwgqgttvsvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3786,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsirsyfwnwvrqppgkglewigyiyysgstnykpsfksrvtisldtsknqislklssvtaadtavyycaratwlrdafgiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3787,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvaseftfssywmswfrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3788,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqvslklssvtaadtavyycarfrrsygsgsyynisfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3789,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3790,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarhqrycsssschvwdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3791,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscqasgytftsydinwvrqatgqglewmgwmksnsgntgyaqkfqgrvtmtrntsistaymeltslrsedtavyycarmrsgwpthgrpddlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3792,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3793,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycariqyqlngmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3794,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3795,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3796,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqllesggalvqpggslrlscaasgftfsccamgwvrqapgrglewvssihddgvgtfyavsvkgrfsisrdnskntvylqmnglraedtgvyycakwagpivmkyylqywgqgalvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3797,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsvstnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardyrdwiwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3798,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycasaklvatisyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3799,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgnagygqkfqgrvtmtrntsistaymelsslrsedtavyycarmrsgwpthgrpddywgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3800,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvgytisrqwlvgefdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3801,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartptlynwfhpwgqgtpvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3802,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3803,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3804,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3805,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3806,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3807,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnpnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrsgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3808,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3809,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3810,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3811,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftshtmnwvrqapgqglewmgwintntgnpmyaqgftgrfvfsldtsgstaylqisslkaedtavyycarwgpdygdyasndywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3812,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3813,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalissdggnkfyadsvkgrftisrdnskntlylqmnslraedtavyycardvpttvtaftvftywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3814,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycararggynwnfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3815,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3816,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdttynpsfqgqvtisadkslttaflhwsslkasdtaiyycarrfygpssfdywgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3817,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3818,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3819,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvscisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpvwvdgellsggipfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3820,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3821,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),nvqlvesggglvqpggslrlscaasgftfhhyamhwvrqapgkglewvsgisgssdyrayadslkgrftisrdyaknslwlqmnsltsedtafyycakgvdyggklayfdswgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3822,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlresgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavfycarmsrgynyaytfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3823,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3824,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3825,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3826,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiaytdsvkgrftisrdnaknslylqmnslraedtalyycakahstghqyyygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3827,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3828,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3829,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3830,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymevsslrsedtavyycarscgdcysadldfwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3831,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgfgynftnywigwvrqmpgkglewmgiiypgdsetrnspsfqgqvtisadksmstaylqwsslkasdtamyycarlgvskycsggrclsggsnwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3832,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdysmnwvrqapgkglewvssissggsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarggsilwwlidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3833,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3834,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarllwlrghfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3835,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evhlvgsgggliqpggslrlscaasgftvssnfmswvrqapgkglewvsiihnggdsyytdsvkgrftisrdnskntlylqmnnlraedtavyycassswlrgafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3836,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmclswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtgtyycartmatinafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3837,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewighiyytgssyynpslksrvtisldtsknqfslklnsvtaadtavyycarlrwlrggidfwgqgtlvivss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3838,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3839,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiistsggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3840,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3841,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftlddyglswvrhapgkglewvsginwnggrtayadsvkgrftisrdnaknslylqmnslraedtalyhcarargpseqyydlltgyydafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3842,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslttsgmcvswirqppgkalewlaridwdddkyystslqtrltiskdtsknqvvltmtnmdpvdtatyycaretpvtaidywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3843,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrtedtalyycamgpfgellpyyfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3844,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3845,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3846,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsrtcavygasfsnyywswirqppgkglewigeinhsentnynpslksrvtisvdtsknqfslrlssvtaadtavyycarlrysssgghifdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3847,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiisssggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3848,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltmtnmdpvdtgtyycarhqivvlfdmwgqgtrvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3849,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3850,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3851,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3852,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3853,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaggytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrtgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3854,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3855,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvgsnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqlnslraedtavyycarevvgyfdcwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3856,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3857,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfvtsgihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggpnkevlyfgelldygmdvwgqgttvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3858,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissagyywswirqhpgkglewigyiyysgrtyynpslksrvtmsvdtsknqfslrlrsvtaadtavyycarvvptrgpvawfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3859,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3860,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3861,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglecvsviyaggntyyadsvkgrftisrdnskntlylqmnslraedtavyycargdggyyspfdywgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3862,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3863,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtsssytvgwvrqapgqglewmgriipilgiaysaqkfqgrltitadkststsymelsslrsedtavyycargvvaatpgwfdpwgqgtlvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3864,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwiavgsgntnyaqkfqervsitrdmststaymelsslrsedtavyycaapycsrtschdafdiwgqgtkvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3865,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3866,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssrsyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhtvdcggdcfpndafdiwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3867,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VH: anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
3868,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3869,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3870,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3871,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3872,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3873,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3874,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3875,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3876,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3877,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvvviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3878,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3879,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3880,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3881,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3882,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3883,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3884,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprllifgassratgipdrfsgsgsgtdftltisrlepedfavyychqygtspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3885,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3886,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3887,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3888,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3889,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3890,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsllytsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3891,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscragqtvsssylawyqhkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3892,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsdgytyldwylqkpgqspqlliylgskrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3893,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapkllmyaastlqsgvpsrfsgsgsgteftltintlqpedfatyycqqlnsypitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3894,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkprqapvliisgnnnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3895,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrffgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3896,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpgfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3897,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswfqhhpdkaprlmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpfvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3898,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3899,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvvviygknnrpsgipdrfsgsssgnkasltitgaqagdeadyycnsrdnsgnlnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3900,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigtkgvhwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3901,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3902,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkfvcwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsstgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3903,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3904,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,itcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfggsasgtdftltisslqpedfatyycqqsystftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3905,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagynvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsfdsslsgsdvfgtgtkvsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3906,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3907,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystppytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3908,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3909,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3910,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedvatyycqqynshpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3911,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigarydvhwyqqlpgtapkllmygnnnrpsgvpdrfsgsksgtsvslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3912,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwsvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3913,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgssrgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3914,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3915,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3916,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3917,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3918,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3919,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3920,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqyygsspfgfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3921,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtsgdvgaynyvswyqqhpvkapklmiydvskrpsgvsnrfsgsksgntasltisglqtedeadyycssytssstlwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3922,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalprqytywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadtigtywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3923,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkysswyqqkpgqspvlviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawssstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3924,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3925,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3926,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyanwyqqkpgqapvvvifgknnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdssgyiwgwmfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3927,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvkvvyhdgdrpsgiperfsgsnsgntatltinrveagdeadyscqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3928,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3929,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3930,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllqftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3931,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnslswyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlllftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3932,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3933,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3934,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3935,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvsrflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3936,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3937,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvgnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3938,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3939,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqsphlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3940,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3941,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3942,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvqik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3943,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3944,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3945,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3946,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasldiskylnwyqhkpgkapnlliydafnlergvpsrfsgsgsgtdftftisslqpediatyycqqydnlppgvsttfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3947,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3948,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3949,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsyasslsahvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3950,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3951,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvvgynyvswyqqhpgkapklmiydvrnrpsgvsnrfsgsksgntasltisglqaedeadyfcisytssrtlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3952,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgntasltisglqaedeadyycssytssstpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3953,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvtkrpsgvperfsgsksgntasltisglqaedeadysccsyagsytyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3954,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaisglqaedeadyscqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3955,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsystwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3956,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkrgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3957,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3958,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnenylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyssytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3959,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgvtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3960,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3961,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3962,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3963,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3964,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsfdigrggwifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3965,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvsageratlscrasqsissnlawyhqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3966,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqpssvsvspgqtaritcsgdalpkryaywyrqksgqapvlvihedskrpsgiperfsgstsgtmatltitgaqledeadyycfsmdssgdlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3967,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3968,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3969,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3970,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqysiyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3971,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvvtqppsasgtpgqrvtiscsgsssnigynivnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslsisglqsedeadyycaawddslngyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3972,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3973,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,fyeltqppsvsvspgqtagitcsgdklghkyaywyqqkpgqspilliyqddkrpsgiperfsgsnsgtiatltisgtqpvdeadyycqawdndagvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3974,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalptkyaywyqqksgqapvlviyddskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3975,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatfycqqsystpmhtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3976,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsadalskqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssshwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3977,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrssgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3978,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmaqtplslpvtpgepasiscrssqslldsddgntyfdwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkinrveaedvgvyycmqriefpwtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3979,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3980,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsadalpkhyaywyqqrpgqapvlviykdierpsgiperfsgsssgttvtltitgaqaedeadyycqsvdgsgssvvfgggtklavl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3981,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgetyvswyqqkpgqspvlviyedskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstggvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3982,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyfwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3983,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvassylawyqqkpgqaprlliygasgratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3984,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspgtlsvspgeratlscrasqslsshlawyqqkpgqaprlliygvstratgiparfsgsgsgteftlaisslqsedsavyycqqyhvwppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3985,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3986,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggytyvswyqqhpgkapklmiydvnkrpsgvpdrfsgsksgitasltisglqaedeadyyccsyagrytwvfgggttltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3987,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvisedskrpsgiperfsgsssgtvatltisgaqvedeadyycystdssgnhrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3988,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3989,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyasssivvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3990,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratviparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3991,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsadalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdssgsyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3992,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyssnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3993,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqipgtapkllfygnnnrpsgvpdrfsdsksgtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3994,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvihqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3995,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3996,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrvqaedvgvyycmqalqtpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3997,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyahwyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyyccstdssgnqrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3998,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspgtlsvspgeratlscrasqtlssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyhcqqynnwplafgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
3999,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgygtdftltisslqpedfatyycqqsyntprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4000,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkytywyqqksgqapvvviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgkgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4001,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4002,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspgtlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4003,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqrgvpsrfsgsgsgtdftltisslqpedfatyycqqanslpltfgggtkvevk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4004,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dfvmtqspgslavslgeratincrssqsvldnssnknhlawhqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysshwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4005,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4006,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspdfqsvtpkekvtitcrasqnigsslhwyqqkpdqspkviikyasqsfsgvpsrfsgsgsgtdftltinsleaedaatyychqssslpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4007,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvvvvyddsdrpsglperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4008,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgnrvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4009,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4010,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4011,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinhylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftitslqpedvatyycqqsdnlpmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4012,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4013,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssslrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4014,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4015,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqgnsfpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4016,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysptfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4017,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4018,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylgwyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4019,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvsprqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdtsgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4020,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4021,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqlitifcngsisdvggwnyvswyqqhpdkapkmmiydvrhrpsgvssrfsgsksgntasltisglqaedegdyycssftsrgalvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4022,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4023,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4024,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvrdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4025,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4026,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sneltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqstassgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4027,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4028,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaykrdtgiparfsgsgsgtdftltisslepedfavyycqqrsnwpliftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4029,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvvtqspsasaslgasvkltctldsghrsyaiawhqqrpekgprflmrittdgrhtkgdgipdrfsgsgsgteryltisslqsedeadyycqtwgtfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4030,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqppsasaslgasvtltctlssgysnykvdwfqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4031,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynfvswhqqhpgkapknmiydvskrpsgvsnrfsgsksgntasltisglhtedeadyycssytststpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4032,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqttritcsgdalpkqygywyqqkagqapilviykdserpsgiperfsgsssgttvtltisgvqaedeahyycqsgdssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4033,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalskqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdrsgtyfnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4034,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4035,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgrtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgskfgntatliisrveagdeadyscqvwdsgsdhvvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4036,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4037,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4038,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4039,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4040,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4041,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwgfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4042,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4043,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystrtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4044,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4045,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qlvltqspsasaslgasvkltctlssghttyaiawhqqqpekgprylmklnsdgshtrgdgipdrfsgsssgaeryltisslqsedeadyycqswdtgigvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4046,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4047,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkprkapklliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4048,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4049,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatvsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsasgsgteftltisslqsedfavyycqqynnwppmytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4050,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4051,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlvmckdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4052,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4053,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtftcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgigsgtdftltisslqpedvatyycqkynsapwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4054,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4055,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqypgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyaggntfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4056,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4057,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyyvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsstlnvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4058,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqspsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4059,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgstsnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgpsaslaisglqsvdeadyycaawddslngwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4060,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyiswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4061,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4062,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdkmgdkyacwyqqkpgqspvvviyednkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsslvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4063,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nivmtqsplslpvtpgepasiscrssqsllnsngltyldwylqkpgqspqlliyfvsnrasgvsdrfsgsgsgadftltisrveaedvgvyycmqalqtpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4064,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtlarfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4065,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4066,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4067,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4068,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4069,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4070,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4071,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4072,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4073,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4074,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgitnylawfqqkpgkapksliyavsslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4075,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsghvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4076,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggyhyvswyqhhpgkapkliiydvikrpsgvsnrfsgsksgntasltisglqaedeayyycssytssttwvfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4077,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4078,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4079,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4080,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvseaprqrvtiscsggssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaswddsligpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4081,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvvvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4082,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4083,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylhwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyhnlppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4084,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllftfgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4085,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrpsqsittylnwyqqkpgkaprlliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4086,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qpvltqsssasaslgssvkltctlssghssyiiawhqqqpgkaprylmklegsgsynkgsgvpdrfsgsssgadcyltisnlqsedeadyycetwdsntrvfaggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4087,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsylgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4088,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviyrdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadstgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4089,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpfyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4090,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4091,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4092,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsiisylnwyhqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4093,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4094,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssyyhpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4095,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasigdrvtitcrasqnirsylnwyqhkpgkapklliyaastlqsgvpsrfsgsesgtdftltisslqpedfatyycqqsssspitfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4096,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4097,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdafpkqygywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsrgavfgsgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4098,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dfqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnllifaasslhsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyssewtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4099,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyyctsytssstlnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4100,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4101,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcfgdalpkqyaywyqqkpgqgpvlviykdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4102,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4103,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslstsvgdrvtitcrasqsirsylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4104,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssipyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4105,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qtvvtqepsltvspggtvtltcasstgavtsgyfpnwfqqkpgqapralifstnnrhswtparfsgsllgdkaaltlsgvqpedeaeyycllyyggpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4106,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4107,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4108,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4109,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyhqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4110,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqyddwppevtfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4111,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgsrfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4112,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4113,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdawpnqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyfcqssdssgvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4114,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkagkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4115,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsvsiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltvsslqpedfatyycqqsysmppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4116,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4117,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4118,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4119,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprtwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4120,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4121,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4122,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4123,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslksgvpsrfggsgsgtdftltisslqpedfatyycqqsyemppwtfgqgtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4124,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4125,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssaayvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4126,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4127,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpnqyaywyhqkpgqapvvviykdserpsgipqrfsgsssgttvtltisgvqaedeadyycqsadssgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4128,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4129,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4130,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4131,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syvltqppsvsvapgktasitcegnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4132,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4133,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctrssgsiassyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4134,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4135,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvssrdsgvpdrfsgsgsgtaftlkisrveaedvgvyycmqgthwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4136,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4137,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4138,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglmtedeadyycqsydgsnhavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4139,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqsvtiscsgsssnignnkvnwyqqlpgtapkvliynsnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslhsyvfgtetkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4140,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,dmevtqfpsslsasigdrvtitcratqsistylnwyqqkpgkapnlliysashlqrgvparfsgsgsgteftltittlqpedvgtyychqsygvpitfgggtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4141,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4142,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4143,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycatwddslngpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4144,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4145,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4146,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4147,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagiwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4148,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4149,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrryyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnprwfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4150,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltva,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4151,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssflawyqqkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspqfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4152,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklllyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4153,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqekpgqaprllmysassratgipdrfsgsgsatdftltinrlepedfavyycqqyveppftfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4154,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsrynigsnyvywyqqlpgtaprlliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsglifgggtkltvq,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4155,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syelaqppsvsvapgetatifcratyigrknvqwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgdtatltisrieagdeaayycqvwdgindrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4156,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapelliydasnletgvpsrfsgsgsgtdfiftisslqpediatyychqydylpytfgqgtkldik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4157,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnerpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsayvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4158,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlalsvgeratlscvasqrvssdyiawyqkkpglaprllvyhgsawatgssarfsgsgsgtaftltisslepedfavyycqqygnspftfgpgtkvefk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4159,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4160,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4161,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4162,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4163,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4164,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4165,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4166,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyarsstrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4167,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgitasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4168,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgntnrpsgvpdrfsgsksgtstslaitglqaedeadyycqsydsslngdvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4169,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgshgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgstsgntasltisglqaedeadyyccsyagivlfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4170,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4171,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapkllifgnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4172,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgqgtrleir,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4173,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgnsgsiasnyvqwyqqrpgsapttviyedsqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsfdsgnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4174,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedennyycavwddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4175,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyvgsstyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4176,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4177,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4178,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapklliydnnqrtsgvpdrlsgsksgtsaslaisglqsedeanyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4179,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4180,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4181,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4182,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyychqsyftpqtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4183,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qslltqppsvsgapgqrvtlscagatsnigagsdvhwyqqlpgtapklliyyntnrpsgvpdrfsgsksatsaslvitglqtedeadyycqsydislggwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4184,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyhnlprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4185,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvseaprqrvtiscsgsssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4186,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtfscsgsnsnigsytvnwyqqlpgtapklliydnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4187,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdvgtynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4188,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsnslnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4189,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4190,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4191,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4192,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfalyycqqynnwwrtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4193,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4194,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4195,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4196,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaisglqseaeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4197,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4198,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,syeltqpssvsvspgqtaritcsgdvlaknyarwfqqkpgqapvlviykdserpsgipkrfsgsssgttvtltisgaqvedeadyycysaadnnrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4199,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4200,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4201,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4202,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4203,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvtitcqgdslrshyaswykvkpgqapllviygrnnrpsgipdrfsgsrsgntasltitgaqvddeadyycssgdsstdhhvvfaggtklavv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4204,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4205,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4206,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssniesnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4207,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4208,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqsplslpvtpgepasiscrssqsllhslgynslswylqkpgqsphlliylgsnrasgvpdrfsgsgsatdftlkisrleaedvgvyycmqalqtpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4209,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklkiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4210,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4211,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4212,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4213,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaafnlqsgvpsrfsgsgsgtdftltisslqsedfatyycqqsyntpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4214,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,etvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4215,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4216,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4217,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsissflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4218,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4219,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstsrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4220,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4221,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4222,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4223,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasagdrvtitcrasqsiryylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsfstprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4224,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,nlmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsnnqvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4225,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdfiftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4226,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4227,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4228,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscgasqsisssylawyqqkpgqaprlliygassraagipdrfsgsgsgtdftltisrlepedfavyfcqqyggsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4229,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4230,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4231,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4232,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4233,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqksgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqydnlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4234,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4235,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtgsdvggsnyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlfgggtklsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4236,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfetfgpgtkvaik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4237,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4238,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4239,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4240,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeasyyclawddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4241,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4242,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypgytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4243,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4244,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqtplslsvtpgqpasfsckssqsllhsdgktylywylqkpgqspqlliyavsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4245,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltistlqpedfatyycqqsystllytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4246,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4247,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4248,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaastmqsgvpsrfrgsgsgtdftltisslqledfatyycqqsystpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4249,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4250,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivmtqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgggsgteftltisslqsedfavyycqqynnfltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4251,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,evvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyhcqhfgsssqwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4252,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4253,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapllviygknnrpsgipdrfsgsssgntpsltitgaqaedeadyycnfrdssghhpvfgegtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4254,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.","VL: anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4255,not found,SARS-CoV-2,Homo sapiens (human),evqlvesraemkkpgeslkisckgsgytftnhwiawvrqmpgkglewmgiiypgdsdtryspsfegqvtisadksistaylqwsslkasdtamyycarrgytygadfygldvwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4256,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakmgpdpahdygrkndafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4257,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgfiftnywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarerylttdgwfdpwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4258,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakaepevggydyymdvwgkgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4259,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesraevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgitnyaqkfqgrvtitadkststaymelsslrsedtavyycardapdyydssgptyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4260,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycataysvdtamvrgvgywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4261,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsvkstagydfwsgdpfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4262,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakeiavagcfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4263,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardweeqwlvafdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4264,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargpaatyyyymdvwgkgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4265,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdsaknslylqmnslraedtalyycakvatyyydrsgyyyggaldywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4266,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctasggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpsglyqllnwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4267,not found,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgasvkisckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargdgdyydssgyyrptlynwldpwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4268,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnsltaedtavyycaregsrqwlviyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4269,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqpgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngdtnyaqklqgrvtmttdtststaymelrslksddtavyycarfdygypysswsvlsidywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4270,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsgasitsggyywtwirqhpgkglewigyiyysgssfynpslmsrvsisvdtskkqfslklrsvtaadtavyycakegsgggsqnwfdlwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4271,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscsasgftfsnynmdwvrqapgkglewvssisssssyiyladsvkgrftisrdnaknslylqmnslraedtavyycarvqkdivvvpvaladyyyygmdvwgqgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4272,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgssnynpslksrvtisvdksknqfslklnsvtaadtavyycagrycsggrcgwfdpwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4273,not found,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4274,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlpltctvsggsissssyywgwirqppgkglewigsvfysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycarqvrqwleddafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4275,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkgldwmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatspavmsvgwvdpwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4276,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgifypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhnpdyydssgpldywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4277,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnsknmvylqmnslraddtavyycardgsnescsggfcsdswgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4278,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4279,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsgysftshwiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarlkvitifgvvrddygmdvwgqgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4280,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgratittdeststaymelsslgsedtavyycarthsydnsgqyfdywgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4281,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgvevkkpgasvkvsckafgytftgqdmhwvrqapgqglewmgwinpssagtnyaqkfqgrvtmtrdtsistaymelsrlrsddtsvyycrkmltifgkvnqtmlliswgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4282,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargvedpvvpaaipwcwfdpwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4283,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaslpvvpaaigplpafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4284,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmdslraedtamyycakdkappcssgwyyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4285,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarvvgsswypvdafdiwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4286,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrgdsygyyycmdvwgkgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4287,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqtpgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptiaaaatnwfdpggqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4288,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarpnpaggydssgwvdafdiwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4289,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprycsstscyagvyfdywgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4290,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycarwkyndrfdywgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4291,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslipssvtaadtavyycarggelphynwfdpwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4292,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaspllltppdyyyymdvwgkgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4293,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasvvggriaaagclgywgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4294,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtittdeststaymelsslrsedtavyycarvysydssgyyleywgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4295,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyginwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycasfgddsgdegvrwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4296,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycassdssgfvgsrgfdywgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4297,not found,SARS-CoV-2,Homo sapiens (human),qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4298,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycarvryydssgyyedywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4299,not found,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldtmggmdvwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4300,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfgsysmswvrqapgkglewvssisrsssyiynadsvrgrltisrdnaknslylqmnslrvedtavyycardqplpdiltgyytgpldywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4301,not found,SARS-CoV-2,Homo sapiens (human),vqtggilgaevkkpgpsvkvscqagrapsssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprgcsstscygsyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4302,not found,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslklscaasgftfssyamswvrqapgkglewvsaisgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycakglrgqqlvipteyfqhwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4303,not found,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsnyywtwirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslwlssvtaadtavyycargrnyvlqfsewphprahfdnwgqgtlvtiss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4304,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarviggnyfgafdiwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4305,not found,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycareaygmdvwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4306,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlpltctvsggsissfywswirqppgkglewigyihnngntnynpslksrvtmsidtsknqfslklssvtaadaavyycarggwsldswgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4307,not found,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmrpsiaarpgyqyymdvwgkgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4308,not found,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4309,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycareansdfwsgylgyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4310,not found,SARS-CoV-2,Homo sapiens (human),vqlqqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrstsrwgyyymdvwgkgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4311,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglqwvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarggdrypvgyfdlwgrgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4312,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtpvyycarhnraeewepgfdiwgqgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4313,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissggyywswirqlpgkglewigyiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycarqqldyydssgcfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4314,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlnydfwsgyysyalyymdvwgkgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4315,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgyrfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwssltasdtaiyycaryyydsrgytsidfwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4316,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppddssgwtmgyfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4317,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngytnsaqklqgrvtmttdtststaymelrslrsddtavyycardlvdtamvqtlddygmdvwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4318,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdntkntlylqmnslraedtavyycardseyydiltgylapthyyyyymdvwgkgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4319,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrddaknslflqmnslraedtavyycagdqnlycsgdscyyhyygmdvwgqgtvvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4320,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwksdyydssgyypaafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4321,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4322,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgttnyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycareavaarpgnfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4323,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4324,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycarprggnylagfdpwgqgtrvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4325,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnlyywiwirqppgkglewigyvyytgstnynpslksrvtmsvdtsksqfslkmsavtaadtavyycarrgevngyrgafdiwgqgarvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4326,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnrlraedtavyycaretptstyssgwynyyyymdvwgkgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4327,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgtevkkpgasvkvsckasgytfpgyyihwvrqapgqglewmgwinpnsgvaksaqkfqgrvtmtrdssistvyldvtsddtavyycardlvwatvsgtmdvwgqgttvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4328,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafgywgqrtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4329,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvtstymtwvrrapgkglewvsiiynddttyyadsvkdrvtvsrddskntlylqmnslraedtaiyycarggyyydpsgyysrsfsfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4330,not found,SARS-CoV-2,Homo sapiens (human),qlqlvesgpglvkpsetlsltctvsggsissyfwswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhsqgwlqqavafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4331,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaredyydssgsfdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4332,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlssyaitwvrqapgqglewvggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgysndywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4333,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsggglvqpgrslrlscaasgftfgeyamhwvrqapgkglewvsgiswnsgsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdmgeavagthygmdvwgqgtmvtass,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4334,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsrvrgvsnwfdpwgqgtpitiss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4335,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaripgydssgyyrgdywgqgtlvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4336,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgqyydfwsgylgartnphyyyymdvwgkgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4337,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyamhwvrqapgkglewvavisydgsnqyyadsvrgrftisrgnskntlylqmnslrpedtavyycararggsyndafdiwgqgtmvtvss,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4338,not found,SARS-CoV-2,Homo sapiens (human),hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgtrghrlf,,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VH: anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",2022-03-01
4339,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4340,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4341,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4342,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4343,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4344,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngphwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4345,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4346,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4347,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4348,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4349,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgthftltisslqaedvavyycqqyystppltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4350,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllsltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4351,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4352,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttfiytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4353,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4354,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvtsnlawyqqkrgqaprlliydasnratgiparfsgsgsgtdftltisglepedfavyycqqrsnwptfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4355,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqpedfavyycqqcynwppwtfgqgtrvefk,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4356,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyeaskrpsgisnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkptvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4357,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4358,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4359,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliydnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4360,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4361,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqppsvsvapgqtaritcggdnigskdvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsstdhvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4362,not found,SARS-CoV-2,Homo sapiens (human),,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlglyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4363,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydsskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4364,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4365,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtplslsvtpgqpasiscksgqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpptfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4366,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4367,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4368,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywplitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4369,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4370,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4371,not found,SARS-CoV-2,Homo sapiens (human),,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgdtasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4372,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4373,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4374,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4375,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysrtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4376,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspsslsvsvgnivtitcrasqgirndlggisrnqgkplsaiygasslqsgvpsrfrgrgwgteftlpisslqledfaiyyciqhnsylwtfgqgpkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4377,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtclclqgkshplcrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspntfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4378,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4379,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4380,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypplfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4381,not found,SARS-CoV-2,Homo sapiens (human),,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4382,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppmytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4383,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4384,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4385,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4386,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4387,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqsvlfstnsknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4388,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfalyycqqydnwplftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4389,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgswsgtdftltisrlepedfavyycqqygsspgtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4390,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlplspgeratlscrasqsvtnnylawyqqkpgqaprllihatstratgipdrfsgsgsgtdftltisrlepedfavyycqqyggplpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4391,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4392,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4393,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpqvtfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4394,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklllyaasdlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4395,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4396,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspgtlslspgeratlscrasqnvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4397,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlhsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4398,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysitfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4399,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsaapgqkvtiscsgsssnignnfvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4400,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtysvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4401,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvtyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4402,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlsyrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppgtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4403,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4404,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4405,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4406,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4407,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4408,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllidgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4409,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4410,not found,SARS-CoV-2,Homo sapiens (human),,airmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4411,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsasgspgqsvtisctgtssdigtynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaddegdyycssyvgnnnwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4412,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4413,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqpasvsgspgqsitisctgsssdiapytfvswyqqhsgtapkliiydvrnrpsgisdrfsgsrsgntaslsisglqaedeadyycsaytttstswvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4414,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvrdrvtitcrasqsitsslnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4415,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4416,not found,SARS-CoV-2,Homo sapiens (human),,diqltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4417,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqppsvsvspgqtasipcsgdklgdiyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsttakvfgggtkltvp,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4418,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccscagsstyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4419,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlpiydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4420,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappafgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4421,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqpasvsgspgqsitisctgassdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpvvfgggteltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4422,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspppftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.","VL: anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-01
4423,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
4424,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregycsggscysgyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-01
4425,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4426,not found,SARS-CoV-2,Homo sapiens (human),,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.","VL: anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
4427,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardimfgddwlqkqpdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4428,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytinwvrqapgqglewmgriipilgiadyaqkfqgrvtitadkststaymelsslrsedtavyycardlvedtamvtgaaagtwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4429,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisaysgntnyaqklqgrvtmttdtststaymevrslrsddtavyycarvglwwlghpdvfdiwgqgtmvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4430,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsikyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4431,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvtveaifgvvilplknwfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4432,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardltstssspysyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4433,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvtvvhfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4434,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqkvqgrvtmttdtststaymelrslrsddtavyycardrgyaatfgvfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4435,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartkggsyfapfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4436,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssygiswvrqdpgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvglwwlghpdafdiwgqgtmvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4437,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrsmrlscaasgfnlssyamhwvrqasgkglewvslisydgsikyyadsvkgrftvsgdnskntlflqmsslraddsalyycvrggvsgpnafdiwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4438,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqtahysssfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4439,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycararvaydyiwgsyrykafdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4440,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelnrlrsddtavyfcardltttagtdyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4441,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4442,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsyggsyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4443,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardsvagiyyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4444,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsdvtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareardyygsgsldywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4445,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4446,not found,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4447,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggsyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4448,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardeayydiltgyinapknyyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4449,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardhhydfwsgyssyyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4450,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4451,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycarvwgycsggscyvdafdiwgqgtmvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4452,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardresydiltgysmegcfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4453,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrvydyiwgsyryldywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4454,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareyyydssvypyyyyamdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4455,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycattspivgaitwfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4456,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvdygsgsygwgwfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4457,not found,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarqssfyssgwysygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4458,not found,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardfnsyqllwyyyygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4459,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4460,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsvkyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4461,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarettghfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4462,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcnvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4463,not found,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycathivvvtatpnwyfdlwgrgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4464,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarlvptwasyydfwsgypggygmdvwgqgttvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4465,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4466,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgppycsstscehwfdpwgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4467,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvtckasgytftsyylhwvrqapgqglewmgiinpsggttsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragrrysssddgafdiwgqgtmvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4468,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4469,not found,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4470,not found,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvrgsyylfdywgqgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4471,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VH: anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",2022-03-01
4472,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4473,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4474,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4475,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitaftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4476,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4477,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4478,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4479,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4480,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprfgpgtkvdikr,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4481,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4482,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4483,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4484,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4485,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppkytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4486,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrgtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4487,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4488,not found,SARS-CoV-2,Homo sapiens (human),,dvvmtqsplslpvtlgqpatiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4489,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppiftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4490,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagspwtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4491,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4492,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4493,not found,SARS-CoV-2,Homo sapiens (human),,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsssytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4494,not found,SARS-CoV-2,Homo sapiens (human),,divmtqspdslavslgeratinckssqnvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyitpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4495,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4496,not found,SARS-CoV-2,Homo sapiens (human),,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4497,not found,SARS-CoV-2,Homo sapiens (human),,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppsltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-01
4498,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4499,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssltlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4500,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4501,not found,SARS-CoV-2,Homo sapiens (human),,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4502,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtymifgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4503,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4504,not found,SARS-CoV-2,Homo sapiens (human),,syeltqphsvsvataqmaritcggnnigskavhwyqqkpgqdpvlviysdsnrpsgiperfsgsnpgntatltisrieagdeadyycqvwdsssdhvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4505,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4506,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4507,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4508,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4509,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4510,not found,SARS-CoV-2,Homo sapiens (human),,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4511,not found,SARS-CoV-2,Homo sapiens (human),,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklnsdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgirvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4512,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4513,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4514,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4515,not found,SARS-CoV-2,Homo sapiens (human),,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4516,not found,SARS-CoV-2,Homo sapiens (human),,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.","VL: anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-01
4517,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qqlkesggrlvtpgtpltltctasgfslssyyvswvrqapgkglewigiipgtgptycaswakgrftisktsttvdlkitspttedtatyfcarvyagfstwlyfdlwgpgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4518,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssyamswvrqapgkglewigiisksgstyyaswakgrftisktsttvdlkitspttedtatyfcarddilytsssgyyygmdlwgpgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4519,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssydmiwvrqapgeglewigiidtaggayyaswakgrftisrtsttvdlkitspttedtatyfcarafygsgwgftrldlwgqgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4520,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),eqlkesggrlvtpgtpltltctvsgfdlsscsmgwvrqapgkgleyigiisssgstyyaswpkgrftisktsttvdlkitspttedtatyfcargfwyfnlwgqgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4521,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctasgfslssyymswvrqapgkglewigiiyassstnyaswatgrftisktsttvdlkitspttedtatyfcarvyssgwgdafdlwgpgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4522,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssywmswvrqapgkglewigiiftggstyyaswakgrftisktsttvdlkitspttedtatyfcartsyydvsgwgvgrldlwgqgtlvtvss,,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VH: anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4523,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,dpmltqtaspvsaavggtvtincqasqsisssnwlswyqqkpgqppklliykastlasgvpsrfkgsgsgtqftltisgvqcddaatyyclgyysftsadnafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4524,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,alvmtqtpasvsaavggtvtincqasediysnlawyqqkpgqppklliygastlasgvpsrfkgsgsgteytltisgvqcddaatyycqctydsssytfgggteleik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4525,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,dpvltqtpssasepvggtvnikcqasqsigtrlawyqqkpgqppklliyyastlasgvpsrfkgsgsgteytltisgvqcddaatyyclgehsyssgdgrtafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4526,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,alvmtqtpssvsepvggtvtincqasediysnlawyqqkpgqppklliydasnlasgvpsrfsgsgsgteytltisgvqcadaatyycqtyystvtrafgagtkveik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4527,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,apvltqtpspvsaavggtvtincqaseniysflawyqqkpgqppklliytasklasgvpsrfkgsgsgtqftltisdvqcddaatyycqqtdtysnvdnafgggtevvve,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4528,not found,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),,dpmltqtassvsaavggtvtiscqssqsvydnnwlgwyqqkpgqppklliysastlasgvpsrfkgsgsgtqftltisdlecddaatyycaggysgnifafgggteleil,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.","VL: anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-01
4529,not found,SARS-CoV,Homo sapiens (human),,eltqspatlslspgeratlscrtsqnigtwlawfqqkpgqtprlliydaskraagiparfsgsgsgtdftltinsleaedfavyycqqrlqwatentfgrgtrldikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Kang,X. et al.; Human neutralizing SARS-CoV specific Fab molecules generated by phage display; Unpublished; 2006.","VL: anti-SARS-CoV S protein immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-01
